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Sampl.es for Submitted for 'l'estinq 
Twelve compounds have been synthesized this quarter and 
submitted for testing. In addition, we evaluated the inhibitory 
potency of some of these compounds in vitro with several enzymes 
including human leukocyte elastase, bovine chymotrypsin, and 
porcine pancreatic elastase. The compounds will be tested with 
other enzymes in the future. We plan tests with human skin 
chymase (a chymotrypsin-like enzyme) . Human skin chymases along 
with other proteases such as human leukocyte elastase, human 
leukocyte cathepsin G and skin tryptases may be involved in sulfur 
mustard induced inflammatory lesions. Initial inhibition data are 
shown. in Table I-IV. 




Diphenyl 1-aminoalkylphosphonates derivatives 
Miscellaneous inhibitors 
Isocoumarin derivatives. This class of compounds are the 
most interesting because some of them are potent and specific 
inhibitors of serine proteases. Two isocoumarin derivatives were 
synthesized this quarter. The first one, 3-chloroisocoumarin, was 
obtained directly from homophtalic acid according to a literature 
procedure, although the yield of this reaction is much lower (3-





The second derivative, 3-chloro-4- (2-phenyle1:h.oxy) 





Sacchar~n der~vatives. N-Acyl saccharins have been 
reported to inhibit a variety of serine proteases and to show 
selectivity for the different enzymes based on the nature of the 
acyl group. Therefore we decided to synthesize various N-acyl 
saccharin derivatives and four have already been submitted. Three 
of these derivatives were prepared by a procedure different from 
that used in the literature for the preparation of N-benzoyl and 
N-furoyl saccharin. In our procedure, tetrabutyl ammonium bromide 




a) RCOCl, benzene 





R = Phenyla, phenylacetyla, 2-furylb, diphenylacetyla 
Dipheny1 1-AminoaL1ky1phosphonates. Recently we 
discoverE~d that diphenyl esters of 1-aminoalkylphoshonate 
derivatives are irreversible inhibitors of serine proteases. 
Three simple carbobenzyloxy derivatives were obtained according to 




+ P (OPh) 3 
AcOH 
R-CH-·P (0) (OPh) 3 
~ 
NH-·COOCH2Ph 
The dipeptide derivative related to phenylalanine was 






Cbz - benzyloxycarbonyl 
Phe - phenylalanine 
Cbz-HN-CH-CO-NH-CH-P{O) (0Ph) 2 
I I 
Miscellaneous Inhibitors. Isatoic anhydride is a general 
serine protease inhibitor and has also been submitted. The other 
compound synthesized this quarter was di{p-
isovaleroylphenyl)sulfide which is a good reversible inhibitor of 
human leukocyte elastase. The synthesis of this compound by a 
Friedel-Crafts acylation of diphenyl sulfide is depicted below. 
Q-s () 
Bic,logical Assays. A few of the compounds have been 
assayed for activity against a few enzymes. Since this work is 
incomplete, few correlations can be made at present. 
4 

































Compd. Name Compd. Num. [I] kobs/(I] [I] kobs/[I] [I] 
J.1M M-1s-1 J.1M M-1s-1 J.1M 
Cbz-MetPPh2 II-22 320 1.6 320 NI 230 
BL57959 
Cbz-ValPPh2 II-138A 250 0.4 50 2.5 26 
BL57968 













Table III. Inhibition of Various Serine Proteases by 2-Substituted Benzisothiazolinone-1,1-
dioxide Derivativesa 
Benzisothiazolinone-1,1-dioxide 



















































was prepared according t6 procedure Harper J. W., 
. 0 
C. (1985) Biochemistry 24, 7200: m.p. 99-100 C. 
c17H13o3cl·0.5 H20: C, 65.92; H, 4.52; Cl, 11.46. 
66.20; H, 4.50; Cl, 11.58. 
This compound 
and Powers, J. 
Anal. Calcd. for 
Found: c, 
3-Chloroisocoumarin. This compound was prepared according 
to the procedure of Davis, w., and Poole, H. G. (1928) J. Chern. 
0 
Soc. 1616: m.p.98-99 c. Anal. Calcd. for C9H502Cl, c, 59.85; H, 
2.77; Cl, 19.65. Found, C, 59.74; H, 2.83; Cl, 19.71. 
Diphenyl 1-N-benzyloxycarbonylamino-2-
phenylethylphosphonate was prepared according to the procedure 
of Oleksyszyn, J., Subotkowska, L., and Mastalerz, P. (1979) 
0 
Synthesis 985: m.p. 119-120 c. Anal. Calcd. for c29H260sNP: c, 
68.94; H, 5.33; N, 2.87. Found: C, 69.00; H, 5.40; N, 2.84. 
Diphenyl 1-N-benzyloxycarbonylamino-3-
methylthi.opropylphosphonate was prepared by the same procedure; 
0 . 
m.p. 93-95 C. Anal. Calcd. for C24H2605NSP: C, 61.15; H, 5.52; 
N, 2.97; S, 6.79. Found: C, 61.06~~ H, 5.60; N, 2.91; S, 6.88. 
Diphenyl 1-N-benzyloxycarbonyl-2-methyl-
propllphosphonate was prepared by the same procedure; m.p. 104-
105 C. Anal. Calcd. for C24H2605NP: C,65.56; H, 5.92; N, 3.19. 
Found: C, 65.67; H, 5.98; N, 3.13. 
Diphenyl 1-N-(carbobenzyloxy-phenylalanyl)amino-2-
phenylethylphosphonate. To a solution of 2. 3 g ( 6. 5 mmol) of 
diphenyl 1-amino-2-phenylethylphosphonate [Oleksyszyn, J., 
Subotkowska, L., and Mastalerz, P. {1979) Synthesis 985] and Cbz-
Phe-OH 1.95 g (6.5 mmol) in 50 mL of dry THF, 1.32 g (6.6 mmol) of 
DCC (dicyclohexylcarbodiimide) was added. After 2 days DCU was 
filtered off and solution \'lras washed with water, 2 times with 50 
mL of 5% NaHC03, water, 2 times wit~h 10% citric acid, water and 
dried over MgS04. After evaporation of the solvent, the resulting 
oil was crystallized from THF-hexane to give 3.5 g (85%) of the 
dipeptide as a white solid; m.p. 153-155 °C. Anal. Calcd. for 
C37H3506N2P: C, 70.03; H, 5.52; N, 4.42. Found: C, 69.93; H, 
5.61; N, 4.51. 
Isat·oic anhydride. Isatoic anhydride was purchased from 
• • 0 
Aldr1ch and recrystall1zed from ethanol; m.p. 233 C (decomp). 
Anal. Cald. for C9H503N: c, 58.9; H, 3.07; N, 5.59. Found: c, 
58.90; H, 3.07; N, 8.52. 
Di(4-isovaleroylphenyl)sulfide. A mixture of 10.7 g 




-30 °C under an argon atmosphere. Diphenylsulfide 5.0 g (26.8 
mmol) was added followed by isovaleroyl chloride 7.19 mL (59.0 
mmol). The solution was warmed to 0 °C and stirred 1.5 hr, then 
allowed to reach room temperature and stirred overnight. The 
mixture was poured onto a mixture c)f ice and concentrated HCl 
(5:1). The organic layer was extracted with the methylene 
chloride, washed with 1N NaOH and dried over MgS04. After 
removing the solvent, the residue ,flas recrystallized from 
cyclohexane to give the product as a white solid (89%); m.p. 80-81 
0 
C. Anal. Calcd. for C22H2602S: C, 74.54; H, 7,39; S, 9.04. 
Found: C, 74.45; H, 7.42; S, 8.97. 
2-Benzoy1benzisothiazo1inone-1,1-dioxide. Tetrabutyl 
ammonium bromide (0.1 g) was added to a suspension of finely 
ground sodium saccharin (2.0 g, 9.8 mmol) in 30 mL of benzene. 
Benzoyl chloride (1.2 mL, 10.3 mmol) was added after azeotropic 
removal of water from this suspension and the resulting mixture 
was heated to reflux temperature for 3 h. The reaction mixture 
was filtered while hot, the solid was washed with hot benzene and 
the filtrate was cooled to 5 °C while scratching the sides of the 
flask to induce precipitation of the product. The white solid was 
collected by filtration and recrystallized from benzene/hexane to 
yield 1.39 g (50%) of pure product; m.p. 162-163 °C (Lit. 160-163 
°C) . 1H NMR (CDCl3) 8: 8.14 (d, 1H); 8. 01 (t, 2H); 7. 93 (m, 1H); 
7.78 (d of d, 2H); 7.67 (t, 1H); 7.51 (t, 2H). Anal. Calcd. for 
C14HgN04S: C, 58.53; H, 3.16; N, 4.88. Found: C, 58.66; H, 3.19; 
N, 4.92. 
2-(2-Furoy1)benzisothiazo1inone-1,1-dioxide. 2-Furoyl 
chloride (7.4 mL, 75 mmol) was added to a suspension of finely 
ground sodium saccharin in 40 mL THF and the resulting mixture was 
heated to reflux temperature for 4 h. The reaction mixture was 
filtered and the filtrate was concentrated to dryness to give a 
white solid that was recrystallized from ethyl acetate. The yield 
0 
of pure product was 4.79 g (35%); m.p. 167-168 C (Lit. 133-135 
°C) . lH NMR (CDCl3) 8: 8.19 (d, 1H) ;. 7. 99 (d, 2H); 7. 93 (m, 1H); 
7. 73 (d, 1H); 7. 58 (d, 1H); 6. 66 (d of d, 1H) . Anal. Calcd. for 
C12H7NOsS: C, 51.98; H, 2.55; N, 5.05. Found: C, 51.83; H, 2.52; 
N, 5.07. 
2-Pheny1benzisothiazo1inone-1,1-dioxide. Tetrabutyl 
ammonium bromide (0.1 g) was added to a suspension of finely 
ground sodium saccharin (8.0 g, 39 mmol) in 50 mL of benzene. 
Phenylacetyl chloride (7.7 mL,-58 mmol) was added to this 
suspension after azeotropic removal of water and the resulting 
mixture was heated at reflux temperature for 4 h. The reaction 
mixture was filtered while hot and the solid was washed with hot 
benzene. Hexane was added to the filtrate and the solid that 
resulted was filtered and recrystallized from benzene/hexane to 
yield 5.52 g (47%) of pure product; m.p. 177-179 °C. lH NMR 
(CDCl3) 0: 8.17 (d of d, 1H); 7.99-7.B7 (m, 3H); 7.38-7.28 (m, 5H); 
10 
.. 
4.39 (s, 2H). Anal. Calcd. for C15H11N04S: C, 59.79; H, 3.68; N, 
4.65. Found: c, 59.71; H, 3.73; N, 4.61. 
2-Diphenylacetylbenzisothiazolinone-1,1-dioxide. 
Thionyl chloride (7 mL, 100 mmol) ·was added to a solution of 
diphenylacetic acid (10 g, 50 mmol) in 50 mL of benzene and the 
resulting· mixture was heated to reflux temperature for 1 h. 
Excess thionyl chloride and benzene were removed under reduced 
pressure (1 mm Hg) and then tetrabutyl ammonium bromide (0.1 g), 
fresh benzene (50 mL) and finely ground sodium saccharin (6.8 g, 
30 mmol) were added in one portion. The resulting mixture was 
heated to reflux temperature .for 4 h and was then filtered while 
hot. The white solid that was collected was washed with hot 
benzene and the filtrate was concentrated to a small volume (ca. 
10 mL) . The white solid that came out of solution was collected 
by filtration and recrystallized from benzene/hexane to yield 5.43 
g (48%) of pure product; m..p. 195-197 °C. lH NMR (CDCl3) o: 8. 08 
(d, 1H); 7.95 (d, 2H); 7.89-7.85 (m, 2H); 7.38-7.27 (m, 10H); 6.30 
(s, 1H). Anal. Calcd. for Cz1H1sN04S: c, 66.83; H, 4.01; N, 3. 71. 
Found: C, 66.89; H, 4.01; N, 3.66. 
11 
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Samples for Submi1:ted for Testing 
Three compounds havE= been synthesized this quarter and 
submitted for testing. In addition, a number of·other compounds 
are almost ready to submit. We have evaluated the inhibitory 
potency of many of these compounds in vitro with several enzymes 
including human leukocyte E~lastase, bovine chymotrypsin, porcine 
pancreatic elastase, rat mast cell protease II, and human 
cathepsin G. The compounds will be tested with other enzymes in 
the future. We plan tests with human skin chymases (chymotrypsin-
like enzymes) and human skin tryptases (trypsin-like enzymes) . 
Human skin chymases along with other proteases such as human 
leukocyte elastase, human leukocyte cathepsin G and skin tryptases 
may be involved in sulfur mustard induced inflammatory lesions. 
Inhibition data are shown in Table I-III. 




Diphenyl 1-aminoalkylphosphonates derivatives 
Isocoumarin derivatives. This class of compounds are the 
most interesting because some of them are potent and specific 
inhibitors of serine proteases. The general serine protease 
inhibitor 3,4-dichloroisocoumarin was submitted this quarter. 
This was prepared by a literature procedure, but in very low 















Saccharin derivatives. N-Acyl saccharins have been 
reported to inhibit a variety of serine proteases and to show 
selectivity for the different enzymes based on the nature of the 
acyl grou~. Several saccharins were submitted last quarter and 





Diphenyl 1-Aminoalkylphosphonates. Recently we 
discovered that diphenyl esters of 1-aminoalkylphoshonate 
derivatives are irreversible inhibitors of serine proteases. 
Three simple carbobenzyloxy derivatives were submitted last month 
and we have now submitted the tripeptide derivative Suc-Val-Pro-
PheP(QPh)2. This derivative has turned out to be one of the most 












Deblock & Couple 
with Z-Vai-OH (DCC) 
0 
Deblock & Couple 
with Z-Pro-OH using 




















1. Deblock with 









Planned Syntheses. A few of the structures which we plan 
to submit in the near future are shown below. 
0 0 
0 il_O NH2 
~ o~s)l~H2 
Cl 
A = Ph and 2,4,6-trichlorophenyl 
Biological Assays. Many of the compounds have been assayed 
for activity against several enzymes. The results are showed in 
Tables I-III. At present, no animal studies have been received. 
We plan to submit a variety of different serine protease 
inhibitors until we obtain animal test data. 
4 
Table I. Inactivation Rates of Various Chymases by Substituted Isocoumarins, Phosphonate Derivatives and other Type of Inhibitors a. 
Inhibitors 
Chymotrypsin b 
3,4-dichloroisocoumarine (1) 570 
3-chloroisocoumarine (2) 330 
4-chloro-3-(2-pheny lethoxy )- 3800 
isocoumarin (3) 
isatoic anhydride (4) 580 
di(4-isovalaroylphenyl)-
disulfide (5) 
Z-MetP(QPh)2 (6) 1.6 
Z-ValP(QPh)2 (7) 0.4 
Z-PheP (OPh)2 (8) 260 



























Sue-Val-Pro-PheP(QPh)2 (10) 41,000 36,000 14,700 
alnactivation rates were measured by incubation method in 0.1 M Hepes, 0.5 M :t~aCl, pH 7.5 buffer, containing 9% ~1e2SO 'uid at 25 OC. 
Enzyme concentrations were: chymotrypsin, l.6JlM; cathepsin G, 1.6 JlM; RMCPII, 38 nM. Chymotrypsin and cathepsin G were assayed with 
Sue-Val-Pro-Phe-NA (0.5 mM), and RMCPII were assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 JlM) in the presence of 4,4'-dithiodipyridine 
(0.33mM). 
hinhibitor concentrations were the following: 3, 19.3 J!M; 4, 25 J..LM, 6, 320 J.1M; 7, 250 JlM; 8, 58 JlM; 9, 64 JlM; 10, 5.2 JlM. 
CJnhibitor concentrations were the following: 3, 19.3 JlM; 4, 25 JlM, 5, 158 JlM; 6, 128 JlM; 7, 148 Jllvi; 8, 82 jlivi; 9, 64 jlivi; 10, 8.4 jlivl. 
dJnhibitor concentrations were the following: 3, 20 JlM; 4, 25 JlM; 6, 128 JlM; 7, 148 JlM, 8, 82 JlM; 9, 64 JlM; 10, 3 JlM. 
enata was obtained from Hru-per, et al., (1985) Biochemistry 24, 1831-1841. 
fNo inhibition. 
glnhibition was not time dependent, and% inhibition was obtained at 92 JlM. 
·r , 
-----!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!---------------------------,.-----:r---...,-- - -- .. l' .... ...--
Table II. Inactivation Rates of Various Chymases by Saccharinsa. 
Inhibitors 
Chymotrypsin b Cathepsin oc 
N-benzoyl saccharin (11) 14,400 45,400 
N_nhPnulacetyl ~archarin £1 ?\ ... , t' ..., •• J. .. "' ..., .1..1.& ,_..__, 10,800 30,900 
N-diphenylacetyl saccharin (13) 9,960 13,800 
N-furoyl saccharin (14) 22,000 38,500 
N-cyanomethyl saccharin (15) N.I. 










alnactivation rates were measured by incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, containing 9% Me2SO and at 25 oc. 
Enzyme concentrations were: chymotrypsin, l.6J!M; cathepsin G, 0.8-1.6 J..LM. Chymotrypsin and cathepsin G were assayed with Sue-Val-
Pro-Phe-NA (0.5 mM). 
blnhibitor concentrations were the following: 11, 8.5 J..LM; 12, 12.5 J!M, 13, 8.6 J!M; 14, 7.5 J..LM; 15, 1 mM. 
CJnhibitor concentrations were the following: 11, 7 J..LM; 12, 7.2 J!M, 13, 7.7 J!M; 14,.4.8 J..LM. 
dJnhibitor concentrations were the following: 11, 9 J..LM; 12, 83 J..LM, 13, 13.1 J..LM; 14,.9.8 J..LM. 
Table ill. Inactivation Rates ofElastases by Substituted Isocoumarins, Phosphonate Derivatives, 
and other Types of Inhibitorsa. 





isatoic anhydride (4) 
di( 4-isovalaroyl pheny I)-
disulfide (5) 
Z-MetP(QPh)2 (6) 
Z-V alp (0Ph)2 (7) 
Z-PheP(QPh)2 (8) 
Z-Phe-PheP(QPh)2 (9) 
















ainactivation rates were messured by incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer, containing 9 % Me2SO and at 25 oc. Enzyme concentrations were: PPE, 1.6 J.LM; HLE, 
0.3 JlM. PPE was assayed with Suc-Ala-Ala-Ala-NA (0.75 mM), and HLE was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA (0.5 mJVI). 
brnhibitor concentrations were the following: 6, :320 JlM; 7, 50 JlM; 8, 58 JlM; 9, 64 J.LM; 10, 3 
JlM. 
Cinhibitor concentrations were the following: 6, 230 JlM; 7, 26 JlM; 8, 30 JlM; 9, 35 JlM; 10, 2 
JlM. 
dnata was obtained from Harper, et al., (1985) Biochemistry 24, 1831-1841. 
erc5o was obtained. 
fNo inhibition. 
EXPERIMENTAL SECTION 
Z-Pro-PheP (OPh) 2. Z-Pro-OH ( 1. 5 g, 6 rmnol) was 
dissolved in 60 mL of dry THF and cooled to 0 °C. Diphenyl 
a-amino-2-phenylethylphosphonate (2.1 g, 6 rmnol) and DCC 
(1.22 g, 6 rmnol) were added to this solution. The reaction 
mixture was stirred for 6 h at 0 °C and overnight at room 
temperature. The precipitated DCU was removed by filtration 
and 50 mL of ethyl acetate was added to the filtrate. The 
solution was washed twice with succesive portions of 10% 
citric acid, water, 4% sodium bicarbonate and water. The 
resulting solution was dried over MgS04, filtered and 
evaporated to dryness in vacuo to a residue that was 
dissolved in 10 mL CH2Cl:z. The small amount of DCU that came 
out of solution was removed by filtration and 30 mL of 
pentane was added to the filtrate to effect crystallization 
of the product. After a few days the product was filtered 
and recrystallized from CH2Cl2-Hexane to yield 1.86 g (53%) of 
pure product as a white solid; m.p.: 81-84 °C. Anal. Calcd. 
for C33H3306N2P: C, 67.81; H, 5.65; N, 4.79. Found: C, 67.56; 
H, 5.79; N, 4.72. 
Suc-Va1-Pro-PheP(OPh)2· Palladium on charcoal (0.1 
g, 5% catalyst) was added to a solution of 1.17 g (2 rmnol) of 
Z-Pro-PheP(QPh)2 in 50 mL of methanol and the resulting 
mixture was stirred under an atmosphere of hydrogen at room 
temperature for 2 h. The reaction mixture was filtered 
through Celite and Z-Val-OH (0.5 g, 2 rmnol) was added to the 
filtrate. The solvent was removed in vacuo and the residue 
was dissolved in 60 mi. of dry THF. DCC (0.4 g, 2 rmnol) was 
added to this solution and the resulting mixture was kept for 
6 h at 0 °C and overnight at room temperature. The resulting 
DCU was removed by filtration and the filtrate was washed 
with water, twice with 4% NaHC03, water and twice with 10% 
citric acid and water. After drying over NaS04, the solvent 
was removed in vacuo and the oil that resulted was dried 
under low pressure for a few hours. The dry semisolid was 
dissolved in 60 mL of ethyl acetate and succinic anhydride 
(0.2 g, 2 rmnol) was then added. After addition of 0.1 g of 
5% Pd/C the resulting mixture was stirred under a hydrogen 
atmosphere until TLC indicated only one new spot. The 
catalyst was then removed by filtration through Celite and 
the filtrate was washed several times with water. The 
resulting solution was dried over MgS04, filtered and 
evaporated to dryness in vacuo to yield 0.9 g (65%) of 
product as a hygroscopic: solid; m.p.: 50-53 °C. 31p NMR 8: 
19.75; 19.23 ppm. Anal. Calcd. for C34H4o03N3P·2H20: C, 
59.56; H, 6.42. Found: C, 59.59; H, 6.42. 
2-Cyanomethy1 Benzisothiazo1inone-l,l-dioxide. 
Sodium saccharin (5.0 g, 24 rmnol) was suspended in 50 mL of 
10 
benzene and tetrabutyl ammonium bromide (20 mg) was then 
added. Water was removed azeotropically from this mixture by 
heating the suspension to reflux temperature for 45 min. 
After removal of water, bromoacetonitrile (1.8 mL, 25.6 mmol) 
was added and the reaction mixture was heated to reflux 
temperature for 14 h. The mixture was filtered while hot and 
the solid was washed with hot benzene (5 x 5 mL) . The 
filtrate was concentrated in vacuo to a minimum volume (c.a. 
5 mL) and hexane was then added to effect complete 
precipitation of the product. After one recrystallization 
from chloroform, the yield of pure product was 2.15 g 
(39.6%); m.p.: 134-5 oc. lH NMR (CDCl3) 0: 8.17 (d of d, 1H); 
8.02-7.89 (m, 3H); 4.63 (s, 2H). Anal. Calcd. for CgH6N203S: 
C, 48.64; H, 2.72; N, 12.61. Found: C, 48.73; H, 2.76; 
N, 12.52. 
11 
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Summary. Seven new compounds have been synthesized this 
quarter and submitted for testing as antivesicants. The compounds 
belong to four classes of inactivators: a) isocoumarin 
derivatives, b) benzoxazinones, c) 5-nitro-3H-1,2-benzoxathiole-
2,2-dioxides, and d) derivatives of p-guanidinobenzoic acid. The 
inhibitory potency of many of these compounds along with 
previously submitted compounds has been evaluated in vitro with 
several serine proteases including· a number of chymases, 
elastases, and tryptases. Inhibition data is described in the 
section on biological activity and Tables I-III. Additional 
enzymes and inhibitors will be assayed in the future. We now have 
available very potent general serine proteases inhibitors, and 
specific inhibitors for chymases, elastases, and tryptases. 
Isocoumarin derivatives. ~Te have synthesized many 
isocoumarin derivatives in the course of previous research and 
most of them have been assayed for activity against several 
enzymes. On the basis of kinetic data some of the best coumponds 
were chosen, synthesized, and submitted for testing. One of the 





For trypsin-like enzymes one of the best isocoumarin 
inhibitors is 4-chloro-3-(3-isothiure.idopropoxy)isocoumarin 






The reaction of phenylisocyanate with 7-amino-4-chloro-3-
propoxyisocoumarin afforded one of the best inhibitors for human 
leukocyte elastase. 
0 0 
THF Ph-NHCONH _______ ...... 
OPr Ph-NCO OPr 
Cl Cl 
4 -chloro-7 -(N-phenylcarbamoyl)amino-3-propoxyisocoumarin 
The starting material for ·this reaction is obtained by a multistep 
procedure involving nitration of homophthalic acid, esterification 
of the resulting nitrophthalic acid to the monoester and 
cyclization of the later to 7-nitro-4-chloro-3-alkoxyisocoumarin 
using phosphorus pentachloride. The last step, reduction of the 
nitro group to the amino group can be done only on a small scale 
(about 1 g), probably due to reaction of the amino group with the 
isocoumarin ring. In order to obtain a 3 g sample of the 
inhibitor, we had to repeat this reaction several times. 
Benzoxazinones. Several benzoxazinones have been reported 
to inhibit human leukocyte elastase (HLE) and other serine 
proteases. This quarter we submitted 2-ethoxy-4H-3,1-benzoxazin-
4-one which was synthesiz~d by the following scheme. It is one of 







5-Nitro-JH-1,2-benzoxathiole-2,2-dioxide. This sultone 
is a probably a general inhibitor of serine proteases, but only a 
few enzymes have been tested at present. 
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5-Nitro-3H-1 ,2-benzoxathiole-2,2-dioxide 
Derivatives of p-Guanidinobenzoic Acid. The cationic p-
guanidinobenzoic acid is a weak competitive inhibitor of trypsin-
like enzymes. Its ethyl ester is an active site titrant for 
trypsin-like enzymes. Samples of p-guanidinobenzoic acid and its 
ethyl ester were prepared by a previously reported multistep 
procedure and were submitted this quarter. 
R = IH, Et 
Planned Syntheses. Recently we have synthesized a series of 
isocoumarin derivatives containing the isothiureido moiety. They 
are excellent inhibitors for trypsin-like enzymes. We are 
presently measuring their inhibitory potency against human lung 
tryptase and rat skin tryptase. A few of the most active 
compounds will be synthesized in large amounts and submitted in 
the near future. 
0 
R-CO-NH 
R = Alkyl, Aryl, or Alkyi-NH-
Cl 
n = 2, 3 
Benzoxazinone analogs resembling the best isocoumarin derivatives 
for chymotrypsin-like enzymes will also be synthesized {below 
left) . Coupling of p-guanidino benzoic acid with valine amide and 
chloroacetamide has been accomplished and 3 g samples will soon be 
ready for submission {below right) . 
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QR R = NH-Vai-NH2 , CH2CONH2 
NH 
HN~NH 
2 + 2 
Biological Assays. Human skin chymases along with other 
serine proteases such as human leukocyte elastase, human leukocyte 
cathepsin G and skin tryptases are thought to be major mediators 
of sulfur mustard induced inflammatory lesions. All the compounds 
which we have submitted are listed in Tables I-III along with 
their inhibitory potency toward a number of serine proteases. The 
data with bovine chymotrypsin, rat mast cell protease II, human 
skin chymase, and dog skin chymase is given in Table I. The data 
with porcine pancreatic elastase and human leukocyte elastase is 
given in Table II. The data with bovine trypsin, human lung 
tryptase, and rat skin tryptase is given in Table III. 
The majority of the inhibitors are irreversible inhibitors of 
the various enzymes and the second order inhibition contants 
(kobs/[I]) are reported in the tables. Several of the inhibitors 
have kobs/[I] values of 100,000 M-1s-1 or greater. An inhibition 
constant of this magnitude indicates that the reaction between 
equimolar concentrations of enzyme and the inhibitor is over in 
less than 0.2 min. (the time required for mixing). 
This quarter we started testing some of the inhibitors with 
tryptases and other trypsin-like enzymes, and the data shown in 
Table III has been measured recently. New compounds and new 
measurements have been added to the other two tables. There are 
still many gaps in the various tables. Several of the enzymes are 
hard to obtain and only the most promising inhibitors have been 
assayed with the small amounts of available enzyme. We expect to 
obtain additional supplies of skin enzymes in the near future and 
will carry out additional assays with these enzymes at that time. 
At present, no animal test data has been received. We plan to 
submit a variety of different classes of serine protease 
inhibitors until we obtain animal test data. 
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High Priority Compounds for Testing. 












Table I. Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and Dog Skin 
Chymase by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor 
BL58572 3 ,4-dichloroi ce 
BL57637 3-chloroice 
BL57413 4-chloro-3-(2-pheny letl-toxy )IC 
BM00482 4-chloro-3-benzyloxyiC 
BL57646 isatoic anhydride 



































Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 
Dog Skin Chymase by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor 
BL57842 Z-Phe-PheP(QPh)2 
BL59282 Sue-V al-Pro-PheP (0Ph)2 
BL57977 :to-~~ benzoy lsaccha.....-j_n 
BL57995 N -pheny lacety !saccharin 
BL57986 N-dipheny lacety !saccharin 
BL57931 N-furoy !saccharin 

























alnactivation rates were measured by incubation method in 0.1 M Hepes, 0.5 M NaCI, pH 7.5 buffer, containing 9% Me2SO at 25° C. 
Enzyme concentrations were: chymotrypsin, 1.6 J.J.M; cathepsin G, 0.8-1.6 JlM; RMCP ll, 38 nM. Chymotrypsin and cathepsin G 
were assayed with Suc-Val-Pro-Phe-NA (0.5 J.LM), and RMCP II was assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 JlM) in the 
presence of 4,4'-dithiodipyridine (0.33 mM). 
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Table I (Continued). 
bJnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 19.3 J.l.M; isatoic anhydride, 25 ~; Z-MetP(OPh)2, 320 
J.LM; Z-ValP(QPh)2, 250 J.LM; Z-PheP(QPh)2, 58J.LM; Z-Phe-PheP(QPh)2, 64J.LM; Suc-Val-Pro-PheP(QPh)2, 5.2 J..LM; N-
benzoylsaccharin, 8.5 J.LM; N-phenylacetylsaccharin, 12.5 J.LM, N-diphenylacetylsaccharin, 8.6 J.LM; N-furoylsaccharin, 7.5 J.LM; N-
cyanomethylsaccharin, 1 mM. 
CJnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 19.3)..lM; isatoic anhydride, 25 J..LM; di(4-
isovalaroylphenyl)disulfide, 158 J.l.M; Z-MetP(QPh)2, 128 J,L\1; Z-ValP(QPh)2, 148 JlM; Z-PheP(QPh)2, 82 J.!M; Z-Phe-
PheP(QPh)2, 64J.LM; Suc-Val-Pro-PheP(QPh)2, 8.4J.LM; N-benzoylsaccharin, 7 J.l.M; N-phenylacetylsaccharin, 7.2JlM, N-
diphenylacetylsaccharin, 7.7 J..LM; N-furoylsaccharin, 4.8 ~v1. 
dJnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 20 J.LM; isatoic anhydride, 25 J.!M; Z-MetP(QPh)2, 128 fJM; 
Z-VaiP(QPh)2, 148 J..LM, Z-PheP(QPh)2, 82)..lM; Z-Phe-PheP(QPh)2, 64 J.LM; Suc-Val-Pro-PheP(QPh)2, 3J.LM; N-
benzoylsaccharin, 9 J.l.M; N-phenylacetylsaccharin, 83J.LM, N-diphenylacetylsaccharin, 13.1J.LM; N-furoylsaccharin, 9.8 fJM. 
enata was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841. 
fNo inhibition. 
glnhibition was not time dependent, and the % inhibition was measured at 92 J.LM. 
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Table II. Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte Elastase (HLE) 
by Various Serine Protease Inhibitors. a 
kobs/[I] (M-1 s-1) 
Compound No. Inhibitor HLEC 
Isocoumarin Inhibitors 
BL58572 3,4-dichloroiCd 2,500 9,000 
BL57637 3-chloroiCd 510 3,900 
BL57413 4-chloro-3-(2-phenylethoxy)IC 
BM01096 4-chloro-7-(N-phenylcarbamoyl)amino-
3-propoxy IC 59 140,000 
Miscellaneous Inhibitors 
BL57646 isatoic anhydride 
BL57940 di( 4-isovalaroylphenyl)disulfide 2~Me 
BM00651 2-ethoxy-4H-3, 1-benzoxazin-4-one 110,000 
BM00491 5-nitro-3H-1 ,2-benzoxathiole-2,2-dioxide 50 
Phosphonate Inhibitors 
BL57959 Z-MetP(QPh)2 Nif 0.8 
BL57968 Z-ValP(QPh)2 2.5 90 
BL57422 Z-PheP(QPh)2 NI 6 
BL57842 Z-Phe-PheP(QPh)2 NI NI 
BL59282 Suc-Val-Pro-PheP(QPh)2 NI NI 
alnactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer, containing 9% Me2SO at 25° C. Enzyme concentrations were: PPE, 1.6 J.!M; HLE, 
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Table II (Continued). 
0.3 JlM. PPE was assayed with Suc-Ala-Ala-Ala-NA (0.75 mM), and HLE was assayed with 
MeO-Suc·-Ala-Ala-Pro-Val-NA (0.5 mM). 
blnhibitor concentrations were as foltows: Z-MetP(OPh)2, 320 jlM; Z-ValP(OPh)2, 50 jlM; Z-
PheP(OPh)2, 58 J!M; Z-Phe-PheP(,OPh)2, 64 J.LM; Suc-Val-Pro-PbeP(QPh)2, 3 J!M; 4-chloro-
7-(N-phenylcarbamoyl)amino-3-proJX>xyiC, 52 J.!M. 
Cfuhibitor concentrations were as follows: Z-MetP(QPh)2, 230 J!M; Z-ValP(QPh)2, 26 J.!M; Z-
PheP(QPh)2, 30 J!M; Z-Phe-PheP(QPh)2, 35 ~1M; Suc-Val-Pro-PheP(OPh)2, 2 J!M.2-ethoxy-
4H-3,1-benzoxazin-4-one, 1.8 J.!M; 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide, 127 J!M; 4-
chloro-7-(N-phenylcarbamoyl)amino-3-propoxyiC, 1.2 J!M. 
dnata was obtained from Harper, J.. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 
1831-1841.. 
ernhibition was not time dependent and the IC50 was obtained. 
fNo inhibition. 
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Table lll. Inhibition of Bovine Trypsin, Human Lung Tryptase, and Rat Skin Tryptase by Isocoumarins and Derivatives of p-
Guanidinobenzoic Acida. 
Compound No. Inhibitor Bovine Trypsin b HumanLungC Rat Skind 
TryEtase T!.l:Etase 
Isocoumarin Inhibitors 
BM00642 4-chloro-3-(3-isothioureidopropoxy )isocoumarin 46,000 260,000 650,000 
Guanidinobenzoic Acid Derivatives 
BM01363 p-guanidinobenzoic acid 
BM01185 ethy 1 p-guanidinobenzoate 4.3 1.7 
alnactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 J.JM; rat skin tryptase, 0.015 
iJ.M. Bovine trypsin was assayed with Z-Phe-Gly-Arg-NA·HCl (0.07 mM). Human lung tryptase and rat skin tryptase were 
assayed with Z-Arg-SBzl·HCl (0.07 mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCl2, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as 
follows: 4-chloro-3-(3-isothioureidopropoxy )isocoumarin, 1J.LM; ethyl p-guanidinobenzoate, 0.43 mM. 
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Table III (Continued). 
cconditions were as follows: O.lM Hepes, 0.5M NaCl, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as follows: 4-
chloro-3-(3-isothioureido-propoxy)isocoumarin, 0.42 )lM; ethyl p-guanidinobenzoate, 0.42 mM. 
dConditions were as follows: 25 mM phosphate, 0.5M NaCl, 1mM EDTA, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations 
were as follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.44 J.LM; ethyl p-guanidinobenzoate, 0.45 mM 
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EXPERIMENTAL SECTION 
2-Ethoxy-4H-3,1-benzoxazin-4-one. To a solution of 
anthranilic acid [6.85 g, 0.05 mol) in dry pyridine (50 ml) at 
room temperature under anhydrous conditions was added ethyl 
chloroformate (19.2 ml, 0.2 mol) dropwise over a 15 min period. 
After stirring for 2 h, the solvent was removed under reduced 
pressure and the residue was stirred vigrously into 100 ml of ice-
cold water. The insoluble solid was filtered, washed with water 
and air-dried. The crude product was dissolved in ethyl acetate, 
treated with charcoal and recrystallized to give the benzoxazinone 
as a white solid (8.5 g, 89%); m.p. 88-90° c. Anal. Calcd. for 
c10HgN0 3 : C, 62.83; H, 4.71; N, 7.33. Found: C, 66.78; H, 4.73; N, 
7.31. 
5-Nitro-3H-1,2-benzoxathiole-2,2-dioxide was purchased 
from Eastman Kodak; m.p.: 142-144° c. Anal. Calcd. for c7H5o5NS; 
C, 39.04; H, 2.32; N, 6.51; S, 14.87. Found: C, 39.12; H, 2.33; 
N, 6.51; S, 14.96. 
4-Chloro-3-(3-isothioureidopropoxy)isocoumarin. This 
inhibitor was prepared as described by Kam, C-M .. , Fujikawa, K., 
and Powers, J. C. (1988) B.iochemistry 27, 2547; m.p. 174-176° C 
(decamp) . Anal. Calcd. for C13H14BrCl03N2S; C, 3 9. 6 5; H, 3. 56; N, 
7.12; S, 8.13. Found: C,39.70; H, 3.62; N, 7.08; S, 8.23. 
3-Benzyloxy-4-chloroisocoumarin. This inhibitor was 
prepared as described by Harper, J. W, and Powers, J. C (1985) 
Biochemistry 24, 7200; m.p. 90-92° C. Anal. Calcd. for C16H1103Cl; 
C, 67.02; H, 3.84; Cl, 12.38. Found: C, 66.93; H, 3.92; Cl, 
12.28. 
4-Chloro-7-(N-phenylcarbamoyl)amino-3-propoxyiso-
coumarin. To 3.05 g (0.012 mol) of 7-amino-4-chloro-3-
propoxyisocoumarin [Harper, J. W., and Powers, J. C. (1985) 
Biochemistry 24, 7200] in 20 ml of dry THF, 1.44 g (0.012 mol) of 
phenylisocyjanate was added. The solution was kept at room 
temperature for a few days and the solid which crystallized out 
was filtered, washed with pentane, and air-dried; yield 3.3 g 
(74%), m.p. 235-236° C (decamp). 1\nal. Calcd. for c19H17Cl0 4N2 ; C, 
61.22; H, 4.56; N, 7.52; Cl, 9.52. Found: C, 61.30; H, 4.62; N, 
7.51; Cl, 9.60. 
p-Guanidino benzoic acid. This compound was prepared 
according to the procedure of Chase, T., and Shaw E. (1970) Methods 
in Enzymo_l. 19, 22; m.p. 274° C (dec.). Anal. Calcd. for 
CsH1oClN302: C, 44. 56; H, 4. 67; N, 19. 49; Cl, 16.44. Found: C, 
44.73; H, 4.65; N, 19.34; Cl, 16.58. 
Ethyl p-guanidino benzoate. This compound was made 
according to the procedure of Beyerman, H. C., and Bontekoe, J. S. 
(1953) Rec. Trav. Chim. Pays-Bas 72, 643; m.p. 164-5° C (dec.). 
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Anal. Calcd. for C1oH14ClN30z: C, 49.28; H, 5.79; N, 17.24; Cl, 
14.55. Found: C, 49.34; H, 5.79; N, 17.17; Cl, 14.52. 
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Progress Report. Two new compounds have been synthesized 
this quarter and submitted for testing as antivesicants. The 
compounds are N-(p-guanidinobenzoyl)glycine amide hydrochloride 
and N-(p-guanidinobenzoyl)valine amide hydrochloride (the 
structures are shown below) . 
Several N-substituted derivatives of a-amino(4-
amidinophenyl)methanephosphonate diphenyl ester have been 
synthesized on a small scale as possible tryptase inhibitors using 





The inhibitory potency of these compounds along with several 
previously submitted compounds is being evaluated in vitro with 
several trypsin-like enzymes. 
Isocoumarin derivatives. We have synthesized many 
isocoumarin derivatives in the course of previous research and 
most of them have now been assayed for activity against several 
chymases. On the basis of kinetic data some of the better 
coumponds were chosen, S~{nthesized, and submitted for testing. 
One of the best inhibitors for chymotrypsin-like enzymes is 3-




A logical derivative of this very active analog would posess 
an amino group at position 7, which would provide a synthetic 
handle for many other derivatives with improved binding. 
However,the synthesis of 7-amino-3-benzyloxy-4-chloroisocoumarin 
failed when no method could be found that would reduce the nitro 
group without concurrent removal of the benzyloxy functional group 
or opening of the isocournarin ring. In order to circumvent this 
problem we decided to synthesize the 3-cyclohexylmethyloxy 





The starting isocoumarin is obtained by a multistep procedure 
involving nitration of homophthalic acid, esterification of the 
resulting nitrophthalic acid with cyclohexylmethanol to the 
monoester and cyclization of the later to the 3-alkoxy-4-chloro-7-
nitroisocoumarin using phosphorus pentachloride. The last step, 
reduction of the nitro group to the amino group could be done only 
on a small scale (about 1 sf), probably due to reaction of the 
amino group with the isocoumarin ring. A 3 g sample will soon be 
ready for submission. 
Biological Assays. Human skin chymases along with other 
serine proteases such as human leukocyte elastase, human leukocyte 
cathepsin G and skin tryptases are thought to be major mediators 
of sulfur mustard induced inflammatory lesions. All the compounds 
which we have submitted are listed in Tables I-III along with 
their inhibitory potency toward a number of serine proteases. The 
data with bovine chymotrypsin, rat mast cell protease II, human 
skin chymase, and dog skin chymase is given in Table I. The data 
with porcine pancreatic elastase and human leukocyte elastase is 
given in Table II. The data with bovine trypsin, human lung 
tryptase, and rat skin tryptase is given in Table III. 
The majority of the inhibitors are irreversible inhibitors of 
the various enzymes and the second order inhibition contants 
(kobs/[I]) are reported in the tables. Several of the inhibitors 
have kobs/[I] values of 100,000 M-ls-1 or greater. An inhibition 
constant of this magnitude indicates that the reaction between 
equimolar concentrations oj: enzyme and the inhibitor is over in 
less than 0.2 min. (the time required for mixing). 
This quarter we continued testing some of the inhibitors with 
tryptases and other trypsin-like enzymes, and the data shown in 
Table III has been measured recently. New compounds and new 
measurements have been added to the other two tables. There are 
still many gaps in the various tables. Several of the enzymes are 
hard to obtain and only the most promising inhibitors have been 
assayed with the small amounts of available skin chymase and 
tryptase. At present, no animal test data has been received. We 
plan to submit a variety of different classes of serine protease 
inhibitors until we obtain animal test data. 
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Table I. Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and Dog Skin 
Chymase by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor 
BL58572 3,4-dichloroiCg 
BL57637 3-chloroiCg 





































Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 
Dog Skin Chymase by Various Serine Protease Inhibitors. a 
kobs/[I] (M-1s-1) 
Compound No. Inhibitor ChyTb Cathepsin ac RMCPIId Human Skin Dog Skin 
Chymasee Chymasef 
BL57968 Z-ValP(QPh)2 0.4 Nih Nih 
BL57422 Z-PheP (OPh )2 260 76 89 
BL57842 Z-Phe-PheP(QPh)2 7.5 Nih 18 
BL59382 Sue-Val-Pro-PheP ( OPh )2 41,000 36,000 15,0d0 190,000 
Saccharin Inhibitors 
BL57977 N-benzoy !saccharin 15,000 45,000 16,000 
BL57995 N -pheny lacety !saccharin 11,000 31,000 1,300 
BL57986 N -dipheny lacety !saccharin 10,000 14,000 9,800 
BL57931 N-furoy !saccharin 22,000 39,000 20,000 
BM00464 N-cyanomethylsaccharin Nih 
ainactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, containing 9% Me2SO at 25° 
C. Enzyme concentrations were: chymotrypsin, 1.6 J.!M; cathepsin G, 0.8-1.6 J.!M; RMCP II, 38 nM; human skin chymase, 0.07 
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Table I (Continued). 
J..LM. Chymotrypsin and cathepsin G were assayed with Suc-Val-Pro-Phe-NA (0.5 J..LM), human skin chymase and RMCP II were 
assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 J..LM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
binhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 19.3 J..LM; isatoic anhydride, 25 J..LM; Z-MetP(OPh)2, 320 
J..LM; Z-VaiP(OPh)2, 250 J..LM; Z-PheP(OPh)2, 58 J..LM; Z-Phe-PheP(OPh)2, 64 J..LM; Suc-Val-Pro-PheP(OPh)2, 5.2 J..LM; N-
benzoylsaccharin, 8.5 JlM; N-phenylacetylsaccharin, 12.5 f.!M, N-diphenylacetylsaccharin, 8.6 J..LM; N-furoylsaccharin, 7.5 J..LM; N-
cyanomethylsaccharin, 1 mM. 
CJnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 19.3 J..LM; isatoic anhydride, 25 J..LM; di(4-
isovalaroylphenyl)disulfide, 158 J..LM; Z-MetP(QPh)2, 128 J.!M; Z-VaiP(QPh)2, 148 J..LM; Z-PheP(QPh)2, 82 J..LM; Z-Phe-
PheP(QPh)2, 64 JlM; Sue-Val-Pro-PheP(QPh)2, 8.4 J..LM; N-benzoylsaccharin, 7 J..LM; N-phenylacetylsaccharin, 7.2 JlM, N-
diphenylacetylsaccharin, 7. 7 J..LM; N-furoylsaccharin, 4.8 J..LM. 
dJnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 20 J..LM; isatoic anhydride, 25 J..LM; Z-MetP(OPh)2, 128 J..LM; 
Z-VaiP(QPh)2, 148 J..LM, Z-PheP(OPh)2, 82 J..LM; Z-Phe-PheP(QPh)2, 64 J..LM; Sue-Val-Pro-PheP(QPh)2, 3 J..LM; N-
benzoylsaccharin, 9 J..LM; N-phenylacetylsaccharin, 83 JlM, N-diphenylacetylsaccharin, 13.1 J..LM; N-furoylsaccharin, 9.8 J..LM. 
elnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 45 J..LM; 7-amino-4-chloro-3-cyclohexylmethyliC, 0.44 mM; 
Sue-Val-Pro-PheP(OPh)2, 0.54 J..LM; 
gData was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841. 
hNo inhibition. 
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Table I (Continued). 
iJnhibition was not time dependent, and the% inhibition was measured at 92 Jl.M. 
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Table II. Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte Elastase (HLE) 
by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor PPEb HLEC 
Isocoumarin. Inhibitors 
BL58572 3,4-dichloroiCd 2,500 9,000 
BL57637 3-chloroiCd 510 3,900 
BL57413 4-chloro-3-(2-phenylethoxy)IC 
BM01096 4-chloro-7 -(N -pheny lcarbamoy 1 )amino-
3-propoxy IC 59 140,000 
Miscellaneous: Inhibitors 
BL57646 isatoic anhydride 
BL57940 di(4-isovalaroylphenyl)disulfide 2j.!Me 
BM00651 2-ethoxy-4H-3,1-benzoxazin-4-one 110,000 
BM00491 5-nitro-3H-1 ,2-benzox.athiole-2,2-dioxide 50 
Phosphonate Inhibitors 
BL57959 Z-MetP(QPh)2 Nif 0.8 
BL57968 z-valP(OPh)2 2.5 90 
BL57422 Z-PheP(QPh)2 NI 6 
BL57842 Z-Phe-PheP(QPh)2 NI NI 
BL59282 Sue-Val-Pro-PheP (0Ph)2 NI NI 
ainactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer, containing 9% Me2SO at 25° C. Enzyme concentrations were: PPE, 1.6 J..LM; HLE, 
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Table II (Continued). 
0.3 ~. PPE was assayed with Suc-Ala-Ala-.A.la-NA (0.75 mM), and HLE was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA (0.5 mM). 
bJnhibitor concentrations were as follows: Z-MetP(QPh)2, 320 ~; Z-ValP(QPh)2, 50~; Z-
PheP(QPh)2, 58~; Z-Phe-PheP(QPh)2, 64 ~LM; Suc-Val-Pro-PheP(QPh)2, 3 J.!M; 4-chloro-
7-(N-phenylcarbamoyl)amino-3-propoxyiC, 52~· 
CJnhibitor concentrations were as follows: Z-MetP(QPh)2, 230 J.!M; Z-·ValP(QPh)2, 26 ~; Z-
PheP(QPh)2, 30 ~; Z-Phe-PheP(OPh)2, 35 J.!M; Suc-Val-Pro-PheP(QPh)2, 2 J.!M.2-ethoxy-
4H-3,1-benzoxazin-4-one, 1.8 JJM; 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide, 127 J.!M; 4-
chloro-7-(N-phenylcarbamoyl)amino-3-propoxyiC, 1.2 J.!M. 
dnata was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 
1831-1841.. 
elnhibition was not time dependent and the IC50 was obtained. 
fN o inhibition. 
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Table III. Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human Recombinant 
Tissue Plasminogen Activator by Isocoumarins and Derivatives of p-Guanidinobenzoic Acid a. 
Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Isocoumarin Derivatives 
BM00642 4-chloro-3-(3-isothioureido-
propoxy )isocoumarin 46,000 260,000 650,000 83,000 13,000 
Guanidinobenzoic Add Derivatives 
BM01363 p-guanidinobenzoic acid NI& 
BM01185 ethy 1 p-guanidinobenzoate 4.3 1.7 0.7 Nig 
BM02655 N -(p-guanidinobenzoy 1) 
valine amide 4.4 4.7 1.3 2,000 
BM03143 N-(p-guanidinobenzoy 1) 




Table III (Continued). 
ainactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 JJM; rat skin tryptase, 0.015 
JlM; human skin tryptase, 0.12 JJM; human r-t-PA, 0.017 JlM Bovine trypsin was assayed with Z-Phe-Gly-Arg-NA·HCl (0.07 
mM). Human lung tryptase, human skin tryptase and rat skin tryptase were assayed with Z-Arg-SBzl·HCl (0.07 mM) in the 
presence of 4,4'-dithiodipyridine (0.33 mM). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCl2, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as 
follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, lJlM; p-guanidinobenzoic acid, 0.44 rr.} ... 1; ethyl p-guanidinobenzoate, 
0.43 mM; p-guanidinobenzoyl valine amide,0.44 mM; 2-(p-guanidinobenzoyl)acetamide, 0.44 mM. 
cconditions were as follows: 0.1M Hepes, 0.5M NaCI, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as follows: 4-
chioro-3-(3-isothioureido-propoxy)isocoumarin, 0.42 j.ilVI; ethyl p-guanidinobenzoate, 0.42 IIll\1; p-guanidinobenzoyl valine arr.ide, 
0.42 mM; 2-(p-guanidinobenzoyl)acetamide, 0.42 mM. 
dConditions were as follows: 25 mM phosphate, 0.5M NaCI, 1mM EDTA, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations 
were as follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.44 JlM; ethyl p-guanidinobenzoate, 0.45 mM; p-
guanidinobenzoyl valine amide, 0.42 mM; 2-(p-guanidinobenzoyl)acetamide, 0.44 JlM. 
econditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 oc. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.35 JlM; p-guanidinobenzoyl valine amide, 3.5 JJM; 2-(p-
guanidinobenzoyl)acetamide, 1. 7 mM. 
Page 12 
Table III (Continued). 
fConditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 OC. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 4.3 J.!M; ethyl p-guanidinobenzoate, 0.44 mM; 2-(p-guanidinobenzoyl)acetamide, 
0.43 mM. 
gNo inhibition. 
hinhibition was not time dependent and the % inhibition was measured at 0.42 mM. 
i A mPh = 4-amidinopheny 1 
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EXPERIMENTAL SECTION 
N- (p-Guanidinobenzoyl) gl:ycine Amide Hydrochloride. 
Water was removed azeotropically from a mixture of p-
guan:Ldinobenzoic acid hydrochloride(2.51 g, 12 mmol) and N-
tetrabutylammonium bromide (100 mg) in 50 mL of benzene. 
1,2,2,6,6-Pentamethylpiperidine (PMP) was then added (2.1 mL, 
12 mmol), followed by 2-chloroacetamide (1.2 g, 13.2 mmol). 
The resulting mixture was heated to reflux temperature for 24 
hours, it was filtered while hot and the beige solid was 
throroughly washed with acetone. The crude solid was 
recrystallized from 95% ethanol to yield 1.06 g (34%) of pure 
product as a white solid, mp 249-51°C. lH NMR (d6-Me2SO) 0: 
8.05 (d,2H); 7.75 (broads, 3H); 7.58 (broads, 1H); 7.36 
(d,2H); 7.28 (broads, 1H); 4.66 (s, 2H). Anal. Calcd. for 
C1oH13ClN403: C, 44.04; H, 4.80; N, 20.55; Cl, 13.00. Found: 
C, 43.91; H, 4.85; N, 20.45; Cl, 12.93. 
N-(p-Guanidinobenzoyl)valine Amide Hydrochloride. 
Trie1:hylamine (3. 2 mL, 23 mmo1) was added to a solution of 
valine amide hydrochloride (3.1 g, 23 mmol) in 100 mL of DMF. 
1-Hydroxybenzotriazole: (HOBt, 3.15 g, 23 mmol) was added to 
this mixture, followed by p-guanidinobenzoic acid 
hydrochloride (5.0 g, 23 mmol) and the reaction mixture was 
then cooled in an ice bath. N,N-qiclyclohexylcarbodiimide 
(DCC, 5.2 g, 25 mmol) was added to the cold (0-5 °C) solution 
and the resulting mixture was stirred at 5-10 °C for 24 h. 
The \vhite solid in suspension (DCU) was filtered and washed 
with EtOAc. The filtrate was concentrated to dryness in 
vacuo to a foam which was triturated with chloroform (5 x 200 
mL) with vigorous mechanical stirring to remove NEt3•HCl. 
The resulting amorphous solid was taken up in 100 mL of 
water, filtered through Celite: to remove HOBt and the 
filtrate was lyophylized to yield 5.13 g (71%) of pure 
Paqe 14 
product as a white amorphous solid. lH NMR (d6-Me2SO) 0: 
10.25 (br.s 1 1H); 8.22 (d 1 1H) 1 7.98 (d 1 2H); 7.68 (br.s 1 
3H); 7.54 (s 1 1H); 7.30 (d 1 2H); 7.08 (br.s 1 1H); 4.26 (t 1 
1 H) ; 2 . 11 ( rn 1 1 H) ; 0 . 91 ( d 1 3 H) ; 0 . 8 9 ( d 1 3 H) . An a 1 C a 1 cd . 
for C13H2oClNs02•0.8 H20: C1 47.56; H1 6.63; N1 21.33; Cl1 
10.80. Found: C1 47.56; H1 6.52; N1 21.26; Cl 1 10.68. 
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Dr. Jozef Oleksyszyn left Georgia Tech for a job at Cortec in 
Denver, CO in early March 1990 and was replaced by Dr. Girish 
Patil who started in late March. 
















Three new compounds have been synthesized 
this quarter and submitted for testing as antivesicants. The 
compounds are 4-chloro-3-methylisocoumarin, 7-amino-4-chloro-3-
cyclohexylmethoxyisocoumarin (BM04319) and diphenyl N-
benzyloxycarbonyl amino-(4-amidinophenyl)methane phosphonate 






The inhibitory potency of the last two compounds was tested 
respectively towards trypsin-like enzymes and human skin chymase 
Page 2 
and kinetic data were repor1:ed in the Annual Report which was 
recently submitted. 
4-Chloro-3-methyl isocoumarin was prepared by reaction of 
homophthalic acid with acetic anhydride in pyridine to obtain 4-
acetyl homophthalic anhydride which was then treated with cone. 
H2S04 to yield 3-methylisocoumarin. The latter compound gave the 
final product by reaction w:Lth N-chlorosuccinimide. This 
isocoumarin should be a gE:neral protease inhibitor with enhanced 
stability towards hydrolysis. 
NCS 
7-Amino-4-chloro-3-cyclohexylmethoxyisocoumarin was obtained 
by a multistep procedure involving :nitration of homophthalic acid, 
esterifica1:ion of the resulting nit.rohomophthalic acid with 
cyclohexanemethanol to the monoester and cyclization of the latter 
to the 3-alkoxy-4-chloro-7-nitroisocoumarin using phosphorus 
pentachloride. The last step, reduction of the nitro group to the 
amino group can only be done on a small scale (about 1 g), 






Diphenyl N-benzyloxy carbonylamino(4-amidinophenyl)methane 
phosphonate was obtained by a-amidoalkylation of triphenyl 
phosphite using 4-cyanobenzaldehyde and benzyl carbamate to give 
diphenyl N-benzyloxycarbonylamino(4-cyanophenyl)methane 
phosphonate. The cyano group was then converted to an imino ether 
by reaction with HCl in ethanol and finally to an amidino moiety 
by reaction with ethanolic ammonia. 
NC-o-CHO + P(OPh)3 + H2N-Cbz AeOH 
HCI/ EtOH Eto, -:0-' -------11-....... C .. CH-P03Ph2 
CHCI3 ~ - I 
NH HCI NH-Cbz 
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EXPER~MENTAL SECTION 
Cyc1ohexanemethy1 4-nitro-2-carboxypheny1acetate. A 
solution containing 10 g (44 mmol) of 5-nitro homophtalic acid 
(prepared according to H. E. Ungnade, D.V. Nightingale and H. E. 
French, J. Org. Chem. 1945 .10, 533), cyclohexanemethanol (14 mL, 
111 mmol) and 6 drops of cone. H2S04 in 150 mL of benzene was 
heated to reflux temperature with azeotropic removal of water for 
4.5 h. The reaction mixture was cooled to room temperature and 
then extracted with a saturated solution of NaHC03 (5 x 25 mL) and 
water (2 x 25 mL) . Excess concentrated HCl was added to the 
aqueous extract and the white solid which precipitated was 
collected by filtration and dried to yield 8.58 g (61%) of product 
that was pure enough to be used in the next step; m.p. 141-2 °C. 
4-Ch1oro-3-cyc1ohexy1methoxy-7-nitroisocoumarin. A 
solution of cyclohexanemethyl 4-nit:ro-2-carboxyphenylacetate (8.58 
g, 27 mmol) and PCls (13.9 g, 67 mmol) in 100 mL of benzene was 
heated to :reflux temperature for 4 h and then the solvent was 
removed in vacuo. The residue was .recrystallized from 95% EtOH to 
yield the product as bright yellow needles (5.13 g, 56%); m.p. 
102-104 oc .. 
7-Amino-4-ch1oro-3-c:yc1ohe:xy1methoxyisocoumarin. 
Palladium on charcoal (150 mg, 5% catalyst) was added to a 
solution o:f 4-chloro-3-cyclohexylmethoxy-7-nitroisocoumarin (1.24 
g, 3.7 mmol) in 200 mL of EtOAc and the resulting mixture was 
stirred under a hydrogen atmosphere for 6 h at atmospheric 
pressure. The catalyst was then removed by filtration through a 
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bed of Celite and the filtrate was concentrated to dryness in 
vacuo. The residue was rec1~ystallized from ethanol/water to yield 
the product as bright yellow needles (801 mg, 71%); m.p. darkens 
>180 °C. lH NMR (d6-MeS04) 0: 7.4 (d, 1H), 7.25 (d, 1H), 7.14 (d 
of d, 1H), 5.76 (br. s, 2H), 4.05 (d, 2H), 1.76-1.58 (m, 6H), 
1.30-0.98 (m, 5H). Anal Calcd. for C16H1aClN03: C, 62.44; H, 5.89; 
N, 4.55; Cl, 11.52. Found: C, 62.50; H, 5.93; N, 4.51; Cl, 11.42. 
Diphenyl N-benzyloxycarbonylamino(4-cyanophenyl)-
methanephosphonate. Obtained from 9.75 g 4-cyano-benzaldehyde, 
7.65 g benzyl carbamate and 13.5 ml of triphenyl phosphite in 20 
ml of glacial acetic acid
4
, according to procedure described 
earlier (Oleksyszyn J, Subotkowska :L, Mastalerz P, SYNTHESIS, 
1979,985). Yield 70%; mp. 135-138 °C; Anal. Calcd. for C29H2305N2P 
. 1/2 H20: C, 66.27; H, 4.73; N, 5.52. Found; C, 66.03; H, 4.51; 
N, 5.49. 
Diphenyl N-benzyloxycarbonylamino(4-amidinophenyl)-
methanephosphonate hydrochloride. A solution of 7 g diphenyl 
Z-benzyloxycarbonylamino(4-cyanophenyl)-methanephosphonate in 150 
mL of dry chloroform and 15 mL of absolute ethanol was saturated 
with dry HCl at 0 oc. The reaction mixture was kept in the 
refrigerator until TLC showed no presence of starting material 
(about 24 h) . An excess of pentane was added and the precipitate 
was removed by filtration and dried under high vacuum. The solid 
was dissolved in 200 ml of dry methanol and gaseous dry ammonia 
was bubbled through the solution (one equivalent is required) for 
approximately 20 min. Methanol and excess amonnia were removed as 
fast as possible in the rotary evaporator. A portion of fresh 
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methanol (100 mL) was added and the solution was heated at 50 °C 
by about 8 h, until TLC shows no presence of imino ether. The 
solvent was evaporated and the resulting oil was dissolved in 
chloroform. Addition of ether caused separation of an oil which 
solidified after a while. The solid that resulted was again 
dissolved in chloroform, the solution was filtered and the solid 
product was precipitated using ether. In several experiments the 
yields were 70-80%; mp. 154-158 oc (decamp); 31p NMR 14,87 ppm. 
Anal. Calcd. for C28H2705N3ClP·0.3NH4Cl·H20; C, 57.41; H, 5.16; 
N, 7.52; Cl, 7.31. Found; C, 57.75; H, 5.00; N, 8.86; Cl, 7.43. 
Diphenyl amino(4-amidinophenyl)methanephosphonate 
dihydrochloride. A sample of 1.8 g of diphenyl N-benzyloxy-
carbonylamino(4-amidinophenyl)methanephosphonate hydrochloride was 
dissolved in 150 mL of 2N HCl/methanol solution and after addition 
of 5% Pd/C catalyst the resulting mixture was stirred under an 
atmosphere of hydrogen until the theoretical amount of hydrogen 
was consumed. The catalyst was removed by filtration and after 
evaporation of methanol a residue was crystallized from ethanol-
ether. In several experiments the yields were 60-80%; mp. 213-
215 °C; Anal. Calcd. for C20H22N3CJ.P·1/2H20: C,51.85; H, 4.97; N, 
9.08; Cl, 15.34. Found: C, 51.73; H, 5.02; N, 9.10; Cl, 15.36. 
4-Chloro-3-methylisocc>umarin. To a stirred solution of 
10 g (0.06 mol) of 3-methylisocoumarin (Tirodkar,R.B. and 
Usgaonkar, R. N. J. Ind. Chem. Soc. 1969 46, 935) in 25 mL of DMF 
was added 11.16 g (0.08 moles) of N-chlorosuccinimide and the 
reaction mixture stirred at: room temperature overnight. The 
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reaction mixture was then diluted with ether and the ether layer 
was washed successively with 10 % HCl, 5 % NaHC03, water and 
finally dried over anhydrous MgS04. Ether was evaporated and the 
solid obtained was recrystallized from hexane to give 3.5 g (29 %) 
of the title compound as yellowish needles; m.p. 91-93 oc; H1 NMR 
(CDC l3 ) 0 : 2 . 4 8 ( s , 3 H) , 7 . 55 ( m, 1 H) , 7 . 8 0 ( m, 2 H) , 8 . 31 ( d, 1 H) . 
Anal. Calcd. for c 1 oH7Cl02 0.2 H20 : C, 60.54; H, 3.53; Cl, 17.91. 
Found : C, 60.68; H, 3.66; Cl, 17.98. 
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Prog:r:ess Report. Three new •compounds have been synthesized 
this quarter and submitted for testing as antivesicants. The 
compounds are 2-phenylamino-4H-3, 1-·benzoxazin-4-one, 2-
Benzylamino-4H-3,1-benzoxazin-4-one, and 4-cyanophenyl p-guanidino 
benzoate. The structures are shown below. 
0 
~0 





2-Phenylamino benzoxazin-4-one was prepared by the 
cyclodehydration of 2-(3-phenylureido)benzoic acid. The latter was 
prepared by the reaction of phenyl isocyanate with anthranilic 
acid in THF. 
Page 2 
+ 
2-Benzylamino-4H-3,1-benzoxazin-4-one was also prepared by a 
cyclodehydration reaction using H2S04 as the dehydrating agent. 
The starting compound for this reaction was methyl 2-(3-
benzylureido)benzoate. This in turn was prepared by the reaction 




4-Cyanophenyl p-guanidinobenzoate was prepared from p-
guanidinobenzoic acid and 4-cyanophenol using DCC as the coupling 
agent. 
Bioloqical Assays o ~rhe new compounds have not yet been 
assayed with various proteases 
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EXPERIMENTAL SECTION 
2-Phenylamino-4H-3,1-benzoxazin-4-one. Phenyl isocyanate 
(3.57 g, 0.03 mol) was dissolved in 10 mL THF and to this stirred 
solution was added anthranilic acid (4.1 g, 0.03 mol) and the 
reaction stirred overnight at room temperature. The solvent was 
then removed under reduced pressure to get 2-(3-phenylureido) 
benzoic acid as a white solid. 
The product from the above reaction (3.84 g) was dissolved in 
10 mL cone. H2S04 and kept at room temperature for 1 h. The 
reaction was then poured over ice, neutralized with saturated 
NaHC03 solution, the precipitated white solid filtered and dried 
in air and recrystallized from benzene to get the title compound 
as white crystals; m.p. 191·-192 oc. 1H NMR (DMSO-d6) o: 7 01-8 0 0 
(aromatic). Anal. Calcd.for C14H10N202 0.27 H20 : C, 69.13; H, 
4.12; N, 11.52. Found: C, 69.10; H, 4.32; N, 10.71. 
2-Benzylamino-4H-3,1-benzoxazin-4-one. To a stirred 
solution of benzylamine {634 mg, 0.0059 mol) in dry THF {40 mL) 
was added 2-carbomethoxy phenylisoc:yanate (1 g, 0.0056 mol) and 
the reaction stirred at room temperature overnight. The solvent 
was removed under reduced pressure to obtain methyl 2-(3-
benzylu·reido) benzoate as a white solid. 
The product {1.13 g) from the reaction above was dissolved in 
2 mL cone. H2S04 and left at room temperature for 1 h. The 
re~ction was worked up as in the previous experiment and the 
product recrystallized from ethyl acetate-benzene to get the title 
compound a.s a white solid; m.p. 177-178 oc. 1H NMR (DMSO-d6) o: 4.3 
(d, 2H, -CH2-), 6.9-8.4 (a:r:·omatic),. 10.2 (s, 1H, NH) o Anal. 
Calcd. for C1~H12N202 x 1.1 H20: C, 66.17; H, 5.22; N, 10.29. 
Found: C, 66.20; H, 5.24; N, 10.15. 
4-Cyanophenyl p-GuallLidino l3enzoate. Dicyclohexyl 
carbodiimide (2.33 g, 11.3 rnmol) was added to a solution of p-
guanidinobenzoic acid hydrochloridE~ {2. 43 g, 11.3 rnmol) in 50 mL 
pyridine. 4-Cyanophenol {1.34 g, 11.3 rnmol) was added to this 
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solution and the resulting mixture was stirred at room temperature· 
for 14 h with protection from moisture. Dicyclohexylurea was 
removed from the reaction mixture by filtration and the filtrate 
was concentrated in vacuo to a foant which was triturated with 30 
mL EtOAc. The beige solid that resulted was collected by 
filtration and washed throughly with EtOAc. The crude product 
(2.5 g) is taken up in approx. 3 L of water and the solid 
remaining is removed by filtration through a bed of Celite. The 
filtrate was lyophilized to obtain 1.75 g (70 %) of pure product; 
m.p. 160-62 oc. 1H NMR (d6-Me2SO) 0: 10.58 (s, 1H), 8.18 (d, 2H), 
7.99 (d, 2H), 7.88 (br.s., 3H), 7.52 (d, 2H), 7.42 (d, 2H). Anal. 
Calcd. for C15H13ClN402 x 1.98 H20: C, 51.13; H, 4.85; N, 15.90. 
Found: C, 51.13; H, 4.70; N, 15.79. 
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This quarter, we have focused on the 
synthesis of inhibitors for tryptase and related enzymes such as 
plasminogen activator. Three new compounds have been synthesized 
this quarter and one was submitted for testing as an antivesicant. 
The other two will be submitted shortly. The compounds are 1-(4-
amidinophenyl)-3-phenylurea•hydrochloride (1), 1-(4-
amidinophenyl)-3-(4-chlorophenyl)urea•hydrochloride (2), and N-(4-
amidinophenyl)-4-(phenylcarbamoylamino)benzamide (3). The 





The inhibitory potency of these compounds and several 
compounds which we submitted in the previous quarters was tested 
towards porcine pancreatic elastase (PPE), human leukocyte 
elastase (HLE) , chymotrypsin, cathE~psin G, trypsin and human lung 
tryptase. The values for the inhibition constants are reported in 
the table in the Biological Assays section. 
Synthesis. The synthesis of p-guanidino benzoic acid 
derivatives was discontinued due to numerous problems ~n the 
synthetic/purification procedures \vhen the substituents on the 
carboxyl group were more complex aromatic structures than a single 
phenyl group. We are presently concentrating on derivatives of 4-
aminobenzamidine as inhibitors for trypsin-like enzymes. Although 
the synthesis and purification procedures are still difficult, 
better results are being obtained 1..rith more complex aromatic 
structures containing benzamidine-like moieties. 
Numerous attempts to make 1-(4-amidinophenyl)-3-phenylurea 
(1) and its 4-chloro analog (2) by condensing 4-aminobenzamidine 
with phenylisocyanate and 4-chlorophenylisocyanate failed. These 
compounds were finally made by a different route. 1-(4-
AmidinophE~nyl) -3-phenylurea (1) was finally prepared starting from 
4-am~nobenzonitrile. Phenylisocyanate and 4-aminobenzonitrile 
were condensed in refluxinsr benzene and the resulting urea was 
converted to the imidate ester by treatment with dry methanol in 
the presence of dry HCl. 'l'he final amidino compound was obtained 
by refluxing the imidate ester in isopropanol saturated with dry 
ammonia. The product was isolated as its hydrochloride salt and 
was submitted this quarter. 











1-(4-Amidinophenyl}-3·-(4-chlorophenyl)urea (2) was prepared 
using the same reaction scheme except that phenylisocyanate was 
replaced by 4-chlorophenylisocyanate. This compound is ready to 
be submitted. 
N-(4-Amidinophenyl}-4·-(phenylcarbamoylamino)benzamide (3) was 
synthesized by DCC coupling of 4-(phenylcarbamoylamino}benzoic 
acid with 4-aminobenzamidine using 1-hydroxybenzotriazole in DMF. 
The acid was prepared from 4-aminobenzoic acid and phenyl 
isocyanate as depicted below. 
0 
~=O THF/Benzen~ ~ 0 ~OH v r.T. ~NJlN,JV 
H H 
DCC I HOBt I N Et3 
----------------------
3 
Ready to Submit 
An attempted synthesis of this compound by the acid chloride 
method gave very complex reaction mixtures from which no product 
could be isolated. In addition, the desired product was not 
formed when 1-hydroxybenzotriazole was omitted in the DCC coupling 
procedure and instead we obtained the N-acyl urea derivative of 
DCC and the starting acid. N-Acyl ureas are isolated as 
byproducts of DCC coupling reactions when the intermediate 0-acyl 
urea fails to react fast enough with the amine component in the 
reaction mixture. 
Biological Assays. Two of the inhibitors showed moderate 
inhibition of porcine pancreatic elastase and chymotrypsin and two 
were excellent trypsin and human lung tryptase inhibitors. These 
lead compounds will be pursued to prepare yet better inhibitors. 
Results are summarized in Table I. 
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EXPERIMENTAL SECTION 
1-(4-Amidinophenyl)-3-phenylurea. To a stirred solution 
of 4-aminobenzonitrile (4.72 g, 0.04 mol) in dry benzene (200 
mL)was added phenylisocyanate (9.52 g, 0.08 mol) and the resulting 
solution refluxed for 5 h and further stirred at room temperature 
overnight. The precipitatE=d solid was filtered and recrystallized 
from methanol to get the urea as a white crystalline solid (8.3 
g) . 
Dry HCl gas was passed through a solution of the urea (4.74 
g, 0.02 mol) in dry dimethoxyethane (100 mL} for 1 h. The 
reaction mixture was then stirred at room temperature for 24 h. 
The precipitated imidate ester was filtered and stored over KOH in 
a vacuum desiccator (3.5 g) for 24 h. 
The imidate ester (2 g, 0.006 mol) was dissolved in 
isopropanol saturated with ammonia (100 mL) and the reaction 
mixture was refluxed for 6 h and further stirred at room 
temperature overnight. The solvent was then evaporated under 
reduced pressure, a white solid that was obtained, and this was 
recrystallized from 2N HCl to get the title compound as its HCl 
salt (1.5 g); m. p. 240 °C (decomp.). lH NMR (DMSO-d6) 0: 7.00 (t, 
1H}, 7.30 (t, 2H), 7.45 (d, 2H), 7.65 (d, 2H), 7.80 (d, 2H}, 8.80 
( s , 2 H) , 9 . 15 ( s , 2 H} , 9 . 4 0 ( b s , 1 H) , 9 . 8 0 ( b s , 1 H) . An a 1 . C a 1 c d . 
for C14H15ClN40·H20: C, 54.53; H, 5.56; Cl, 11.35; N, 18.18. 
Found: C, 54.53; H, 5.46; Cl, 11.42; N, 18.13. 
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Table I. Inhibition of Bovine Trypsin, Human Lung Tryptase, Human Leukocyte Elastase, Porcine Pancreatic Elastase, 
Chymotrypsin, and Cathepsin G by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Benzoxazinones and Aminobenzamidine 
Derivatives. a 
kobs/[I] (M -1 s-1) 
Inhibitor Bovine Human Lung 
Try:f!Sinb TryEtasec fiLEd PPEd Ch'fd Catod 
Isocoumarin Derivatives 
4-chloro-3-methyl IC N~ N1'e 72%f Nlg 66 8 
4-chJoro-3-methoxy IC N~ me 87 601 206 25 
Benzoxazinones 
2-phenylamino-4H-3, 1-benzoxazin-4-one Nrre N1'e Nlg 216 77 reactivates 
2-benzylamino-4H-3,1-benzoxazin-4-one Nrre N'J:'e Nlg Nlg Nlg Nig 
Guanidinobenzoic Acid Derivatives 
4-cyanophenyl p-guanidinobenzoate 150,000 91,000 
Aminobenzamidine Derivatives 
N -( 4-amidinopheny 1 )- 14,000 600 
4-(phenylcarbamoylamino )benzamide 
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Table III (Continued). 
alnactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 f.!M; Human Lung Tryptase, 
0.02 f.!M; HLE, 0.3 f.!M; PPE, 1.6 ~; Chymotrypsin, 1.6 f.!M; Cathepsin G, 1.6 f.!M. Bovine trypsin and human lung tryptase 
were assayed with Z-Arg-SBzl·HCl (0.07 mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). HLE was assayed with MeO-
Suc-Ala-Ala-Pro-Val-NA (0.5 mM). PPE was assayed with Suc-Ala-Ala-Ala-NA (0.75 mM). Chymotrypsin (ChT) and Cathepsin 
G (CatG) were assayed with Suc-Val-Pro-Phe-NA (0.5 f.!M). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCl2, pH 7.5 and 8-12% Me2SO at 25 °C. LYlhibitorconcentrations were as 
foiiows: 4-cyanophenylp-guanidinobenzoate, 0.46 f.!M; N-(4-amidinophenyl)-4-(phenylcarbamoylamino)benzamide, 1.22 f.!M. 
cconditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as follows: 
4-cyanophenyl p-guanidinobenzoate, 0.22 ~1; N-(4-arnidinophenyl)-4-{phenylcarbamoyiamino)benzamide, 11.6 f.!M. 
dconditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were in the range 
41 f.!M-1mM. 
eNot tested. 
finhibition was not time dependent. 
gNo inhibition. 
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Hernandez left this project at the end of the quarter and will not 
be reduced. 















Progress Report. This qua1:ter we have continued the 
synthesis of inhibitors for the tryptase family of serine 
proteases. Six new compounds wez~e synthesized this quarter and 
submitted for testing as antivesicants. The compounds are 1,2,3-
benzotriazole-1-(4-phenylcarbamoylaminophenyl)carboxylate, N-(2-
isothioureido}ethyl phtalimide hydrobromide, 1,2,3-benzotriazole-
1-benzoate, 1-{4-amidinophenyl)-3-(4-chlorophenyl)urea, 1-(4-
amidinophenyl}-3-(4-chlorophenyl)urea, and 1-{4-amidinophenyl)-3-
(4-phenoxyphenyl)urea. Their structures are shown below. 
N=N ~-o- -o oN-o-c ~ J NHCONH ~-D 
~ NH 
~N'-../"-.s--1{ • HBr 
0 NH2 
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Cl-0-' NHCONH~NH . HCI 
-- ~--~ NH2 
Q-o-0-NHCONH--o--<:~ HCI 
2 
The inhibitory potency of these compounds was tested towards 
trypsin. A complete compilation of the biological data obtained 
with the compounds submitted to date will be included in the 
Annual Report. 
Synthesis. The synthesis of N-(4-amidinophenyl)-4-
(phenylcarbamoylamino)benzamide was discussed in the last 
quarterly report and at that time the compound was reported as a 
mixture of salts because the elemental analysis could not be 
matched with the expected structure. The fact that it was a good 
trypsin and human lung tryptase inhibitor further suggested that 
it must contain the amidino moiety in its structure. On the other 
hand, all the analytical data could be explained by a compound 
with the structure corresponding to an acylated 1-hydroxy-1,2,3-
benzotriazole, namely, 1,2,3-benzotriazole-1-(4-phenylcarbamoyl· 
aminophenyl)carboxylate. ~rhe compound is therefore reported as 
such in the Experimental Scection. A spectrophotometric study of 
the hydrolysis of this compound in the buffer used to assay 
inhibition of trypsin shows at least two isosbestic points over a 
5 h period. However, no significant hydrolysis was observed 
during the short time periods used in the inhibition assays and 
therefore the inhibition constants reported are accurate values. 
Kinetic studies are being performed to elucidate a mechanism for 
the inhibition of trypsin by this compound. The benzoyl 
derivative was made in order to compare its inhibition of trypsin 
with that of the more complex derivative discussed above. It was 
also made in order to ascertain if an acyl derivative of 1-
hydroxy-1,2,3-benzotriazole could indeed inhibit trypsin. We 
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found this to be the case, and 1,2,3-benzotriazole-1-benzoate had 
a kobs/[I] value of 1,100 M~1s-1 towards trypsin. It was made by 
acylation of 1-hydroxy-1,2,3-benzotriazole with benzoyl chloride 
in THF/pyridine. This type of inhibitors are a new and 
interesting class of trypsin inhibitors and mechanistic studies 
will help us elucidate their mode of action. 
The synthesis of N-(2-isothioureido)ethyl phtalimide 
hydrobromide was done by alkylation of thiourea with N-(2-
bromoethyl)phtalimide in THF. This compound was modeled after the 
isothioureido isocoumarins prepared in our laboratories which have 
showed significant inhibitory potency towards trypsin and trypsin-
like enzymes. 
1- ( 4-Amidinophenyl) -~3- ( 4-chlorophenyl) urea, 1- ( 4-
amidinophenyl)-3-benzylurea. and 1-(4-amidinophenyl)-3-(4-
phenoxyphenyl)urea were made using essentially the same set of 
reactions. Some modifications were required in going from one 
product to the other. These changes are clearly noted in the 
Experimental Section. Following is a general procedure used for 
making all the amidino compounds submitted so far. 
4-Aminobenzonitrile was condensed with the corresponding 
isocyanate in refluxing benzene. The resulting urea was converted 
to the imidate ester by treatment ~~ith methanol in the presence of 
HCl. The imidate ester on refluxing with isopropanol saturated 
with dry ammonia gave the desired amidino compound. All the 
amidino compounds were isolated as their hydrochloride salts. A 
general reaction scheme is shown below. 
HCI/MeOH 
NH -o-<NH -3-~ RNHCONH f ' · HCI 




carboxylate. Triethylamine (0.19 mL, 1.4 mmol) was added to a 
solution of 4-aminobenzamidine dihydrochloride (284 mg, 1.4 mmol) 
in 6 mL DMF. 1,3-Dicyclohexylcarbodiimide (311 mg, 1.5 mmol) was 
then added, followed by 1-hydroxy-1,2,3-benzotriazole (185 mg, 1.4 
mmol) . This mixture was cooled to 10 °C and 4-phenylaminocarbamoyl 
benzoic acid was then added (350 mg, 1.4 mmol). The reaction 
mixture was stirred at 5-10 °C for 14 h and dicyclohexylurea was 
removed by filtration. It was washed with fresh DMF, and the 
filtrate was concentrated to dryness and coevaporated with acetone 
to obtain an amorphous whit:e solid that was washed with CHCl3: EtOH 
4:1 to obtain 225 mg (40 %) of pure product as a white solid; mp 
217-8 °C (dec) . The product can be recrystallized from 
CHCl3/DMF/hexane. 1H NMR (DMSO-d6) 0: 9.45 (br s, 1H); 8.96 (br s, 
1H); 8.22 (d, 2H); 8.18 (d, 1H); 7.85 (d, 1H); 7.78 (d, 2H); 7.67 
(t, 1H); 7.54 (t, 1H); 7.49 (d, 2H); 7.32 (t, 2H); 7.02 (t, 1H). 
Anal Calcd. for C20H15N503•0.2 H20: C, 63.71; H, 4.12; N, 18.58. 
Found: C, 63.71; H, 4.36; N, 18.80. 
N-(2-Isothioureido)ethyl phtalimide hydrobromide. 
N-(2-Bromoethyl)phtalimide (4.6 g, 18 mmol) was dissolved in 50 mL 
THF and then thiourea (1.52 g, 20 mmol) was added in one portion. 
The resulting mixture was heated to reflux temperature for 2 days 
and then allowed to cool to 5-10 oc in an ice bath. The white 
solid in suspension was filtered and washed with THF and hexane to 
yield 3.21 g (54%) of pure product; mp 245-6 °C (dec). 1H NMR 
(DMS0-d6) 0: 9. 04 (br s, 4H); 7. 86-7.91 (m, 4H); 3. 87 (t, 2H); 3. 49 
(t, 2H). Anal. Calcd. for C11H12BrN302S: C, 40.01; H, 3.66; N, 
12.73; Br, 24.20. Found: C, 40.10; H, 3.71; N, 12.72; Br, 24.14. 
1,2,3-Benzotriazole-1-benzoate. A solution of benzoyl 
chloride (6.2 mL, 53 mmol) in 30 mL of THF was added dropwise to a 
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pyridine (4.3 mL, 53 mmol) in 65 mL THF. The resulting mixture 
was stirred at room temperature for 24 h under protection from 
moisture, and the solvent was then removed under vacuum. The 
white solid obtained was purified by low temperature 
recrystallization from CHCl3/hexane and cooling at 0-5 °C for 2 
days. The pure product was obtained as a white solid (5.15 g, 47 
%); mp 78-9 °C. A second crop can be obtained from the mother 
liquor by concentration to 2/3 of the volume, addition of hexane, 
and further cooling at 0-5 °C for 2 days. 1H NMR (DMSO-d6) o: 
7. 98-7.92 (m, 3H); 7. 72 (d, 1H); 7. 64-7.38 (m, 5H) . Anal. Calcd. 
for C13H9N302: C, 65.26; H, 3.79; N, 17.56. Found: C, 65.36; H, 
3.81; N, 1.7.61. 
1-(4-Amidinophenyl)-3-(4-c.hlorophenyl)urea 
hydrochloride. To a stirred solution of 4-aminobenzonitrile 
(4.72 g, 0.04 mol) in dry THF (50 mL) was added 4-
chlorophenylisocyanate (6.1.2 g, 0.04 mol) in one portion and the 
reaction stirred magnetically overnight. The separated white solid 
was filtered out and recrystallized from methanol ~o get the cyano 
urea as a white crystalline solid (9.2 g, 85 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (5.43 g, 0.02 mol) and dry methanol (3.2 g, 0.10 mol) in dry 
dimethoxyethane (100 mL) for 2 h and the reaction further stirred 
at room temperature for 36 h. Solvent was then evaporated under 
reduced pressure and the imidate ester obtained as a yellow solid 
was stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (6 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white crystals of the title compound (4.8 g, 84 %); mp 275 
°C (dec.) . 1H NMR (DMSO-d6) 0: 7. 32 (d, 2H) ; 7. 50 (d, 2H) ; 7. 66 (d, 
2H); 7.80 (d, 2H); 8.85 (s, 2H); 9.18 (s, 2H); 9.70 (s, 1H); 9.98 
(s, 1H). Anal. Calcd. for C14H14Cl2N40•0.69 H20: C, 49.80; H, 
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4.58; Cl, 21.01; N, 16.59. Found: C, 50.21; H, 4.62; Cl, 20.73; N, 
16.19. 
1- ( 4-Amidinophenyl.) -·3-benzyl.urea hydrochl.oride. To a 
stirred solution of 4-ami.nobenzonitrile (3.9 g, 0.03 mol) in dry 
benzene ( 1.00 mL) was adde~d benzylisocyanate ( 4. 5 g, 0. 03 mol) in 
one portion and the reaction heated under reflux for 6 h and 
stirred magnetically at room temperature overnight. The separated 
white solid was filtered out and recrystallized from methanol to 
get the cyano urea as a white crystalline solid (6.1 g, 72 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (3 g, 0.012 mol) and dry methanol (1.92 g, 0.060 mol) in dry 
dimethoxyethane (150 mL) for 2 h and the reaction further stirred 
at room temperature for 24 h. Solvent was then evaporated under 
reduced pressure and the imidate ester obtained as a yellow solid 
was stored in a vacuum desiccator over KOH for 24 h (3.2 g). 
The imidate ester (3.2 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained recrystallized from 2N HCl to 
get white crystals of the title compound (3 g, 84 %); mp 292 °C 
(dec,.) . 1H NMR (DMSO-dG) 0: 4. 31 (d, 2H); 7.17 (t, 1H); 7. 20-7.38 
(m, SH); 8.82 (s, 2H); 9.12 (s, 2H); 9.66 (s, 1H). Anal. Calcd. 
for C1sH17Cl2N40: C, 59.11; H, 5.62; Cl, 11.63; N, 18.38. Found: 
C, 59.23; H, 5.64; Cl, 11.63; N, 18.28. 
1-(4-Amidinophenyl)-3-(4-phenoxyphenyl.)urea 
hydrochl.oride. To a stirred solution of 4-aminobenzonitrile 
(2.95 g, 0.025 mol) in dry benzene (50 mL) was added 4-
phenoxyphenylisocyanate (5.25 g, 0.025 mol) in one portion and the 
reaction heated under reflux for 10 h and stirred at room 
temperature overnight. The~ separated white solid was filtered out 
and recrystallized from methanol to get the cyano urea as a white 
crystalline solid (6.5 g, 79 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (5 g, 0.015 mol) and dry methanol (2.43 g, 0.075 mol) in dry 
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dimethoxyethane (100 mL) for 2 h and the reaction stored in the 
refrigerator for 48 h. Solvent was then evaporated under reduced 
pressure and the solid obtained stored in a vacuum desiccator over 
KOH for 24 h. 
The imidate ester (5 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 7 h 
and further stirred at room temperature for 24 h. Solvent was 
evaporated and the solid obtained recrystallized from 2N HCl to 
get white crystals of the t.itle compound (4. 6 g, 95 %) ; mp 202-205 
°C. 1H NMR (DMSO-d6) 0: 6.90-7.01 (m, 4H); 7.09 (t, 1H); 7.35 (m, 
2H); 7.47 (m, 2H); 7.65(d, 2H); 7.80 (d, 2H); 8.80 (s, 2H); 9.15 
(s, 2H); 9.39 (s, 1H); 9.75 (s, 1H). Anal. Calcd. for 
C2oH1gCl1N402•0.7 H20: C, 60.74; H, 5.16; Cl, 8.98; N, 14.17. 
Found: C, 60.36; H, 5.05; Cl, 9.00; N, 14.08. 
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Progress Report. We continued to work on the synthesis of 
inhibitors for trypsin-like enzymes this quarter. Five new 
compounds were synthesized and submitted for testing as 
antivesicants this quarter. The compounds are (4·-amidinobenzyl) 
benzyl ether hydrochloride {GP 9), bis(4-amidinophenyl)urea 
dihydrochloride (GP 10), 1-(3-amidinophenyl)-3-phenylurea 
hydrochlo:ride (GP 11), { 4-amidinobenzyl) phenylethyl ether 
hydrochloride (GP 12), 1-(3-amidinophenyl)-3-{4-phenoxyphenyl)urea 




GP 11 GP 12 
GlP 13 
The inhibitory potency of these compounds was tested with 
trypsin. A complete compilation of the biological data obtained 
for the compounds submitted to date will be included in the Final 
Report. 
Synthesis. (4-Amidinobenzyl)benzyl ether (GP 9) was 
synthesized from the cyano ether obtained by the reaction of 
sodium benzyloxide and a-bromo-p-tolunitrile. The cyano ether was 
converted to the imidate ester by treating with dry methanol in 
the presence of HCl. The imidate ester on reacting with ammonia 
gave the desired amidino compound. 
(4-Amidinobenzyl)phenylethyl ether hydrochloride (GP 12) was 
prepared by replacing benzyl alcohol with phenylethyl alcohol and 
keeping the rest of the procedure as in GP 9. 
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Bis(4-amidinophenyl)urea dihydrochloride (GP 10) was made by 
condensing 4-aminobenzamidine dihydrochloride with urea. 
cr + 
1-(3-amidinophenyl)-3-phenylurea hydrochloride (GP 11) was 
prepared starting from 3-aminobenzonitrile. Phenyl isocyanate and 
3-aminobenzonitrile were condensed in refluxing benzene and the 
resulting urea was converted to the imidate ester by the treatment 
with dry methanol in presence of dry HCl. Refluxing the imidate 
ester in dry isopropanol saturated with ammonia afforded the 
desired amidino compound. 
1- (3·-Amidinophenyl) ·-3- (4-phenoxyphenyl) urea hydrochloride (GP 
13) was prepared using the procedure described above except that 






HCI I MeOH 
EXPERIMENTAL SECTION 
(4-~nidinobenzyl)benzyl ether hydrochloride (GP 9). A 
solution of benzyl alcohol (1.08 g, 0.01 mol) in dry THF {10 mL) 
was added slowly to sodium hydride (2.4 g, 0.10 mol) and the 
suspension stirred at room temperature for 15 min. To this 
stirred suspension was then added dropwise a solution of a-bromo-
p-tolunitrile {1.96 g, 0.01 mol) in dry THF (10 mL) and the 
reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction taken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
Dry HCl was passed through a cooled solution of the cyano 
ether (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporated under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (1 g) was dissolved in dry isopropanol 
saturated with ammonia (50 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white crystals of the title compound (0.41 g, 44 %); mp 
102-104 °C. 1u NMR (DMSO-d 6 ) 0: 4.58 (s, 2H); 4.65 (s, 2H); 7.25-
7.40 (m, 5H); 7.59 (d, 2H); 7.84 (d, 2H); 9.23 (bs, 2H); 9.41 (bs, 
2H). Anal. Calcd. for C15H17Cl1N20: C, 65.10; H, 6.19 Cl, 12.81; 
N, 10.12. Found: C, 64.98; H, 6.20; Cl, 12.73; N, 10.02. 
Bis(4-amidinophenyl)urea dihydrochloride (GP 10). A 
suspension of urea (0.60 g, 0.01 mol) and 4-aminobenzamidine (4.16 
g, 0.02 mol) in water (5 mL) was heated under reflux for 24 h. 
The condenser was then removed and the heating further continued 
for 24 h. The reaction was then trichurated with water (25 mL). 
The solid was filtered out dissolved in water and the clear 
solution acidified with HCl to get the product as a white solid 
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(3 .1 g, 84 %) ; mp >250 °C. 1H NMR (DMSO-d6) 0: 7. 68 (d, 4H); 7. 84 
(d, 4H); 9.00 (s, 4H); 9.23 (d, 4H); 10.45(s, 2H). Anal. Calcd. 
for C1SH18Cl2N60•0.3 H20: C, 48.07; H, 4.96; Cl, 18.96; N, 22.43. 
Found: C, 48.06; H, 5.05; Cl, 19.03; N, 22.55. 
1-(3-Amidinophenyl.)-3-phenylurea hydrochloride (GP 
11). To a stirred solution of 3-aminobenzonitrile {4.72 g, 0.04 
mol) in benzene (100 mL) was added phenyl isocyanate (5.00 g, 
0.042 mol) and the reaction refluxed for 5 h and further stirred 
at room temperature overnight. The separated white solid was 
filtered out and recrystallised from methanol (8.2 g, 84 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (4.00 g, 0.016 mol) and dry methanol (2.7 g, 0.08 mol) in dry 
dimethoxyethane (100 mL) for 2 h and the reaction stored in a 
refrigerator for 14 h. Solvent was then evaporated under reduced 
pressure and the imidate ester obtained, as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (4 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white solid of the title compound (2.1 g, 55%); mp 252-254 
°C . 1 H NMR ( DMSO-d 6 ) 0 : 6 . 9 8 ( t , 1 H) ; 7 . 2 0-7 . 3 5 ( m, 3 H) ; 7 . 4 0 -7 . 5 5 
(m, 3H); 7.70 (d, 1H); 7 .. 95 (s, 1H); 9.1 (bs, 2H); 9.32 (bs, 2H); 
9.45 (bs, 1H); 9.18 (bs, 1H). Anal. Calcd. for C14H15Cl1N40: C, 
57.83; H, 5.20 Cl, 12.19; N, 19.27. Found: C, 57.74; H, 5.20; Cl, 
12.16; N, 19.21. 
( 4-Amidinobenzyl) phe1nylethyl ether hydrochloride (GP 
12) . This compound was prepared using the procedure described for 
compound GP 9 and replacing benzyl alcohol with phenyl ethyl 
alcohol. 1H NMR (DMSO-d6) o: 2.88 (t, 2H); 3.69 (t, 2H); 4.60 (s, 
2H); 7.15-7.30 (m, SH); 7.49 (d, 2H); 7.80 (d, 2H); 9.17 (bs, 2H); 
9.37 (bs, 2H). Anal. Calcd. for C14H14Cl2N40: C, 66.09; H, 6.59; 
C 1 , 12 . 1 9 ;· N, 9 . 6 3 . Found : C , 6 6 . 18 ; H , 6 . 61 ; C 1 , 12 . 0 9 ; N , 9 . 5 6 . 
1-(3-Amidinophenyl)-3-(4-phenoxyphenyl)urea 
hydrochloride (GP 13) . This compound was prepared using the 
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procedure described for compound GP 11 and substituting 4-
phenoxyphenyl isocyanate for phenyl isocyanate. 1H NMR (DMSO-d6) 
o: 6.91-7.20 (m, 4H); 7.10 (t, 1H); 7.30-7.40 (m, 3H); 7.45-7.58 
(m, 3H); 7.70(d, 1H); 7.95 (s, 1H); 9.00 (s, 2H); 9.34 (s, 1H); 
9.36 (s, 2H); 9.55 (s, 1H). Anal. Calcd. for C20H19Cl1N402·0. 75 
H20: C, 60.60; H, 5.17; Cl, 8.96; N, 14.14. Found: C, 60.62; H, 
5.19; Cl, 8.96; N, 14.05. 
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Dr. Patil worked on this project until the end of June and so the 
percent time represents only May and June. For the quarter, his 
percent time would be 66.7 %. 















Progress Report. In the final three months of the project 
work on the sythesis of tryptase inhibitors was continued. Two 
new compounds were synthesized and submitted for testing as 
antivesicants during this period. The compounds are (4-
amidinobenzyl)-3-phenylpropyl ethe:r hydrochloride (GP 14) and (4-
amidinobenzyl) 3-phenoxybenzyl ethe:r hydrochloride (GP 15) . Their 





A complete compilation of the biological data obtained for 
the compounds submitted to date will be included in the Final 
Report. 
Syntb.esis. (4-Amidinobenzyl)-3-phenylpropyl ether (GP 14) 
was synthesized from the cyano ether obtained by reaction of 
sodium phenylpropyloxide and a-bromo-p-tolunitrile. The cyano 
ether was converted to the imidate ester by treating it with dry 
methanol in the presence of HCl. The imidate ester on refluxing 
with a saturated solution of ammonia in isopropanol gave the 
desired amidino compound. 
(4-Amidinobenzyl) 3-ph•:noxybenzyl ether hydrochloride (GP 15) 
was prepared by replacing phenylpropyl alcohol with 3-
phenoxybenzyl alcohol and keeping the rest of the procedure as in 
GP 14. 
ROH +BrCH2~CN ---- ROCH2~CN HCI •~ '-=J '*==T- . MeOH 
EXPERIMENTAL SECTION 
(4-Amidinobenzyl) -p3-phenylpropyl ether hydrochloride 
(GP 14). A solution of 3-phenylpropyl alcohol (2.72 g, 0.02 mol) 
in dry THF (20 mL) was added slowly to sodium hydride (2.4 g, 0.10 
mol) and the suspension stirred at room temperature for 15 min. 
To this stirred suspension was then added dropwise a solution of 
a-bromo-p-tolunitrile (3.92 g, 0.02 mol) in dry THF (20 mL) and 
the reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction taken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
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Dry HCl was passed through a cooled solution of the cyano 
ether (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h. and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporated under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (1 g) was dissolved in dry isopropanol 
saturated with ammonia (50 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. The solvent 
was evaporated and the solid obtained was recrystallized from 2N 
HCl to get white crystals of the title compound (0.295 g, 31 %); 
mp 76-78 oc. 1H NMR (DMSQ--·d6) 0: 1. 84 {m, 2H); 2. 62 {t, 2H); 3. 45 
(t, 2H); 4. 55 (s, 2H); 7.10-7.90 {aromatic, 9H); 9. 20 (bs, 2H); 
9.45 (bs, 2H). Anal. Calcd. for C17H21Cl1N20: C, 66.99; H, 6.94 
Cl, 11.63; N, 9.19. Found: C, 67.05; H, 6.95; Cl, 11.54; N, 9.20. 
(4-Amidinobenzyl)-3-phenoxylbenzyl ether hydrochloride 
(GP 15). This compound was prepared using the procedure 
described for compound GP 14 and replacing 3-phenylpropyl alcohol 
with 3-phenoxylbenzyl alcohol. 1H NMR {DMSO-d6) 0: 4.55 {s, 2H); 
4.63 (s, 2H); 6.95-7.80 {art:)matic, 13H); 9.16 (bs, 2H); 9.40 (bs, 
2H). Anal. Calcd. for C21H21Cl1N202: C, 68.38; H, 5.74; Cl, 9.61; 
N, 7.59. Found: C, 68.20; H, 5.78; Cl, 9.48; N, 7.44. 
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During the last portion of this contract, we focused on 
inhibitors for trypsin-like enzymes since Smith et al. [Smith, w. 
J., Cowan, F. M., and Broomfield, C. A. 1991, FASEB Journal 5, 
A828] have recently reported increased hydrolysis rates for 
substrates of trypsin-like enzymes (tryptases) by mustard 
stimulated lymphocytes. Thus, these enzymes may be significant 
proteases involved in blistering. Aromatic benzamidine 
derivatives are reversible inhibitors for trypsin-like enzymes and 
we prepared a series of derivatives to see if we could increase 
their inhibitory potency for tryptases. The most potent inhibitor 
thus far for both trypsin and the human lung tryptase is 1-
(amidinophenyl)-3-(4-phenoxyphenyl)urea {GP 8) which has a Kr 
value of 1.6 ~M with bovine trypsin and inhibits 71% of the 
activity o~f human lung tryptase at 226 ~· Tables with complete 
biological data are included in the final report. 
SYNTHESIS 
Benzam.idines. Six new benzarnidines were synthesized in the 
final six months of the project We successfully overcame the 
initial difficulties in the synthesis of these class of compounds 
and submitted a total of eleven benzamidines. The last compounds 
submitted are (4-amidinobenzyl) benzyl ether hydrochloride (GP 9), 
bis{4-amidinophenyl)urea dihydrochloride (GP 10), 1-(3-
amidinophe~nyl)-3-phenylurea hydrochloride (GP 11), (4-
amidinobenzyl)phenylethyl ether hydrochloride {GP 12), 1-(3-
amidinophenyl) -3- ( 4-phenox:yphenyl) urea hydrochloride {GP 13), ( 4-
amidinobenzyl)-3-phenylpropyl ether hydrochloride (GP 14) and (4-
amidinobenzyl)3-phenoxybenzyl ether hydrochloride (GP 15). The 
structures are shown below. 
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o-CH2C:CH2-o-' <H2+ Cr - NH2 
GP 9, BM08004 
GP 10, BM08184 
GP 11, BM08308 _}~~/ 
Q-o--0-NHCONH-u 
GP 12, BM08595 
GP 13, BM08764 
~O~:H2CI" 
GP 14, IBM09903 NH2 
GP 15, BM09912 
Synthetic Schemes. (4-Amidinobenzyl)benzyl ether (GP 9) 
was synthesized from the cyano ether obtained by the reaction of 
sodium be:nzyloxide and a-bromo-p-tolunitrile. The cyano ether was 
converted to the imidate ester by treating it with dry methanol in 
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the presence of HCl. The imidate ester on reacting with ammonia 
gave the desired amidino compound. 
( 4-A.midinobenzyl) phenyl ethyl ~ether hydrochloride (GP 12) was 
• prepared by replacing benzyl alcohol with phenylethyl alcohol and 
keeping the rest of the procedure as in GP 9. 
-o-<NH+ ROCH2 2 cr NH2 
(4-Amidinobenzyl)phenylpropyl ether hydrochloride (GP 14) and 
(4-amidinobenzyl)3-phenoxybenzyl e1:her hydrochloride {GP 15) were 
also synthesized using the same method with ROH being phenylpropyl 
alcohol and 3-phenoxybenzyl alcohol respectively. 
Bis(4:-amidinophenyl)urea dihydrochloride (GP 10) was made by 
condensing 4-aminobenzamidine dihydrochloride with urea. 
+ 
1- ( 3-Amidinopheny 1) -·.3 -pheny 1 uJ::ea hydrochloride ( GP 11) was 
prepared starting from 3-aminobenzonitrile. Phenyl isocyanate and 
3-aminobenzonitrile were·condensed in refluxing benzene and the 
resulting urea was converted to the imidate ester by the treatment 
with dry methanol in presence of dry HCl. Refluxing the imidate 
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ester in dry isopropanol saturated with ammonia afforded the 
desired amidino compound. 
1- (3-·Amidinophenyl) -3-· (4-phenoxyphenyl) urea hydrochloride (GP 
13) was prepared using the procedure described above except that 





HCI I MeOH 
----n--
EXPERIMENTAL SECTION 
(4-Almidinobenzyl)benzyl ether hydrochloride (GP 9). A 
solution of benzyl alcohol (1.08 g, 0.01 mol) in dry THF (10 mL) 
was added slowly to sodium hydride (2.4 g, 0.10 mol) and the 
suspension stirred at room temperature for 15 min. To this 
stirred suspension was then add~d dropwise a solution of a-bromo-
p-tolunitrile (1.96 g, 0.01 mol) in dry THF (10 mL) and the 
reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction taken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
Dry HCl was passed through a cooled solution of the cyano 
ether (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporated under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (1 ~r) was dissolved in dry isopropanol 
saturated with ammonia (50 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white crystals of the title compound (0.41 g, 44 %); mp 
102-104 °C. 1H NMR (DMSO-d6) B: 4.58 (s, 2H); 4.65 (s, 2H); 7.25-
7.40 (m, SH); 7.59 (d, 2H); 7.84 (d, 2H); 9.23 (bs, 2H); 9.41 (bs, 
2H). Anal. Calcd. for C15H17Cl1N20: C, 65.10; H, 6.19 Cl, 12.81; 
N, 10.12. Found: C, 64.98; H, 6.20; Cl, 12.73; N, 10.02. 
Bis(4-amidinophenyl)urea dihydrochloride (GP 10). A 
suspension of urea (0.60 g, 0.01 mol) and 4-aminobenzamidine (4.16 
g, 0.02 mol) in water (5 mL) was heated under reflux for 24 h. 
The condenser was then re:moved and the heating further continued 
for 24 h. The reaction was then trichurated with water (25 mL). 
The solid was filtered out dissolved in water and the clear 
solution acidified with HCl to get the product as a white solid 
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(3.1 g, 84 %); mp >250 °C. 1H NMR (DMSO-d6) 0: 7.68 (d, 4H); 7.84 
(d, 4H); 9.00 (s, 4H); 9.23 (d, 4H); 10.45(s, 2H). Anal. Calcd. 
for C15H18Cl2N60•0.3 H20: C, 48.07; H, 4.96; Cl, 18.96; N, 22.43. 
Found: C, 48.06; H, 5.05; Cl, 19.03; N, 22.55. 
1-(3-Amidinophenyl.)-3-phenylurea hydrochloride (GP 
11). To a stirred solution of 3-aminobenzonitrile {4.72 g, 0.04 
mol) in benzene (100 mL) was added phenyl isocyanate (5.00 g, 
0.042 mol) and the reaction refluxed for 5 h and further stirred 
at room temperature overnight. The separated white solid was 
filtered out and recrystallised from methanol (8.2 g, 84 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (4.00 g, 0.016 mol) and dry methanol (2.7 g, 0.08 mol) in dry 
dimethoxyethane (100 mL) for 2 h and the reaction stored in a 
refrigerator for 14 h. Solvent was then evaporated under reduced 
pressure and the imidate ester obtained, as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (4 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white solid of the title compound (2.1 g, 55%); mp 252-254 
°C. 1H NMR (DMSO-d6) 0: 6.98 (t, 1H); 7.20-7.35 (m, 3H); 7.40-7.55 
(m, 3H); 7.70 (d, 1H); 7.95 (s, 1H); 9.1 (bs, 2H); 9.32 {bs, 2H); 
9.45 (bs, 1H); 9.18 (bs, 1H). Anal. Calcd. for C14H15Cl1N40: c, 
57.83; H, 5.20 Cl, 12.19; N, 19.27. Found: C, 57.74; H, 5.20; Cl, 
12.16; N, 19.21. 
(4-Amidinobenzyl) phe1nylethyl ether hydrochloride (GP 
12). This compound was prepared using the procedure described for 
compound GP 9 and replacing benzyl alcohol with phenyl ethyl 
alcohol. 1H NMR (DMSO-d6) 0: 2.88 (t, 2H); 3.69 (t, 2H); 4.60 (s, 
2H); 7.15-7.30 (m, 5H); 7.49 (d, 2H); 7.80 (d, 2H); 9.17 (bs, 2H); 
9.37 (bs, 2H). Anal. Calcd. for C14H14Cl2N40: C, 66.09; H, 6.59; 
Cl, 12.19; N, 9.63. Found: C, 66.18; H, 6.61; Cl, 12.09; N, 9.56. 
1-(3-Amidinophenyl)-3-(4-phenoxyphenyl)urea 
hydrochloride (GP 13). This compound was prepared using the 
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procedure described for compound GP 11 and substituting 4-
phenoxyphe~nyl isocyanate for phenyl isocyanate. 1H NMR (DMSO-d6) 
0: 6.91-7.20 (m, 4H); 7.10 (t, 1H); 7.30-7.40 (m, 3H); 7.45-7.58 
(m, 3H); 7.70(d, 1H); 7.95 (s, 1H); 9.00 (s, 2H); 9.34 (s, 1H); 
9.36 (s, 2H); 9.55 (s, lH). Anal. Calcd. for C20H19Cl1N402•0.75 
H20: C, 60.60; H, 5.17; Cl, 8.96; N, 14.14. Found: C, 60.62; H, 
5.19; Cl, 8.96; N, 14.05. 
(4-Amidinoben.zyl)-3-phenylpropyl ether hydrochloride 
(GP 14). A solution of 3-phenylpropyl alcohol (2.72 g, 0.02 mol) 
in dry THF (20 mL) was added slowly to sodium hydride (2.4 g, 0.10 
I· mol) and the suspension stirred at room temperature for 15 min. 
To this stirred suspension was then added dropwise a solution of 
a-bromo-p-tolunitrile (3.92 g, 0.02 mol) in dry THF (20 mL) and 
the reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction t;~ken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
Dry HCl was passed through a cooled solution of the cyano 
ether (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporated under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (1 g) was dissolved in dry isopropanol 
saturated with ammonia (50 rnL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. The solvent 
was evaporated and the solid obtained was recrystallized from 2N 
HCl to get white crystals of the title compound (0.295 g, 31 %); 
mp 76-78 °C. 1H NMR (DMSO-d6) 0: 1.84 (m, 2H); 2.62 (t, 2H); 3.45 
( t , 2 H) ; 4 . 55 ( s , 2 H) ; 7 . 1 0-7 . 9 0 (aromatic , 9 H) ; 9 . 2 0 ( b s , 2 H) ; 
9.45 (bs, 2H). Anal. Calcd. for C17H21Cl1N20: C, 66.99; H, 6.94 
Cl, 11.63; N, 9.19. Found: C, 67.05; H, 6.95; Cl, 11.54; N, 9.20. 
(4-Amidinoben.zyl)-3-phenoxylben.zyl ether hydrochloride 
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(GP 15) . This compound was prepared using the procedure 
described for compound GP l4 and replacing 3-phenylpropyl alcohol 
with 3-phenoxylbenzyl alcohol. 1H NMR (DMSO-d6) 0: 4.55 (s, 2H); 
4 . 6 3 ( s , 2 H) ; 6 . 9 5-7 . 8 0 ( aromatic, 13 H) ; 9 . 1 6 ( b s , 2 H ) ; 9 . 4 0 ( b s , 
2H). Anal. Calcd. for C21H21Cl1N202: C, 68.38; H, 5.74; Cl, 9.61; 
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FOREWORD 
Opinions, interpretations,, conclusions and recommendations are 
those of the author and are not necessarily endorsed by the u.s. 
Army. 
Where copyrighted ma·terial is quoted, permission has been 
obtained to use such material. 
Where material from documents designated for limited· 
distribution is quoted, permission has been obtained to use the 
material. 
Citations of commercial organizations and trade names in this 
report do not constitute an official Department of Army 
endorsement or approval of the products or services of these 
organizations. 
In conducting the research described in this report, the 
investigator(s) adhered to the "Guide for the Care and Use of 
Laboratory Animals," prepared by the Committee on Care and Use of 
Laboratory Animals of the Institute of Laboratory Animal 
Resources, National Research Council (DHEW Publication No. (NIH) 
86-23, Revised 1985) . 
For the protection of human subjects, the investigator(s) 
adhered to policies of applicable Federal Law 45 CFR 46. 
1 
~i · ' ·r' - - \ l; .: I_~~ ., u 
-~+·~-·r_v~~--~-----~'-+lL~;-v~v-~~'~2~------
U.meS C. Powers DATE 
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ABSTRACT 
Bis-(2-chloroethyl)sulfide (HD, sulfur mustard) is a potent 
vesicant which was used in the Iran-Iraq conflict. Sulfur mustard 
penetrates the skin rapidly and after a latent period of several 
hours under temperate climatic conditions, causes extensive 
blistering of the skin. The mustard is thought to alkylate DNA 
which eventually results in the release of potent proteolytic 
(protein degrading) enzymes, particularly serine proteases. These 
serine proteases are capablE~ of destroying a number of connective 
tissue proteins and several of the enzymes seem to be able to 
specifically cleave proteins at the junction of the dermis and 
epidermis (outer non-vascular layer of skin) . The destruction of 
these basement membrane and connective tissue proteins results in 
an epidermal-dermal separation, fluid accumulation, and formation 
of a blister. 
The goal of this research program is the design and synthesis 
of inhibitors for the skin proteolytic enzymes involved in 
blistering for use as antivesicants. A total of 26 serine 
protease inhibitors have been submitted in 3-5 g quantities for 
animal testing. The structural classes include 7 isocoumarins, 6 
phosphonates, 1 benzoxazinone, 5 saccharins, 3 misc. compounds, 
and 4 derivatives of p-guanidino benzoic acid. The inhibitors 
have been surveyed for inhibitory potency against human neutrophil 
elastase, human neutrophil cathepsin G, rat skin tryptase, human 
skin tryptase, human skin chymase, human plasminogen activator, 
porcine pancreatic elastase,. rat mast cell protease II, dog skin 
chymase, human lung tryptase and bovine chymotrypsin. 
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BACKGROUND 
Su1ft~Lr Mustard. Bis- (2-chloroethyl) sulfide (HD, sulfur 
mustard) is a potent vesicant which was used in the Iran-Iraq 
conflict. Sulfur mustard penetrates the skin rapidly and after a 
latent period of several hours under temperate climatic 
conditions, causes extensive blistering of the skin. Antimustard 
ointments which attempt to inactivate the free mustard are 
ineffective since the mustard quickly reacts with components in 
the skin and other tissues. Therefore, an effective therapy for 
sulfur mustard exposure must be based on reversing the 
physiological processes that result upon contact with this potent 
vesicant (Cullurnbine, 1947) . 
Bis-(2-chloroethyl)sulfide is a potent alkylating agent which 
can react with the heterocyclic bases in nucleic acids (Ludlum et 
al., 1984) and with a wide variety of the side chain functional 
groups (thiols, thioethers, carboxyl groups, amino groups, 
imidazole rings, etc.) found in proteins. The majority of the 
sulfur mustard is secreted in the form of various metabolites such 
as thiodiglycol, but some is carried by the circulation to other 
organs, and a significant portion is stored in skin reservoirs 
(Klain and Bonner, 1987) . While the most significant mustard 
induced injury occurs in th1e skin (vesication and inflammation), 
significant numbers of mustard casualties have ocular injuries and 
cornea impairment for 2-4 months. In cases of severe exposure, 
there is serious lung and bone marrow damage which results in 
death. 
Mechanism of Su1fur Mustard Induced B1isterinq. The 
molecular mechanisms by which sulfur mustard causes toxicity are 
unknown but mustard is a powerful alkylating agent of DNA and RNA. 
Papirmeister has suggested that the alkylated purine bases in DNA 
are unstable and undergo both spontaneous and enzymatic 
depurination (Papirmeister et al., 1985). This results in DNA 
strand breaks, and activation of nucleases and other DNA repair 
mechanisms. As a result, poly(ADP-ribose)polymerase is activated, 
NAD+ is depleted, glycolysis is inhibited, and the hexose 
monophosphate shunt is stimulated-(Meier et al., 1987). This 
causes the release of potent proteolytic enzymes which produces 
the observed pathology of basal cell necrosis and vesication. 
Evidence for the Papirmeister hypothesis includes the 
isolation and structural characterization of several DNA 
alkylation products upon treatment of DNA with sulfur mustard 
(Benschop et al., 1989) and the demonstration of single strand 
breaks in the DNA after exposure of keratinocyte cultures to low 
levels of sulfur mustard (Bernstein et al., 1989). In addition, 
other agents which result in DNA damage such as UV light and 
radiation have been shown to stimulate the synthesis or release of 
proteases in fibroblast cultures (Miskin and Reich, 1980) . 
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Proteases are normally controlled by natural plasma protein 
protease inhibitors such as a1-protease inhibitor, a1-
antichymotrypsin, and a2-macroglobulin. If this antiprotease 
screen is destroyed tissue destruction results. Several of the 
plasma serpins (serine protease inhibitors) including a1-protease 
inhibitor and a1-antichymo~trypsin have essential methionine 
residues and are susceptible to inactivation by oxidizing agents 
or alkylating agents. A single dose of sulfur mustard in the 
mouse brain has recently been shown to cause a burst of oxidants 
(Elsayed et al., 1989). The serpin screen could then be removed 
directly by sulfur mustard alkylation or indirectly by oxidation 
as a result of this oxidative burst. Thus, sulfur mustard 
exposure probably results bc,th in the release of powerful 
proteolytic enzymes and in the partial destruction of the protease 
inhibitor screen which would normally protect the organism from 
proteolysis. 
Other Blistering I>if;ease States Involve Proteases. 
Blistering disease states which have been described include 
dermatitis herpetiformis (DH), bullous pemphigoid (BP), chronic 
bullous disease of childhood, and p1emphigus vulgar is. These 
diseases are characterized by destruction of various connective 
tissue components of the epidermis or dermis followed by tissue 
separation and the formation of fluid-filled blisters. Blister 
fluids from patients with all of these diseases have been shown to 
contain proteases including elastase and collagenase (Oikarinen et 
al., 1983). Human polymorphonuclear leukocyte elastase is the 
major enzyme in DH fluid, while BP fluid predominantly contains 
the metalloprotease collagenase. A trypsin-like enzyme and a 
thiol protease have also bee~n implicated in blister formation 
respectively in recessive dystrophic epidermolysis bullosa and 
epidermolysis bullosa simple~x (Takamori et al., 1985). Incubation 
of normal human skin with the blister fluid from patients with 
epidermolysis bullosa letalis, a severe and usually fatal 
congenital blister disease~, results in dermal-epidermal 
separation. A number of common serine protease inhibitors 
prevented the separation (Ma~tsumoto and Hashimoto, 1986) . 
Proteases are Associated with Inflammation. Prot eases 
are important mediators and modulators of inflammation and have 
been demonstrated in non-blistering inflammatory disease states 
such as psoriasis and arthritis. The most abundant enzymes are 
the serine proteases elastase and cathepsin G (a chymotrypsin-like 
enzyme) from leukocytes; chymases (chymotrypsin-like enzymes), and 
tryptases (trypsin-like) enzymes from mast cells; plasminogen 
activator; and the metalloprotease collagenase from leukocytes. 
These enzymes are capable of cleaving a variety of connective 
tissue proteins including elastin, collagen, proteoglycans, and 
other basement membrane components. 
Sulfur Mustard Induced Inflammatory Lesions Contain 
Proteases and Protease-Inhibitor Complexes. The proteolytic 
enzymes released upon exposure to sulfur mustard have not yet been 
isolated or characterized, but likely candidates include chymases 
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and tryptases from mast cells, elastase and cathepsin G from 
leukocytes, plasminogen activator, and collagenase. Culture 
fluids from mustard-induced inflammatory lesions in rabbit skin 
show 3 to 6 fold increased levels of proteases both in developing 
and healing lesions (Higuchi et al., 1987). These fluids will 
hydrolyze ·two synthetic peptide substrates, Boc-Leu-Gly-Arg-AFC 
(Boc = t-butyloxycarbonyl, ~1\.FC = 7-amino-4-trifluoromethyl 
coumarin) and Bz-Phe-~-naphthyl ester (Bz = benzoyl) . The first 
peptide is a substrate for trypsin, tryptases, plasmin, 
plasminogen activator and other trypsin-like enzymes, while the 
latter is a substrate for chymotrypsin-like enzymes including 
chymases and cathepsin G. The rabbit skin culture fluids did not 
consistently hydrolyze four other synthetic peptide substrates 
(two for elastase and two for cathepsin G) or the protein elastin 
(elastase's natural substrate). Exposure of human skin in culture 
to sulfur mustard results in a 41 % increase in plasminogen 
activator activity (Dannenberg et al., 1989), an enzyme which is 
known to be associated with blister formation (Hashimoto et al., 
1983). The·enzymatic activity of chymases, tryptases, and 
angiotensin converting enzyme toward small synthetic substrates 
were not elevated. 
The proteases found in the culture fluids from mustard-
induced inJElammatory lesions in rabbit skin are not present as 
free active enzymes, but are found as inactive complexes with 
their natural plasma protease inhibitors a1-protease inhibitor and 
a2-macroglobulin (Harada et al., 1987; Dannenberg et al., 1987; 
Higuchi et al., 1987). These complexes are formed as natural 
protein protease inhibitors from the plasma react with the 
proteases being released at the site of inflammation. The 
protease-inhibitor complexes are incapable of hydrolyzing protein 
substrates and complex formation thus protects the organism from 
further damage. The natural plasma protease inhibitors are 
probably not completely destroyed by exposure to low levels of 
sulfur mustard and are still available to react with some of the 
proteases released in the blister. 
Protease-inhibitor complex formation hinders the 
identification of the proteases present in sulfur mustard induced 
culture fluid. Complexes of: elastase and cathepsin G respectively 
with a1-protease inhibitor and a1-antichymotrypsin are inactive 
toward both synthetic peptide substrates and natural protein 
substrates. Thus the lack of hydrolysis of elastin or elastase 
substrates does not preclude the presence of inactivated elastase 
in the culture fluids. Similarly the lack of hydrolysis of the 
protein fibrin by the culture fluids doesn't exclude the presence 
of plasmin or plasminogen activator. In summary, it is now clear 
that there is a chymotrypsin-like enzyme (chymase), a trypsin-like 
enzyme (tryptase), and plasminogen activator in the sulfur mustard 
induced inflammatory lesions, but the presence of other enzymes 
has not been excluded. 
Skin Serine Protease:3 Have Been Iso~ated and 
Characterized. The dermis of human skin is a rich source of 
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mast cells and salt extraction of human skin has yielded two 
serine proteases, a chymase and a tryptase. These serine 
proteases are localized in the granule fraction of mast cells, a 
cell type which is located predominantly in connective tissue. 
The chymase has been demonstrated immunocytochemically to bind to 
the dermo-epidermal junction in skin (Sayama et al., 1987). Both 
the mast cell chymase and tryptase are able to specifically cleave 
proteins found in the dermal-epidermal boundary and cause 
vesication. The chymase is incompletely inhibited by plasma due 
to a 650 fold slower rate of reaction with the serpins a1-protease 
inhibitor and a1-antichymotrypsin (Schechter et al., 1989), while 
the tryptase appears not to be inhibited by most protein protease 
inhibitors (Schechter et al., 1983). This may explain the ready 
detection of chymase and tryptase activity in culture fluids from 
mustard-induced lesions in rabbit skin. 
Rat mast cells contain two chymases (RMCP I and RMCP II) 
which have been more extensively characterized that the chymase 
from human skin. Both of these serine proteases are highly 
homologous· to human mast chymase and human leukocyte cathepsin G. 
RMCP I and RMCP II have both been sequenced and the x-ray crystal 
structure of RMCP II has been determined, while the x-ray 
structure of RMCP I is underway (Woodbury and Neurath, 1980; 
Remington et al., 1988). The sequence of dog mast cell tryptase 
and a related dog mast cell protease have been determined by gene 
sequencing techniques (Vanderslice et al., 1989) and it is likely 
that the sequences for human skin tryptase and chymase will be 
available in the next few years. 
The substrate specificity and inhibition profile of human 
skin chymas:e, human skin tryptase, RMCP I, RMCP II, and related 
enzymes have been studied in the laboratory of the principle 
investigator (Powers et al., 1985). Human skin chymase hydrolyzes 
peptide substrates containing aromatic amino acid residues and 
prefers Phe-AA and Tyr-AA bonds over Trp-AA bonds (AA = any amino 
acid residue) in contrast to chymotrypsin which prefers Trp over 
Phe and Tyr. One of the best peptide substrates is Suc-Phe-Val-
Pro-Phe-NA (Sue = succinyl, NA = 4-nitroanilide) . Human skin 
tryptase is a trypsin-like enzyme, but seems to prefer double 
basic residues in its substrates (Tanaka et al., 1983). For 
example, the thioester substrate Z-I.ys-Arg-SBu-i ( z = 
benzyloxycarbonyl, SBu-i = thioisobutyl ester) is hydrolyzed by 
human skin tryptase with a kcatiKM =: 59,000,000 M-1s-1, a second 
order rate constant which is close to the diffusion controlled 
rate. 
Serine Protease Speci1:icity. The specificity of serine 
proteases toward natural peptide substrates or synthetic 
inhibitors is determined by ·the nature of the primary substrate 
specificity pocket (Sl) and secondary subsites (82, S3, etc.) on 
the surface of each individual enzyme. Trypsin's primary 
specificity site contains an Asp residue in the back of the S1 
pocket so that trypsin will only bind to and hydrolyze peptide 
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substrates containing lysine or arginine residues (a schematic 
model of trypsin with a bound subst.rate is shown below) . The 
three-dimensional structure of chymotrypsin is quite similar 
except that the Asp-189 in trypsin is replaced by Gly-189 in 
chymotrypsin. As a result the S1 pocket of chymotrypsin in very 
hydrophobic and chymotrypsin prefers substrates containing 
aromatic amino acid residues such as Trp, Tyr, and Phe. With many 
serine proteases, interactions of inhibitors with the extended 
substrate binding site (S2, S3, etc.) are important to increase 
the specificity and reactivity of the inhibitor. This is clearly 
the case with human skin chymase and tryptase. For example, 
interaction of the Lys in the substrate Z-Lys-Arg-SBu-i with the 
S2 subsite of human tryptase results in an accelerated rate of 
hydrolysis, while little change in hydrolysis rate is observed 
with trypsin. 
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It is clear-no matter the exact mechanism of their release or 
their source-that proteases are major factors in the tissue 
destructio,n that accompanies mustard induced vesication. We 
propose that protease inhibitors will be effective antivesicants 
and should be useful both in preventing blistering and in the 
treatment of blisters. Appropriate target proteases are the mast 
cell chymase and tryptase, serine proteases which are localized in 
the skin and have the ability to cleave proteins at the dermal-
epidermal junction. However other serine protease such as 
elastase and cathepsin G from leukocytes, and plasminogen 
activator may also be involved. Evidence for the involvement of 
other classes of proteases such as the metalloprotease collagenase 
or the thiolprotease cathepsin B is incomplete or lacking at 
present, although the mast cell tryptase is able to activate 
latent collagenase (Gruber et al., 1989). 
Research Strategy. Since the exact target enzyme (or 
enzymes) is not known with certainty, we have decided to 
synthesize general serine p:rotease inhibitors, specific chymase 
inhibitors, specific tryptase inhibitors, specific plasminogen 
activator inhibitors, and specific inhibitors for other enzymes as 
appropriate. We plan to shift our emphasis to a particular enzyme 
or group of enzymes when more biological data is obtained on the 
role of specific proteases in blistering or when we receive animal 
test data on the compounds which we have already submitted. Until 
that time, we plan to submit for testing a wide variety of 
potentially active structures including both general serine 
protease inhibitors and inhibitors which are more enzyme specific. 
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Research Goals 
1. Prepare and submit for animal testing 3-5 inhibitors of 
serine proteases such as 3,4-dichloroisocoumarin and saccharins 
each year. 
2. Prepare and submit for testing 3-5 inhibitors of human skin 
chymase each year. 
3. Prepare and submit for testing 3-5 inhibitors of human skin 
tryptase each year. 
4. Prepare and submit for testing each year 3-5 inhibitors for 
other human serine proteases-such as human leukocyte elastase, 
cathepsin G, and plasminogen activator-which may have a role in 
vesication. 
5. Assay all inhibitors with human skin serine proteases and 
related enzymes for in vitro effectiveness. 
Research Progress-Summary 
1. A total of 26 serine protease inhibitors have been submitted 
in 3-5 g quantities for animal testing during the first year of 
the contract. The structural classes include 7 isocoumarins, 6 
phosphonates, 1 benzoxazinone, 5 saccharins, 3 misc. compounds, 
and 4 derivatives of guanidine benzoic acid. All the inhibitors 
submitted are listed below in the section on biological testing of 
the inhibitors. 
2. The inhibitors have been surveyed for inhibitory potency 
against human neutrophil elastase, human neutrophil cathepsin G, 
rat skin tryptase, human skin tryptase, human skin chymase, human 
plasminogen activator, porcine pancreatic elastase, rat mast cell 
protease II, dog skin chymase, human lung tryptase and bovine 
chymotrypsin. 
Inhibitors Submitted. 
Isocoumarins-General Inhibitors. Dichloroisocoumarin 
(BL58572) is an excellent general inhibitor of serine proteases 
and was discovered in the laboratory of the principal investigator 
(Harper et al., 1985). With the exception of the bacterial enzyme 
subtilisin,, 3,4-dichloroisocoumarin is an inactivator of all 
serine proteases which have been tested, including human leukocyte 
elastase, human skin chymase, dog skin chymase, rat mast cell 
protease I, and rat mast cell protease II. 
The dichloroisocoumarin ring system contains a masked acid 
chloride (or ketene) functional group which is exposed when an 
acyl enzyme is formed upon reaction with the active site serine of 
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a serine protease (Harper et. al., 1985). The acyl enzyme (top 
right of figure) which is formed initially can react further by 
acylating the active site histidine to form a doubly acylated 
enzyme derivative (bottom left) or can hydrolyze to form an acyl 
enzyme stabilized by a salt link between the protonated histidine 
and the inhibitor carboxyl group (bottom right) . The monochloro 
derivative, 3-chloroisocoumarin (BL57637), inhibits chymotrypsin-
like enzymes at slower rates than 3,4-dichloroisocoumarin and does 
not touch trypsin. The acyl enzyme.s formed upon reaction with 
dichloroisocoumarin have variable stabilities, but in general the 
half-lives for reactivation (deacylation) are greater than 8 hrs 
at pH 7.5. 
0 











Dichloroisocoumarin and 3-chloroisocoumarin are formed by 
reaction of homophthalic acid with PCl5. 
Isocoumarins-Specifi.c Inhibitors. We have also 
synthesized a number of isocoumarin inhibitors which are more 
specific for the active sites of chymases or tryptases. 
Inhibitors targeted for chymase should contain an aromatic side 
chain which resembles the side chain of Phe, Tyr or Trp, while 
those inhibitors targeted for tryptase should containing a charged 
group which resembles the side chain of Arg or Lys. Several of 
the more specific isocoumarin inhibitors are shown below. 
Inhibitors with the benzyloxy (such as BM00482) or phenylethoxy 
groups (BL57413) were targeted at the chymases, while those with 








The mechanism of inhibition of serine proteases by 3-alkoxy-
4-chloroisocoumarins involves acylation of the active site serine-
195 to form acyl enzymes with varying stabilities (t1/2 = hrs to 
days) depending on the nature of the alkoxy group (Harper and 
Powers, 1985). 
0 
______ ....; ...... 
OR 
Cl 
Analogous isocoumarins with electron donating substituents in 
the ?-position such as 3-alkoxy-7-amino-4-chloroisocoumarins 
(below) are mechanism-based or suicide inhibitors of serine 
proteases (Powers et al., 1989). These inhibitors also acylate 
serine proteases, but form stable acyl enzymes which are not 
reactivated upon long standing or upon treatment with 
hydroxylamine. The inhibition mechanism involves formation of an 
acyl enzyme which can then eliminate chloride to form a quinone 
imine methide (center) . This intermediate then irreversibly 
alkylates His-57 with the formation of a stable covalent bond 
between enzyme and inhibitor. This mechanism is supported by x-
ray crystallographic studies of complexes of isocoumarin 
inhibitors bound to the active site of porcine pancreatic elastase 
(Bode et al., 1989). Thus far, four separate isocoumarins have 
been studied crystallographically, two give simple acyl enzyme 
structures (above) and two give acyl enzyme structures where His-
57 has been alkylated. 
0 0 0 
H2N 0 
HN ~ /Ser195 H2N ..,.....ser19s v:o 0 .. yco2R FN OR N~His57 
Cl H C02R 
Isocoumarins which have been submitted and should inhibit 




. a-Aminoalkylphosphoncn.tes Diphenyl Esters. Peptidyl 
derivatives of a-aminoalkylphosphonate diphenyl ester are 
effective and specific inhibitors of serine proteases at low 
concentrations (Oleksyszyn and Powers, 1989) . These peptide 
derivatives phosphonylate the active site serine to form stable 
phosphonyl derivatives. Good interactions with the S1 pocket of 
the target serine protease are necessary before nucleophilic 
substitution on phosphorus atom occurs to give a stable phosphonyl 
derivative. 
Active Site 
Substrate S1 Ser195 
Binding Site r-----, 0-H ---His 
___j R I 57 




R I H H' 
R-CO-NH-dH-P~O - 1s57 
11 OPh 
0 0 .. 
H
,' .... H 
1 1 
oxyanion 
N N hole 
Phosphonate diphenyl ester inhibitors are chemically stable, 
relatively easy to synthesize, do not react with 
acetylcholinesterase, form very stable derivatives possibly due to 
their resemblance to the tetrahedral intermediate involved in 
peptide bond hydrolysis, and have considerable potential utility 
as therapeutic agents. 
We have submitted a number of simple amino acid and peptide 
derivatives of phosphonate diphenyl est~rs including Z-MetP(OPh) 2 
(BL57646), Z-ValP{OPh)2 {BL57968), Z-PheP(OPh)2 (BL57422), Z-Phe-
PheP(OPh)2 (BL57842), and Suc-Val-Pro-PheP(OPh)2 (BL59382). More 
recently, we have accomplished the synthesis of an amidinophenyl 
phosphonate derivative by the route ~hown below. The · 
benzyloxycarbonyl (Z) derivative has been submitted recently for 
testing. We have also synthesized a few peptide derivatives of 
the amidinophenyl phosphonate, but not in sufficient quantities 
for submission. 
-o- I'POaPh2 HCVEtOH ,..... NC CH, CHCI3 24 hrs .. P(OPh)3 AcOH 60-90°C, 2hrs NH-Z 
Saccharin Inhibitors~ N-Acyl and N-aryl saccharins are 
potent acylating agents of HL elastase, cathepsin G, and 
chymotrypsin (Zimmerman et al., 1980; Ashe et al., 1981). A few 
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of the N-acyl derivatives such as N-furoyl, N-thienoyl, and N-
benzoylsaccharin inhibit trypsin with IC50 values of 0.7-2.4 J..l.M. 
These structures were initially designed as acyl transfer 
reagents, but studies using 35s-labeled N-furoylsaccharin 
indicated that the saccharin portion of the inhibitor becomes 
covalently and stoichiometrically bound to both HL elastase and 




R = acyl or aryl wtth 
electronegative groups 
Two of the saccharins which we have submitted are shown 
below. 
BL57986 
Benzoxazin-4-ones. Substituted benzoxazin-4-ones were 
discovered to be potent inhibitors of human leukocyte (HL) 
elastase, porcine pancreatic (PP) elastase, cathepsin G, and 
chymotrypsin by the PI (Teshima et al., 1982). Mechanistic 
studies by Abeles showed thcLt these compounds were forming stable 
acyl enzyme derivatives (shown below) with chymotrypsin (Hedstrom 
et al., 1984) and this has been confirmed by x-ray 
crystallographic studies with two benzoxazinones bound to PP 
elastase (Radhakrishnan et al., 1987). Due to the potential of 
benzoxazinone inhibitors of HL elastase for treatment of 
emphysema, a group at Syntex Canada has synthesized over 100 new 
benzoxazinones, carried out a structure-function study as 
substituents were varied on the ring system, and studied the 
plasma stability of these compounds (Spencer et al., 1986; Krantz 
et al., 1987; Krantz et al., 1990). Thus far, we have submitted 







Guanidinobenzoic Aci~ Inhibitors. Esters of p-
guanidinobenzoic acid ha~e been reported to be potent inhibitors 
for various trypsin-like enzymes (Okutome et al., 1984; Fujii et 
al., 1977) and p'-nitrophenyl-p-guanidinobenzoate is widely used 
as an active-site titrant for these enzymes (Chase and Shaw, 
1970) . An active-site titrant for trypsin-like enzymes developed 
in the laboratories of the PI is benzyl p-guanidinothiobenzoate 
(Cook and Powers, 1983) . We have submitted samples of four p-
guanidinobenzoic acid derivatives for testing. 
R = OH (BM01363) , OEt (BM01185), 
NH-Vai-NH2 (BM02655), OCH2CONH2 (BM03143) 
Miscellaneous Inhibitors. Two heterocyclic general serine 
protease inhibitors have been submitted. They are isatoic 
anhydride which has been shown to acylate the active site of 
chymotrypsin and form a stable acyl enzyme (Moorman and Abeles, 
1982) and 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide which forms a 







0 2N ·n)so2 
5-Nitro-31-1-1 ,2-benzoxathiole-2,2-dioxide 
BM00491 
The sulfide shown below is an effective inhibitor of elastase 
which was discovered in the laboratory of the PI. 
BL57940 
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Biological Test Data. 
All the inhibitors which we have synthesized have been tested 
for inhibitory potency against a variety of serine proteases. 
Kinetic data obtained with the various inhibitors are shown in 
Tables I-IV. Most of the inhibitors are irreversible or slowly 
reversible inhibitors and we report the second order inhibition 
rate constants kobs/[I]. Several of the inhibitors reported in the 
tables have kobs/[I] values of 100,000 M-1s-1 or greater. A 
second order inhibition rate constant of this magnitude indicates 
that the reaction between equimolar concentrations of enzyme and 
the inhibitor is over in less than 0.2 min. (the time required for 
mixing the enzyme and inhibitor in the assays) . The half-life of 
the inhibition reaction can be calculated from the equation t112 = 
0.693/{ [I]*kobs/[I]}. Thus, an inhibitor with a kobs/[I] value of 
100,000 M-ls-I would have an inhibition half-life of 6.93 sec. at 
an inhibitor concentration of 1 J..LM, while an inhibitor with 
kobs/[I] = 10,000 would have a half-life of 69 sec. For the few 
reversible inhibitors investigated, KI values (dissociation 
constant of the enzyme-inhibitor complex) or IC50 values are 
given. 
The data with bovine chymotrypsin, cathepsin G, rat mast cell 
protease II, human skin chymase, and dog skin chymase is given in 
Table I. The best isocoumarin inhibitor in this table is 3-
benzyloxy-4-chloroisocoumarin (BM00482) with a kobsd/[I] = 12,000 
M-1s-1 for the human skin chymase. Increasing the length of the 
side chain at position 3 by one methylene group [4-chloro-3-(2-
phenylethoxy)isocoumarin, BL57413] reduces the activity by a 
factor of 35. Thus far, we have been unable to synthesize the 7-
amino derivative of BM00482 which would allow the synthesis of 
many additional acylamino analogs which we would expect to be 
better inhibitors due to increased interaction with the extended 
substrate binding site of chymases. We synthesized the 7-nitro 
derivative, but during attempted reduction of the nitro group, 
cleavage of the benzyloxy functional group took place concurrently 
with reduction of the nitro group. In order to avoid this problem 
we synthesized the 3-cyclohexylmethyloxy derivative shown below 
which contains a cyclohexane ring in place of the phenyl in the 3-
benzyloxy derivative. Unfortunately this modification resulted in 
a much weaker inhibitor and the compound has kobsd/(I] = 25 M-1s-1 




The best phos§'honate inhibitor for chymotrypsin-like enzymes 
is Suc-Val-Pro-Phe (0Ph)2, which corresponds to the sequence of an 
excellent 4-nitroanilide substrate for these enzymes. NMR studies 
with chymotrypsin indicate that only one of the two stereoisomers 
reacts with the enzyme (kobsd/[I] = 146,000 M-1s-1 calculated for 
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the single isomer, the value in the table is for the DL mixture) . 
The 31p NMR of chymotrypsin inhibited by this peptide phosphonate 
shows one broad signal at 25.98 ppm corresponding to the Ser-195 
phosphonylated enzyme derivative. The tripeptide phosphonate Suc-
Val-Pro-PheP (OPh) 2 makes bei:ter interactions with the extended 
substrate binding site of the enzyme than is possible with the 
shorter dipeptide or amino acid phosphonate derivatives. 
All of the saccharins submitted so far have high kobsct/[I] 
values with the various chymotrypsin-like enzymes and low IC50 
values with the elastases tested. One of the better inhibitors in 
this family is N-furoylsaccharin. The acyl enzymes formed upon 
acylation of serine proteases by acyl saccharins have variable 
stabilities. Furoyl saccharin and benzoyl saccharin form 
inhibited elastase derivatives which are very stable and have 
half-lives for deacylation of 80-160 hrs. In contrast the 
chymotrypsin derivatives have much shorter half-lives in the range 
of 1.9 hrs. One disadvantage of some acyl saccharins is their 
fairly rapid hydrolysis at neutral pH values. 
The data with porcine pancreatic elastase (PPE) and human 
leukocyte elastase (HLE) is given in Table II. All the 
isocoumarin derivatives reported in this table are excellent 
inhibitors of HLE, the best one being the 7-ureido derivative 
BM01096 with a kobsd/[I] = 140,000 M-1s-1 for HLE. It is also 
highly selective compared with 3,4-dichloroisocoumarin and 3-
chloroisocoumarin which is a logical consequence of the 
improvement in binding resulting from substitution at the 7-amino 
group. We have also submitt:ed an excellent benzoxazinone 
inhibitor for HLE (BM00651) and analogs of this derivative will be 
made in the future. 
The phosphonate derivatives which we have submitted thus far 
are not good inhibitors for PPE or HLE. This is not surprising 
since the sequence of the tripeptide was chosen for chymase 
inhibition and this sequence is very specific for the chymases as 
discussed earlier. An excellent phosphonate inhibitor for the 
elastases has been synthesized only in a small scale. This 
inhibitor, Boc-Val-Pro-ValP(OPh)2, has kobsd/[I] value of 27,000 
M-1s-1 for human leukocyte elastase (HLE) and 11,000 M-1s-1 for 
porcine pancreatic elastase (PPE) . Again this sequence 
corresponds to a good HLE substrate sequence and at low 
concentrations this peptide did not react with chymotrypsin. 
The inhibition data obtained with bovine trypsin, human lung 
tryptase, rat skin tryptase, human skin tryptase, and human 
recombinant tissue plasmino9en activator is given in Table III. 
The best tryptase inhibitor submitted is the 3-
(isothioureidopropoxy)isocoumarin BM00642 with a kobs/[I] = 650,000 
M-1s-1 for the rat skin tryptase, an extremely rapid inhibition 
rate. However, the acyl-enzyme formed with this inhibitor is 
unstable and the enzyme regains its activity within 5 min. We 
plan to synthesize analogs of this inhibitor which should form 
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more stablte acyl enzyme derivatives and thus be longer acting 
inhibitors. 
Several p-guanidinobenzoic acid derivatives have been tested 
as inhibitors for the various tryptases. One of these 
derivatives, 0-(p-guanidinobenzoyl)glycolamide is an excellent 
inhibitor of the rat skin tryptase, but is a much poorer inhibitor 
of human skin tryptase. In contras·t to the isocoumarin BM00642, 
the inhibited derivative did not regain enzyme activity upon 
standing. Thus, we plan to pursue this lead and synthesize 
additional derivatives in the near future. Our goals will be 
improvemen1: of the inhibitory potency toward the human skin 
tryptase while maintaining the stability of the acyl enzyme 
derivatives which are formed. 
Table IV lists the inhibition data with bovine trypsin, human 
lung tryptase, rat skin tryptase, human skin tryptase, and human 
recombinant tissue plasminoc:ren activator by the isocoumarin 
isothiureido derivatives depicted below. The CiTEtOIC derivatives 
are based on 4-chloro-3-(isothioureidoethoxy)isocoumarin and the 
CiTPrOIC derivatives are based on 4-chloro-3-
(isothioureidopropoxy)isocoumarin. These inhibitors were 
synthesized in the course of another research project and were 
tested with the tryptases in order to obtain information about the 
nature of the active site of the tryptases which will be useful 







R H, alkyl-CO, arylalkyl-CO, AA-CO (amino acyl), aryl-NHCO, 
arylalkyl--NHCO 
The following correlations can be made from the data reported 
in Table IV: a) the propoxy derivatives (RNH-CiTPrOIC) are better 
inhibitors for the rat skin tryptase while the ethoxy derivatives 
(RNH-CiTEtOIC) are better inhibitors for the human tryptases and 
recombinant tissue plasminogen activator; b) acyl derivatives were 
weaker inhibitors of the rat skin tryptase and human recombinant 
tissue plasminogen activator and equally potent for the human lung 
tryptase; c) an extra CHz in the urea side chain results in better 
inhibitors for rat skin and human lung tryptases while shorter 
chains are preferred by human recombinant tissue plasminogen 
activator; d) longer chains on the simple acyl derivatives 
increase inhibitory potency toward all the tryptases and e) N-acyl 
substitution of a D-Phe results in greater inhibitory potency for 
all the tryptases when compared to substitution by L-Phe. 
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Table I. Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease IT, Human Skin Chymase, and Dog Skin 
Chymase by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor 
BL58572 3,4-dichloroiCg 
BL57637 3-chloroiCg 
BL57413 4-chloro-3-(2-pheny lethoxy )IC 
, BM00482 4-chloro-3-benzy loxy IC 
7 -amino-4-chloro-3-
cyclohexy lmethoxy IC 

































Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease ll, Human Skin Chymase, and 
Dog Skin Chymase by Various Serine Protease Inhibitors. a 
Compound No. Inhibitor Cathepsin ac 
BL57968 Z-ValP(QPh)2 0.4 Nih 
BL57422 Z-PheP(QPh)2 260 76 
BL57842 Z-Phe-PheP (OPh )2 7.5 Nih 
BL59382 Sue-Val-Pro-PheP (0Ph)2 41,000 36,000 
Saccharin Inhibitors 
BL57977 N-benzoylsaccharin 15,000 45,000 
BL57995 N -phenylacetylsaccharin 11,000 31,000 
BL57986 N -diphenylacety }saccharin 10,000 14,000 
BL57931 N -furoy !saccharin 22,000 39,000 















alnactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCI, pH 7.5 buffer, containing 9 % Me2SO at 25 
°C. Enzyme concentrations were: chymotrypsin, 1.6 JlM; cathepsin G, 0.8-1.6 JlM; RMCP II, 38 nM; human skin chymase, 0.07 
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Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease ll, Human Skin Chymase, and 
Dog Skin Chymase by Various Serine Protease Inhibitors. a 
JlM. Chymotrypsin and cathepsin G were assayed with Suc-Val-Pro-Phe-NA (0.5 JlM), human skin chymase and RMCP ll were 
assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 J.LM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
binhibitor concentrations were in the range 5.2 J.LM-320 JlM. N-Cyanomethyl saccharin was inactive at 1 mM. 
Cfuhibitorconcentrations were in the range: 4.8 J.LM-158 JlM. 
dinhibitor concentrations were in the range: 3-148 JlM. 
elnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 45 J.!M; 7-amino-4-chloro-3-cyclohexylmethoxyiC, 0.44 
mM; Suc-Val-Pro-PheP(OPh)2, 0.54 JlM. 
finhibitor concentrations were as follows: 3,4-dichloroisocoumarin, 540 JlM; 3-benzyloxy-4-chloroiC, 1.0 JlM. 
gData was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841. 
hNo inhibition. 
iinhibition was not time dependent, and the % inhibition was measured at 92 JlM. 
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Table II. Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte Elastase (HLE) 
by Various Serine Protease Inhibitors. a 
kobsi[I] (M-1s-1) 




























N -benzoy I saccharin 5.2 JJ.Mf 
N -pheny lacetylsaccharin 
N-dipheny lacety !saccharin 
















Table IT (Continued). Inhibition of Porcitne Pancreatic Elastase (PPE) and Human Leukocyte 
















ainactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer, containing 9% Me2SO at 25 °C. Enzyme concentrations were: PPE, 1.6 ~; ID...E, 
0.3 ~· PPE was assayed with Suc-.Ala-Ala-Ala-NA (0.75 mM), and Ill.E was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA (0.5 tnM). 
bJnhibitor concentrations were in the range: 3-320 JlM. 
CJnhibitor concentrations were in the range: 1.2-230 ~. 
dnata was obtained from Harper, J. W.~ Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 
1831-1841. 
elnhibition was not time dependent and the IC5o was obtained. 
fJCso values obtained from Zimmernaan, M., Mom1an, H., Mulvey, D., Jones, H, Frankshun, R. 
and Ashe, B. M. (1980) J. Bioi. Chern. 255, 9848-9851. 
gN o inhibition. 
Page 24 
Table Ill. Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human Recombinant 
Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid and Phosphonate Inhibitors. 
Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Isocoumarin Derivatives 
BL58572 3,4-dichloroisocoumarin 200 190 610 70 
BM00642 4-chloro-3-(3-isothioureido-
propoxy )isocoumarin 46,000 260,000 650,000 83,000 13,000 
Guanidinobenzoic Acid Derivatives 
BM01363 p-guanidinobenzoic acid Nig 
BM01185 ethy 1 p-guanidinobenzoate 4.3 1.7 0.7 Nig 
BM02655 N-(p-guanidinobenzoy 1) 
valine amide 4.4 4.7 1.3 2,000 
BM03143 0-(p-guanidinobenzoy I) 
glycolamide 100 19%h 130,000 5.8 Nig 
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Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid and Phosphonate Inhibitors. 
Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Phosphonate Inhibitors 
Z-NHCH(AmPh)P03Ph21 2,000 16 
a Inactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 J!M; rat skin tryptase, 0.015 
J.!M; human skin tryptase, 0.12 J.!M; human r-t-PA, 0.017 J.!M Bovine trypsin was assayed with Z-Phe-Gly-Arg-NA·HCl (0.07 
mM). Human lung tryptase, human skin t.ryptase and rat slr..in tryptase were assayed with Z-Arg-SBzl·HCi (0.07 mM) in the 
presence of 4,4'-dithiodipyridine (0.33 mM). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCl2, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as 
follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 1J!M; p-guanidinobenzoic acid, 0.44 mM; ethyl p-guanidinobenzoate, 
0.43 mM; p-guanidinobenzoyl valine amide,0.44 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.44 mM. 
cconditions were as follows: O.lM Hepes, 0.5M NaCl, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations were as follows: 4-
chloro-3-(3-isothioureido-propoxy)isocoumarin, 0.42 J.!M; ethyl p-guanidinobenzoate, 0.42 mM; p-guanidinobenzoyl valine amide, 
0.42 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.42 mM. 
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Table III (Continued). 
<~Conditions were as follows: 25 mM phosphate, 0.5M NaCl, 1mM EDTA, pH 7.5 and 8-12% Me2SO at 25° C. Inhibitor concentrations 
were as follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.44 JlM; ethyl p-gu~midinobenzoate, 0.45 mM ; p-
guanidinobenzoyl valine amide, 0.42 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.44 JlM. 
econditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 oc. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.35 JJM; p-guanidinobenzoyl valine amide, 3.5 JlM; 0-(p-
guanidinobenzoyl)glycolamide, 1.7 mM. 
fConditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 OC. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 4.3 JlM; ethyl p-guanidinobenzoate, 0.44 mM; 0-(p-
guanidinobenzoyl)glycolamide, 0.43 mM. 
gNo inhibition. 
hJnhibition was not time dependent and the % inhibition was measured at 0.42 mM. 
i AmPh = 4-amidinophenyl 
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alnhibition rates were measured in 0.1 M Hepes, 0.01 M CaCI2, pH 7.5 buffer for bovine trypsin; 25 mM Phosphate, 0.5 M NaCI, 
1m.M EDTA, pH 7.5 buffer for rat skin tryptase and O.lM Hepes, 0.5M NaCl, pH 7.5 for hurnan lung tryptase, human skin trjptase and 
r-t-PA. All enzymes were assayed with Z-Arg-SBzl (0.07 mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). Enzyme 
concentrations were: trypsin, 0.12~; rat skin tryptase, 0.015 J!M; human skin tryptase, 0.12 J.LM; r-t-PA, 0.017 J.LM. Reaction mixtures 
contained 8% Me2SO and assays were performed at 25 °C. binhibitor concentrations were in the range 1.1-4.6 J.LM. Cinhibitor 
concentrations were in the range 0.35-0.51 ~· dlnhibitor concentrations were in the range 0.42-0.47 J.lM. einhibitor concentrations 
were in the range 4.2-5.0 ~· finhibitor concentrations were in the range 0.34-0.39 J.LM. gData was obtained from Kam et al., 1988. 
hfuhibition was not time dependent and the% inhibition was measured at inhibitor concentrations in the range 0.34-5.0 ~· 
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Animal Testing Priorities 
The various compounds which we have submitted have been 
prioritized for animal testing and the following table lists the 
priority which we have assigned to each compound and the reasons 
for that priority. 
High-1 BL58572 3,4-dichloroisocoumarin 
This isocoumarin is a. general serine protease inhibitor and 
effectively inhibits most of the enzymes tested. 
High-2 BL59282 Suc-Val-Pro-PheP(oPh)2 
This peptide phosphonate is a reactive and specific inhibitor 
for chymotrypsin-like enzymes including chymases. 
High-3 BM00642 4-chloro-3-(3-i.sothioureidopropoxy)isocoumarin 
This isocoumarin is a very reactive inhibitor for the rat 
skin tryptase. 
High-4 BM00651 2-ethoxy-4H-3,1-benzoxazin-4-one 
This benzoxazinone inhibitor is an effective inhibitor for 
elastase. 
High-S BL57931 N-furoylsaccharin 
This saccharin is a general protease inhibitor and inhibits 
elastases and chymotrypsin-like enzyme quite effectively and is 
probably a moderate inhibitor for trypsin-like enzymes. 
High-6 0-(p-guanidinobenzoyl)glycolamide 
This guanidinium substituted derivative is an effective 
inhibitor for trypsin-like~ enzymes 
High-7 BM01096 4-chloro-7-(N-phenylcarbamoyl)amino-3-
propoxyisocoumarin 
This isocoumarin is an effective elastase inhibitor. 
High-8 BL57940 di(4-isovaleroylphenyl)sulfide 
This aromatic derivative is an effective elastase inhibitor. 
High-9 BM00482 4-chloro-3-benzyloxyisocoumarin 
This isocoumarin is an effective inhibitor for chymotrypsin-
like enzymes. 
High-10 BL57977 N-benzoylsaccharin 
This saccharin is an effective inhibitor for many serine 




This compound was prepared according to procedure Harper J. 
w., and Powers, J. C. (1985) Biochemistry 24, 7200: m.p. 99-
o 
100 C. Anal. Calcd. for C17H1303Cl·O.S H20: C, 65.92; H, 
4.52; Cl, 11.46. Found: C, 66.20; H, 4.50; Cl, 11.58. 
3-C:hloroisocoumaril'lL (BL57637) . This compound was 
prepared according to the procedure of Davis, w., and Poole, 
0 
H. G. {1928) J. Chern. Soc. 1616:: m.p.98-99 C. Anal. Calcd. 
for C9H502Cl, C, 59.85; H, 2.77; Cl, 19.65. Found, C, 59.74; 
H, 2.83; Cl, 19.71. 
Diphenyl 1-N-benzyloxycarbonylamino-2-
phenylethylphosphonatE~ (BL57422) was prepared according 
to the procedure of Oleksyszyn, J., Subotkowska, L., and 
Mastalerz, P. ( 197 9) Synthesis 985: m. p. 119-120 °C. Anal. 
Calcd. for c28H260sNP: c, 68.94; H, 5.33; N, 2.87. Found: 
C, 69.00; H, 5.40; N, 2.84. 
Diphenyl 1-N-benzyloxycarbonylamino-3-
methylthiopropylphosphonate (BL57959) was prepared by 
the same procedure; m.p. 93-95 °C. Anal. Calcd. for 
C24H2605NSP: C, 61.15; H, 5.52; N, 2.97; S, 6.79. Found: C, 
61.06; H, 5.60; N, 2.91; S, 6.88. 
Diphenyl 1-N-benzyloxycarbonyl-2-methyl-
propylphosphonate (BL57968) was prepared by the same 
0 
procedure; m.p. 104-105 C. Anal. Calcd. for C24H2605NP: 
C,65.56; H, 5.92; N, 3.19. Found: C, 65.67; H, 5.98; N, 3.13. 
Diphenyl 1-N-(carbobenzyloxy-phenylalanyl)amino-2-
pheny1ethylphosphonate (BL57842). To a solution of 2.3 g 
(6.5 mmol) of diphenyl 1-amino-2-phenylethylphosphonate 
[Oleksyszyn, J., Subotkowska, L., and Mastalerz, P. (1979) 
Synthesis 985] and Cbz-Phe-OH 1.95 g {6.5 mmol) in 50 mL of 
dry THE', 1.32 g (6.6 rnmol) of DCC (dicyclohexylcarbodiimide) 
was added. After 2 days DCU was filtered off and solution 
was washed with water, 2 times with 50 mL of 5% NaHC03, 
water, 2 times with 10% citric acid, water and dried over 
MgS04. After evaporation of the solvent, the resulting oil 
was crystallized from THF-hexane to give 3.5 g (85%) of the 
dipeptide as a white solid; m.p. 153-155 °C. Anal. Calcd. 
for C37H3506N2P: C, 70.03; H, 5.52; N, 4.42. Found: C, 
69.93; H, 5.61; N, 4.51. 
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Isatoic anhydride (BL57646) . Isatoic anhydride was 
purchased from Aldrich and recrystallized from ethanol; m.p. 
0 
233 c (decomp). Anal. Cald. for CsH503N: c, 58.9; H, 3.07; 
N, 5.59. Found: C, 58.90; H, 3.07; N, 8.52. 
Di(4-isovaleroylphenyl)sulfide (BL57940). A mixture 
of 10.7 g (80.2 mmol) of AlCl3 in 125 mL of methylene 
chloride was cooled to -30 °C under an argon atmosphere. 
Diphenylsulfide 5.0 g (26.8 mmol) was added followed by 
isovaleroyl chloride 7.19 mL (59.0 mmol). The solution was 
warmed to 0 °C and stirred 1.5 hr, then allowed to reach room 
temperature and stirred overnight. The mixture was poured 
onto a mixture of ice and concentrated HCl (5:1). The 
organic layer was extracted with the methylene chloride, 
washed with 1N NaOH and dried over MgS04. After removing the 
solvent, the residue was recrystallized from cyclohexane to 
give the product as a white solid (89%); m.p. 80-81 °C. 
Anal. Calcd. for C22H2602S: C, 74.54; H, 7,39; S, 9.04. 
Found: C, 74.45; H, 7.42; S, 8.97. 
2-Benzoylbenzisothiazolinone-1,1-dioxide (BL57977). 
Tetrabutyl ammonium bromide (0.1 g) was added to a suspension 
of finely ground sodium saccharin (2.0 g, 9.8 mmol) in 30 mL 
of benzene. Benzoyl chloride (1.2 mL, 10.3 mmol) was added 
after azeotropic removal of water from this suspension and 
the resulting mixture was heated to reflux temperature for 3 
h. The reaction mixture was filtered while hot, the solid 
was washed with hot benzene and the filtrate was cooled to 5 
0 
C while scratching the sides of the flask to induce 
precipitation of the product. The white solid was collected 
by filtration and recrystallized from benzene/hexane to yield 
1.39 g (50%) of pure product; m.p. 162-163 °C (Lit. 160-163 
° C ) . 1 H NMR (CDC 13 ) d : 8 . 14 ( d, 1 H) ; 8 . 0 1 ( t , 2 H) ; 7 . 9 3 ( m 1 
lH); 7. 78 (d of d, 2H); 7. 67 (t, 1H); 7.51 (t, 2H). Anal. 
Calcd. for C14H9N04S: C, 58.53; H, 3.16; N, 4.88. Found: C, 
58.66; H, 3.19; N, 4.92. 
2-(2-Furoyl)benzisothiazolinone-1,1-dioxide 
(BL57931). 2-Furoyl chloride (7.4 mL, 75 mmol) was added to 
a suspension of finely ground sodium saccharin in 40 mL THF 
and the resulting mixture was heated to reflux temperature 
for 4 h. The reaction mixture was filtered and the filtrate 
was concentrated to dryness to give a white solid that was 
recrystallized from ethyl acetate. The yield of pure product 
was 4 . 7 9 g ( 3 5% ) ; m . p . 1 6 7-1 6 8 ° C (Lit . 13 3-13 5 ° C) . 1 H NMR 
(CDCl3) d: 8.19 (d, 1H); 7.99 (d, 2H); 7.93 (m, lH); 7.73 (d, 
1H) ; 7. 58 (d, 1H); 6. 66 (d of d, 1H) . Anal. Calcd. for 
C12H7N05S: C, 51.98; H1 2.55; N, 5.05. Found: C, 51.83; H1 
2 . 52; N I 5. 07 . 
Page! 32 
2-Phenylacetylbenzisothiazolinone-1,1-dioxide 
(BL57995). Tetrabutyl ammonium bromide (0.1 g) was added to 
a suspension of finely ground sodium saccharin {8.0 g, 39 
mmol) in 50 mL of benzene. Phenylacetyl chloride {7.7 mL, 58 
mmol) was added to this suspension after azeotropic removal 
of water and the resulting mixture was heated at reflux 
temperature for 4 h. ~rhe reaction mixture was filtered while 
hot and the solid was washed with hot benzene. Hexane was 
added to the filtrate and the solid that resulted was 
filtered and recrystallized from benzene/hexane to yield 5.52 
g (4 7%) of pure produc1:; m.p. 177-179 °C. 1H NMR {CDCl3) d: 
8 . 1 7 ( d of d, 1 H) ; 7 . 9 9-7 . 8 7 { rn, 3 H) ; 7 . 3 8-7 . 2 8 ( m, 5 H) ; 4 . 3 9 
(s, 2H). Anal. Calcd. for C15H11N04S: C, 59.79; H, 3.68; N, 
4.65. Found: C, 59.71; H, 3.73; N, 4.61. 
2-Diphenylacetylbenzisothiazo1inone-1,1-dioxide 
(BL57986) . Thionyl chloride (7 mL, 100 mmol) was added to a 
solution of diphenylacetic acid (10 g, 50 mmol) in 50 mL of 
benzene and the resulting mixture was heated to reflux 
temperature for 1 h. Excess thionyl chloride and benzene 
were removed under reduced pressure (1 mm Hg) and then 
tetrabutyl ammonium bromide (0 .. 1 g), fresh benzene (50 mL) 
and finely ground sodium saccharin (6.8 g, 30 mmol) were 
added in one portion. The resulting mixture was heated to 
reflux temperature for 4 h and was then filtered while hot. 
The white solid that was collected was washed with hot 
benzene and the filtrate was concentrated to a small volume 
(ca. 10 mL). The white solid that came out of solution was 
collected by filtration and recrystallized from 
benzene/hexane to yield 5.43 g (48%) of pure product; m.p. 
195-197 °C. 1H NMR (CDCl3) d: 8.08 (d, 1H); 7.95 (d, 2H); 
7.89-7.85 (m, 2H); 7.38-7.27 (m, 10H); 6.30 (s, 1H). Anal. 
Calcd. for C21H15N04S: C, 66.83; H, 4.01; N, 3.71. Found: C, 
66.89; H, 4.01; N, 3.66. 
Z-El'ro-PheP(OPh)2· Z-Pro-OH {1.5 g, 6 mmol) was 
dissolved in 60 mL of dry THF and cooled to 0 oc. Diphenyl 
a~amino-2-phenylethylphosphonat.e (2 .1 g, 6 mmol) and DCC 
(1.22 g, 6 mmol) were added to this solution. The reaction 
mixture was stirred for 6 h at 0 oc and overnight at room 
temperature. The precipitated DCU was removed by filtration 
and 50 mL of ethyl acetate was added to the filtrate. The 
solution was washed twice with succesive portions of 10% 
citric acid, water, 4% sodium bicarbonate and water. The 
resulting solution was dried over MgS04, filtered and 
evaporated to dryness in vacuo to a residue that was 
dissolved in 10 mL CH2Cl2. The small amount of DCU that came 
out of solution was removed by filtration and 30 mL of 
pentane was added to the filtrate to effect crystallization 
of the product. After a few days the product was filtered 
and recrystallized from CH2Cl2-Hexane to yield 1.86 g (53%) 
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of pure product as a white solid; m.p.: 81-84 °C. Anal. 
Calcd. for C33H3305N2P: C, 67.81; H, 5.65; N, 4.79. Found: 
C, 67.56; H, 5.79; N, 4.72. 
Suc-Val-Pro-PheP (OPh) 2 (BL59382) . Palladium on 
charcoal (0.1 g, 5% catalyst) was added to a solution of 1.17 
g (2 mmol) of Z-Pro-PheP(OPh)2 in 50 mL of methanol and the 
resulting mixture was stirred under an atmosphere of hydrogen 
at room temperature for: 2 h. The reaction mixture was 
filtered through Celite! and Z-Val-OH ( 0. 5 g, 2 mmol) was 
added to the filtrate. The solvent was removed in vacuo and 
the residue was dissolved in 60 mL of dry THF. DCC (0.4 g, 2 
mmol) was added to this solution and the resulting mixture 
was kept for 6 h at 0 oc and overnight at room temperature. 
The resulting DCU was removed by filtration and the filtrate 
was washed with water, twice with 4% NaHC03, water and twice 
with 10% citric acid and water. After drying over NaS04, the 
solvent was removed j~n vacuo and the oil that resulted was 
dried under low pressure for a few hours. The dry semisolid 
was dissolved in 60 mL of ethyl acetate and succinic 
anhydride (0.2 g, 2 mmol) was then added. After addition of 
0.1 g of 5% Pd/C the resulting mixture was stirred under a 
hydrogen atmosphere unt.il TLC indicated only one new spot. 
The catalyst was then removed by filtration through Celite 
and the filtrate was washed several times with water. The 
resulting solution was dried over MgS04, filtered and 
evaporated to dryness in vacuo to yield 0.9 g (65%) of 
product as a hygroscopic solid; m.p.: 50-53 oc. 31p NMR d: 
19.75; 19.23 ppm. Anal. Calcd. for C34H4003N3P·2H20: C, 
59.56; H, 6.42. Found: C, 59.59; H, 6.42. 
2-Cyanomethyl Benzisothiazolinone-1,1-dioxide 
(BM00464). Sodium saccharin (5.0 g, 24 mmol) was suspended 
in 50 mL of benzene and tetrabutyl ammonium bromide (20 mg) 
was then added. Water was removed azeotropically from this 
mixture by heating the suspension to reflux temperature for 
45 min. After removal of water, bromoacetonitrile (1.8 mL, 
25.6 mmol) was added and the reaction mixture was heated to 
reflux temperature for 14 h. The mixture was filtered while 
hot and the solid was washed with hot benzene (5 x 5 mL) . 
The filtrate was concentrated in vacuo to a minimum volume 
(c.a. 5 mL) and hexane was then added to effect complete 
precipitation of the product. After one recrystallization 
from chloroform, the yield of pure product was 2.15 g 
(39.6%); m.p.: 134-5 oc. 1H NMR (CDCl3) d: 8.17 (d of d, 
1H); 8. 02-7.89 (m, 3H); 4. 63 (s, 2H) . Anal. Calcd. for 




2-Ethoxy-4H-3,1-benzoxazin-4-one (BM00651). To a 
solution of anthranilic acid (6.85 g, 0.05 mol) in dry 
pyridine (50 ml) at room temperature under anhydrous 
conditions was added ethyl chloroformate (19.2 ml, 0.2 mol) 
dropwise over a 15 min period. After stirring for 2 h, the 
solvent was removed under reduced pressure and the residue 
was stirred vigrously into 100 ml of ice-cold water. The 
insoluble solid was filtered, washed with water and air-
dried. The crude product was dissolved in ethyl acetate, 
treated with charcoal and recrystallized to give the 
benzoxazinone as a white solid (8.5 g, 89%); m.p. 88-90° C. 
Anal. Calcd. for C10H9N03: C, 62.83; H, 4.71; N, 7.33. 
Found: C, 66.78; H, 4.73; N, 7.31. 
5-Nitro-3H-1,2-benzoxathiole-2,2-dioxide (BM00491) 
was purchased from Eastman Kodak; m .p.: · 142-144° C. Anal. 
Calcd. for c7Hs0sNS; C, 39.04; H, 2.32; N, 6.51; S, 14.87. 
Found: C, 39.12; H, 2.33; N, 6.51; S, 14.96. 
4-Chloro-3-(3-isothioureidopropoxy)isocoumarin 
(BM00642) . This inhibitor was prepared as described by Kam, 
C-M., Fujikawa, K., and Powers, J. C. (1988) Biochemistry 27, 
2547; m.p. 174-176° C (decomp) .. Anal. Calcd. for 
C13H14BrCl03N2S; C, 39.65; H, 3.56; N, 7.12; S, 8.13. Found: 
C,39.70; H, 3.62; N, 7.08; S, 8.23. 
3-Benzyloxy-4-chloroisocoumarin (BM00482) . This 
inhibitor was prepared as described by Harper, J. W, and 
Powers, J. C (1985) Biochemistry 24, 7200; m.p. 90-92° c. 
Anal. Calcd. for C16H1103Cl; C, 67.02; H, 3.84; Cl, 12.38. 
Found: C, 66.93; H, 3.92; Cl, 12.28. 
4-Chloro-7-(N-phenylcarbamoyl)amino-3-propoxyiso-
coumarin (BM01096). ~eo 3. 05 g (0. 012 mol) of 7-amino-4-
chloro-3-propoxyisocoumarin [Harper, J. W., and Powers, J. C. 
(1985) Biochemistry 24, 7200] 1n 20 ml of dry THF, 1.44 g 
(0.012 mol) of phenylisocyjanate was added. The solution was 
kept at room temperature for a few days and the solid which 
crystallized out was filtered, washed with pentane, and air-
dried; yield 3.3 g (74%), m.p. 235-236° C (decomp). Anal. 
Calcd. for C19H17Cl04N2; C, 61.22; H, 4.56; N, 7.52; Cl, 
9.52. Found: C, 61.30; H, 4.62;· N, 7.51; Cl, 9.60. 
p-Guanidino benzoic acid (BM01363) . This compound 
was prepared according to the procedure of Chase, T., and 
Shaw E. (1970) Methods i.n Enzymol. 19, 22; m.p. 274° C (dec.). 
Anal. Calcd. for C9H1QClN302: C, 44.56; H, 4.67; N, 19.49; 
Cl, 16.44. Found: C, 44.73; H, 4.65; N, 19.34; Cl, 16.58. 
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Ethyl p-guanidino benzoate (BM01185) . This compound 
was made according to the procedure of Beyerman, H. C., and 
Bontekoe, J. S. (1953) Rec. Trr.xv. Chim. Pays-Bas 72, 643; 
m.p. 164-5° C (dec.). Anal. Calcd. for C10H14ClN302: C, 
49.28; H, 5.79; N, 17.24; Cl, 14.55. Found: C, 49.34; H, 
5.79; N, 17.17; Cl, 14.52. 
O-(p-Guanidinobenzoyl)g1yco1amide Hydrochloride 
(BM03143). (Ganu and Shaw, 1981) Water was removed 
azeotropically from a mixture of p-guanidinobenzoic acid 
hydrochloride(2.51 g, 12 mmol) and N-tetrabutylammonium 
bromide (100 mg) in 50 mL of benzene. 1,2,2,6,6-
Pentamethylpiperidine (PMP) was then added (2.1 mL, 12 mmol), 
followed by 2-chloroa.cetamide (1. 2 g, 13.2 mmol) . The 
result.ing mixture was heated to reflux temperature for 24 
hours, it was filtered while hot and the beige solid was 
thr6roughly washed with. acetone. The crude solid was 
recrystallized from 95% ethanol to yield 1.06 g (34%) of pure 
product as a white solid, mp 249-51°C. 1H NMR (d6-Me2SO) d: 
8.05 (d,2H); 7.75 (broads, 3H); 7.58 (broads, 1H); 7.36 
(d,2H); 7.28 (broads, 1H); 4.66 (s, 2H). Anal. Calcd. for 
C10H13ClN403: C, 44.04; H, 4.80; N, 20.55; Cl, 13.00. Found: 
C, 43.91; H, 4.85; N, 20.45; Cl, 12.93. 
N-(p-Guanidinobenzoyl)valine Amide Hydrochloride 
(BM02655). Triethylamine (3.2 mL, 23 mmol) was added to a 
solution of valine amide hydrochloride (3.1 g, 23 mmol) in 
100 mL of DMF. 1-Hydroxybenzoti~iazole (HOBt, 3.15 g, 23 mmol) 
was added to this mixture, followed by p-guanidinobenzoic 
acid hydrochloride (5.0 g, 23 mrnol) and the reaction mixture 
was then cooled in an ice bath. N,N-
diclyclohexylcarbodiimide (DCC, 5.2 g, 25 mmol) was added to 
the cold (0-5 oc) solution and the resulting mixture was 
stirred at 5-10 °C for 24 h. The white solid in suspension 
(DCU) was filtered and washed with EtOAc. The filtrate was 
concentrated to dryness in vacuo to a foam which was 
triturated with chloroform (5 x 200 mL) with vigorous 
mechanical stirring to remove :~rEt3 · HCl. The resulting 
amorphous solid was taken up in 100 mL of water, filtered 
through Celite to remove HOBt and the filtrate was 
lyophylized to yield 5.13 g (71%) of pure product as a white 
amorphous solid. 1H NMR (d6-Me2SO) d: 10.25 (br.s, 1H); 8.22 
(d, 1H), 7.98 (d, 2H); 7.68 (br.s, 3H); 7.54 (s, 1H); 7.30 
(d, 2H); 7.08 (br.s, 1H}; 4.26 (t, 1H); 2.11 (m, 1H); 0.91 
(d, 3H); 0.89 (d,3H). .Anal Calcd. for C13H2QClN502·0~8 H20: 
C, 47.56; H, 6.63; N, 21.33; Cl, 10.80. Found: C, 47.56; H, 
6.52; N, 21.26; Cl, 10.68. 
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FOREWORD 
Opinions, interpretations, conclusions and recommendations 
are those of the author and are not necessarily endorsed by 
the U.S. Army. 
Where copyrighted material is quoted, permission has been 
obtained to use such material. 
Where material from documents designated for limited 
distribution is quoted, permission has been obtained to use 
the material. 
Citations of commercial organizations and trade names in 
this report do not constitute an official Department of Army 
endorsement or approval of the products or services of these 
organizations. 
In conducting the research described in this report, the 
investigator(s) adhered to the "Guide for the Care and Use of 
Laboratory Animals," prepared by the Committee on Care and 
Use of Laboratory Animals of the Institute of Laboratory 
Animal Resources, National Research Council (DHEW Publication 
No. (NIH) 86-23, Revised 1985). 
For the protection of human subjects, the investigator(s) 
adhered to policies of applicable Federal Law 45 CFR 46. 
In conducting research utilizing recombinant DNA 
technology, the investigator adhered to current guidelines 
promulgated by the National Institutes of Health. 
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PROTEASE INBJ:BITORS AS ANTIVESICANTS 
Keywords: Antivesicants, Protease Inhibitors, Serine Protease, 
Sulfur Mustard 
ABSTRACT 
Bis-(2-chloroethyl)sulfide (HD, sulfur mustard) is a potent 
vesicant which was used in the Iran-Iraq conflict. Sulfur 
mustard penetrates the skin rapidly and after a latent period of 
several hours under temperate climatic conditions, causes 
extensive blistering of the skin. The mustard is thought to 
alkylate DNA which eventually results in the release of potent 
proteolytic (protein degrading) enzymes, particularly serine 
proteases. These serine proteases are capable of destroying a 
number of connective tissue proteins and several of the·enzymes 
seem to be able to specifically cleave proteins at the junction 
of the dermis and epidermis (outer non-vascular layer of skin) . 
The destruction of these basement membrane and connective tissue 
proteins results in an epidermal-dermal separation, fluid 
accumulation, and formation of a blister. 
A total of 39 serine protease inhibitors have been 
submitted in 3-5 g quantities for animal testing. The 
structural classes include 9 isocoumarins, 5 saccharins, 6 
peptide phosphonates, 3 benzoxazinones, 5 benzamidines, 5 
deriva~ive of p-guanidino benzoic acid and 6 miscellaneous 
compounds. The inhibitors have been surveyed for inhibitory 
potency against human neutrophil elastase, human neutrophil 
cathepsin G, rat skin tryptase, human skin tryptase, human skin 
chymase, human plasminogen activator, porcine pancreatic 
elastase, rat mast cell protease II, dog skin chymase, human 
lung tryptase and bovine chymotrypsin. 
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BACKGROUND 
Sulfur Mustard. Bis-1(2-chloroethyl)sulfide (HD, sulfur 
mustard) is a potent vesicant which was used in the Iran-Iraq 
conflict. Sulfur mustard penetrates the skin rapidly and after a 
latent period of several hours under temperate climatic 
conditions, causes extensive blistering of the skin. Antimustard 
ointments which attempt to inactivate the free mustard are 
ineffective since the musta:r·d quickly reacts with components in 
the skin and other tissues. Therefore, an effective therapy for 
sulfur mustard exposure must be based on reversing the 
physiological processes that result upon contact with this potent 
vesicant (Cullumbine, 1947) . 
Bis-(2-chloroethyl)sulfide is a potent alkylating agent which 
can react with the heterocyclic bases in nucleic acids (Ludlum et 
al., 1984) and with a wide variety of the side chain functional 
groups (thiols, thioethers, carboxyl groups, amino groups, 
imidazole rings, etc.) found in proteins. The majority of the 
sulfur mustard is secreted in the form of various metabolites such 
as thiodiglycol, but some is carried by the circulation to other 
organs, and a significant portion is stored in skin reservoirs 
(Klain and Bonner, 1987). While the most significant mustard 
induced injury occurs in the skin (vesication and inflammation), 
significant numbers of mustard casualties have ocular injuries and 
cornea impairment for 2-4 months. In cases of severe exposure, 
there is serious lung and bone marrow damage which results in 
death. 
Mechanism of Sulfur Mustard Induced Blistering. The 
molecular mechanisms by which sulfur mustard causes toxicity are 
unknown but mustard is a powerful alkylating agent of DNA and RNA. 
Papirmeister has suggested that the alkylated purine bases in DNA 
are unstable and undergo both spontaneous and enzymatic 
depurination (Papirmeister et al., 1985). This results in DNA 
strand breaks, and activation of nucleases and other DNA repair 
mechanisms. As a result, poly(ADP-ribose)polymerase is activated, 
NAD+ is depleted, glycolysis is inhibited, and the hexose 
monophosphate shunt is stimulated (Meier et al., 1987). This 
causes the release of potent proteolytic enzymes which produces 
the observed pathology of basal cell necrosis and vesication. 
Evidence for the Papirmeister hypothesis includes the 
isolation and structural characterization of several DNA 
alkylation products upon treatment of DNA with sulfur mustard 
(Benschop et al., 1989) and the demonstration of single strand 
breaks in the DNA after exposure of keratinocyte cultures to low 
levels of sulfur mustard (Bernstein et al., 1989). In addition, 
other agents which result in DNA damage such as UV light and 
radiation have been shown to stimulate the synthesis or release of 
proteases in fibroblast cultures (Miskin and Reich, 1980) . 
Proteases are normally controlled by natural plasma protein 
protease inhibitors such as a1-protease inhibitor, a1-
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antichymotrypsin, and a2-macroglobulin. If this antiprotease 
screen is destroyed, tissue destruction results. Several of the 
plasma serpins (serine protease inhibitors) including a1-protease 
inhibitor and a1-antichymotrypsin have essential methionine 
residues and are susceptible to inactivation by oxidizing agents 
or alkylating agents. A single dose of sulfur mustard in the 
mouse brain has recently been shown to cause a burst of oxidants 
(Elsayed et al., 1989). The serpin screen could then be removed 
directly by sulfur mustard alkylation or indirectly by oxidation 
as a result of this oxidative burst. Thus, sulfur mustard 
exposure probably results both in the release of powerful 
proteolytic enzymes and in t.he partial destruction of the protease 
inhibitor screen which would normally protect the organism from 
proteolysis. 
Other Blistering Dis.ease S·tates Involve Proteases. 
Blistering disease states which have been described include 
dermatitis herpetiformis (DH), bullous pemphigoid (BP), chronic 
bullous disease of childhood., and pemphigus vulgaris. These 
diseases are characterized by destruction of various connective 
tissue components of the epidermis or dermis followed by tissue 
separation and the formation of fluid-filled blisters. Blister 
fluids from patients with all of these diseases have been shown to 
contain proteases including elastase and collagenase (Oikarinen et 
al., 1983). Human polymorphonuclear leukocyte elastase is the 
major enzyme in DH fluid, while BP fluid predominantly contains 
the metalloprotease collagenase. A trypsin-like enzyme and a 
thiol protease have also been implicated in blister formation 
respectively in recessive dystrophic epidermolysis bullosa and 
epidermolysis bullosa simplex (Takamori et al., 1985). Incubation 
of normal human skin with the bliste~r fluid from patients with 
epidermolysis bullosa letalis, a severe and usually fatal 
congenital blister disease, results in dermal-epidermal 
separation. A number of cornmon serine protease inhibitors 
prevented the separation (Matsumoto and Hashimoto, 1986) . 
Proteases are Associated wiit'.h Inflammation. Proteases 
are important mediators and modulators of inflammation and have 
been demonstrated in non-blistering inflammatory disease states 
such as psoriasis and arthritis. The most abundant enzymes are 
the serine proteases elastase and cathepsin G (a chymotrypsin-like 
enzyme) from leukocytes; chymases (chymotrypsin-like enzymes), and 
tryptases (trypsin-like) enzymes from mast cells; plasminogen 
activator; and the metalloprotease collagenase from leukocytes. 
These enzymes are capable of cleaving a variety of connective 
tissue proteins including elastin, collagen, proteoglycans, and 
other basement membrane components. 
Sulfur Mustard Induced Inflammatory Lesions Contain 
Proteases and Protease-Inhibitor Complexes. The proteolytic 
enzymes released upon exposure to sulfur mustard have not yet been 
isolated or characterized, but likely candidates include chymases 
and tryptases from mast cells, elastase and cathepsin G from 
leukocytes, plasminogen activator, and collagenase. Culture 
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fluids from mustard-induced inflammatory lesions in rabbit skin 
show 3 to 6 fold increased levels of proteases both in developing 
and healing lesions (Higuchi et al., 1987). These fluids will 
hydrolyze two synthetic peptide substrates, Boc-Leu-Gly-Arg-AFC 
(Boc = t-butyloxycarbonyl, AFC = 7-amino-4-trifluoromethyl 
coumarin) and Bz-Phe-~-naphthyl ester (Bz = benzoyl) . The first 
peptide is a substrate for trypsin, tryptases, plasmin, 
plasminogen activator and other trypsin-like enzymes, while the 
latter is a substrate for chymotrypsin-like enzymes includ'ing 
chymases and cathepsin G. The rabbit skin culture fluids did not 
consistently hydrolyze four other synthetic peptide substrates 
(two for elastase and two for cathepsin G) or the protein elastin 
(elastase's natural substrate). Exposure of human skin in culture 
to sulfur mustard results in a 41 % increase in plasminogen 
activator activity (Dannenberg et al., 1989), an enzyme which is 
known to be associated with blister formation (Hashimoto et al., 
1983) . The enzymatic activity of chymases, tryptases, and 
angiotensin converting enzyme toward small synthetic substrates 
were not elevated. 
The proteases found in the cult:ure fluids from mustard-
induced inflammatory lesions in rabbit skin are not present as 
free active enzymes, but are found as inactive complexes with 
their natural plasma protease inhibitors a1-protease inhibitor and 
a2-macroglobulin (Harada et: al., 1987; Dannenberg et al., 1987; 
Higuchi et al., 1987). These compl~xes are formed as natural 
protein protease inhibitors from the plasma react with the 
proteases being released at the site of inflammation. The 
protease-inhibitor complexes are incapable of hydrolyzing protein 
substrates and complex formation thus protects the organism from 
further damage. The natural plasma protease inhibitors are 
probably not completely destroyed by exposure to low levels of 
sulfur mustard and are still available to react with some of the 
proteases released in the blister. 
Protease-inhibitor complex formation hinders the 
identification of the proteases present in sulfur mustard induced 
culture fluid. Complexes of elastase and cathepsin G respectively 
with a1-protease inhibitor and 0t1-antichymotrypsin are inactive 
toward both synthetic peptide substrates and natural protein 
substrates. Thus the lack of hydrolysis of elastin or elastase 
substrates does not preclude the presence of inactivated elastase 
in the culture fluids. Similarly the lack of hydrolysis of the 
protein fibrin by the culture fluids doesn't exclude the presence 
of plasmin or plasminogen act:ivator. In summary, it is now clear 
that there is a chymotrypsin-like enzyme (chymase), a trypsin-like 
enzyme (tryptase), and plasminogen activator in the sulfur mustard 
induced inflammatory lesions, but the presence of other enzymes 
has not been excluded. 
Skin Serine Proteases Have Been Isolated and 
Characterized. The dermis of human skin is a rich source of 
mast cells and salt extract.ion of human skin has yielded two 
serine proteases, a chymase and a tryptase. These serine 
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proteases are localized in the granule fraction of mast cells, a 
cell type which is located predominantly in connec·tive tissue. 
The chymase has been demonst.rated immunocytochemically to bind to 
the derma-epidermal junction in skin (Sayama et al., 1987). Both 
the mast cell chymase and tryptase are able to specifically cleave 
proteins found in the dermal-epidermal boundary and cause 
vesication. The chymase is incomplE~tely inhibited by plasma due 
to a 650 fold slower rate of reaction with the serpins a1-protease 
inhibitor and a1-antichymotrypsin (Schechter et al., 1989), while 
the tryptase appears not to be inhibited by most protein protease 
inhibitors (Schechter et al., 1983). This may explain the ready 
detection of chymase and tryptase activity in culture fluids from 
mustard-induced lesions in rabbit skin. 
Rat mast cells contain two chymases (RMCP I and RMCP II) 
which have been more extensively characterized than the chymase 
from human skin. Both of these serine proleases are highly 
homologous 1:o human mast chyrnase and human leukocyte cathepsin G. 
RMCP I and RMCP II have both been sequenced and the x-ray crystal 
structure of RMCP II has been determined, while the x-ray 
structure of RMCP I is underway (Woodbury and Neurath, 1980; 
Remington et al., 1988). The sequence of dog mast cell tryptase 
and a related dog mast cell protease have been determined by gene 
sequencing 1:echniques (Vanderslice et al., 198 9) and it is likely 
that the sequences for human skin tryptase and chymase will be 
available in the next few years. 
The substrate specificity and inhibition profile of human 
skin chymase, human skin tryptase, RMCP I, RMCP II, and related 
enzymes have been studied in the laboratory of the principle 
investigator (Powers et al., 1985). Human skin chymase hydrolyzes 
peptide substrates containing aromatic amino acid residues and 
prefers Phe-AA and Tyr-AA bonds over Trp-AA bonds (AA = any amino 
acid residue) in contrast to chymotrypsin which prefers Trp over 
Phe and Tyr. One of the best peptide substrates is Suc-Phe-Val-
Pro-Phe-NA (Sue = succinyl, NA = 4-nitroanilide) . Human skin 
tryptase is a trypsin-like enzyme, but seems to prefer double 
basic residues in its substrates (Tanaka et al., 1983). For 
example, the~ thioester substrate Z-Lys-Arg-SBu-i (Z = 
benzyloxycarbonyl, SBu-i = thioisobutyl ester) is hydrolyzed by 
human skin tryptase with a kcatiKM = 59,000,000 M-1s-1, a second 
order rate constant which is close to the diffusion controlled 
rate. 
Serine Protease Specificity. The specificity of serine 
proteases toward natural peptide substrates or synthetic 
inhibitors is determined by the nature of the primary substrate 
specificity pocket (S1) and secondary subsites (S2, S3, etc.} on 
the surface of each individual enzyme. Trypsin's primary 
specificity site contains an Asp residue in the back of the S1 
pocket so that trypsin will only bind to and hydrolyze peptide 
substrates containing lysine or arginine residues (a schematic 
model of trypsin with a bound substrate is shown below) . The 
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three-dimensional structure of chymotrypsin is quite similar 
except that the Asp-189 in ·trypsin is replaced by Gly-189 in 
chymotrypsin. As a result the S1 pocket of chymotrypsin in very 
hydrophobic and chymotrypsin p~efers substrates containing 
aromatic amino acid residues such as Trp, Tyr; and Phe. With many 
serine proteases, interactions of inhibitors with the extended 
substrate binding site (S2, S3, etc.) are important to increase 
the specificity and reactivity of the inhibitor. This is clearly 
the case with human skin chymase and tryptase. For example, 
interaction of the Lys in the substrate Z-Lys-Arg-SBu-i with the 
82 subsite of human tryptasE~ results in an accelerated rate of 
hydrolysis, while little change in hydrolysis rate is observed 
with trypsin. 
























It is clear-no matter the exact mechanism of their release or 
their source-that proteaSE!S are major factors in the tissue 
destruction that accompanies: mustard induced vesication. We 
propose that protease inhibitors will be effective· antivesicants 
and should be useful both in preventing blistering and in the 
treatment of blisters. Appropriate target proteases are the mast 
cell chymase and tryptase, serine proteases which are localized in 
the skin and have the ability to cleave proteins at the dermal-
epidermal junction. However other serine protease such as 
elastase and cathepsin G from leukocytes, and plasminogen 
activator may also be involved. Evidence for the involvement of 
other classes of proteases such as the metalloprotease collagenase 
or the thiolprotease cathepsin B is incomplete or lacking at 
present, although the mast cell tryptase is able to activate 
latent collagenase (Gruber et al., 1989). 
Research Strategy. Since the exact target enzyme (or 
enzymes) is not known with certainty, we have decided to 
synthesize general serine protease inhibitors, specific chymase 
inhibitors, specific tryptase inhibitors, specific plasminogen 
activator inhibitors, and specific inhibitors for other enzymes as 
appropriate. We plan to shift our emphasis to a particular enzyme 
or group of enzymes when more biological data is obtained on the 
role of specific proteases in blistering or when we receive animal 
test data on the compounds which we have already submitted. Until 
that time, we plan to submit for testing a wide variety of 
potentially active structures including both general serine 
protease inhibitors and inhibitors which are more enzyme specific. 
During the last portion of this contract, we have been focusing on 
inhibitors for tryptase since this may be the most significant 




1. Prepare and submit for animal testing 3-5 inhibitors of 
serine proteases such as 3,4-dichloroisocoumarin and saccharins 
each year. 
2. Prepare and submit for testing 3-5 inhibitors of human skin 
chymase each year. 
3. Prepare and submit for testing 3-5 inhibitors of human skin 
tryptase each year. 
4. Prepare and submit for testing each year 3-5 inhibitors for 
other human serine proteases-such as human leukocyte elastase, 
cathepsin G, and plasminogen activator-which may have a role in 
vesication. 
5. Assay all inhibitors with human skin serine proteases and 
related enzymes for in vitro effectiveness. 
Research Progress-Summary 
1. A total of 39 serine protease inhibitors have been submitted 
in 3-5 g quantities for animal testing during the first two years 
of this contract. The structural classes include 9 isocoumarins, 
5 saccharins, 6 peptide phosphonates, 3 benzoxazinones, 5 
benzamidines, 5 derivative of p-guanidino benzoic acid and 6 
miscellaneous compounds. All the inhibitors submitted are listed 
in the following table along with their sample numbers. 
2. Various inhibitors have been surveyed for inhibitory potency 
against human neutrophil elastase, human neutrophil cathepsin G, 
rat skin tryptase, human skin tryptase, human skin chymase, human 
plasminogen activator, porcine pancreatic elastase, rat mast cell 
protease II, dog skin chymase, human lung tryptase and bovine 
chymotrypsin. 
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SAMPLES SUBMITTED: DMAD17-89-C-9008 
BOT-NUM WR-NUM SUB-ID SUB RCBD COMPOUND 
ISOCOUMARINS (9 submitted) 
BL58572 268195 II-148 89/05/15 3,4-dichloroisocoumarin 
BL57637 268119 II-134 89/03/20 3-chloroisocoumarin 
BL57413 259666 II-137 89/03/13 4-chloro-3(2-phenylethoxy)isocoumarin 
BM00482 268387 II-151 89/08/08 4-chloro-3-benzyloxyisocoumarin 
BM04319 268693 MA-134 90/04/17 7-amino-4-chloro-3-cyclohexylmethoxyisocoumarin 
BM04668 268715 GP1 90/05/17 4-chloro-3-methylisocoumarin 
BM01096 268440 J0-138 89/09/12 4-chloro-7-(N-phenylcarbamoyl)amino-3-propoxy 
isocoumarin 
BM00642 268397 II-152 89/08/21 4-chloro-3-(3-S-isothiureidopropoxy)isocoumarin 
BM06288 GP2 90/09/05 4-chloro-3-methoxyisocoumarin 
tU SACCHAiliHS (5 submitted) p.! 
I.Q 
(I) 
BL57977 268145 MA-84 89/04/19 N-benzoyl saccharin 
~ BL57995 268147 MA-89 89/04/19 N-phenylacetyl saccharin 1\.) 
BL57986 268146 MA-87 89/04/19 N-diphenylacetyl saccharin 
BL57931 268141 MA-86 89/04/19 N-furoyl saccharin 
BM00464 268385 MA-96 89/08/01 N-cyanomethyl saccharin 
PROS PHONATES (6 submitted) 
BL57959 268143 II-22 89/04/19 Z-MetP(OPh)2 
BL57968 268144 II-138A 89/04/19 Z-ValP(OPh)2 
BL57422 259858 II~137A 89/03/13 Z-PheP(OPh)2 
BL57842 268132 II-139 89/04/10 Z-Phe-PheP(OPh)2 
BL59382 268241 II-147 89/06/14 Suc-Val-Pro-PheP(OPh) 2 























BENZOXAZINONES (3 submitted) 
BM00651 268398 J0-12 
BM05441 GP3 
BM05807 GP4 






MISC. (6 submitted) 
BL57646 015392 II-137B 
BL57940 268142 II-145 














































Isocoumarins-Genera1 Inhibitors. Dichloroisocoumarin 
(WR268195) is an excellent general inhibitor of serine proteases 
and was discovered in the laboratory of the principal investigator 
(Harper et al., 1985). With the exception of the bacterial enzyme 
subtilisin, 3,4-dichloroisocoumarin is an inactivator of all 
serine proteases which have been tested, including human leukocyte 
elastase, human skin chymase, dog skin chymase, rat mast cell 
protease I, and rat mast cell protease II. 
The dichloroisocoumarin ring system contains a masked acid 
chloride (or ketene) functional group which is exposed when an 
acyl enzyme is formed upon reaction with the active site serine of 
a serine protease (Harper et al., 1985). The acyl enzyme (top 
right of figure) which is formed initially can react further by 
acylating the active site histidine to for~ a doubly acylated 
enzyme derivative (bottom left) or ca-n hydrolyze to form an acyl 
enzyme stabilized by a salt link between the protonated histidine 
and the inhibitor carboxyl group (bottom right) . The monochloro 
derivative, 3-chloroisocoumarin (WR268119), inhibits chymotrypsin-
like enzymes at slower rates than 3,4-dichloroisocoumarin and does 
not touch trypsin. The acyl enzymes formed upon reaction with 
dichloroisocoumarin have variable stabilities, but in general the 
half-lives for reactivation (deacylation) are greater than 8 hrs 










Dichloroisocoumarin and 3-chloroisocoumarin are formed by 
reaction of homophthalic acid with PCls. 
Isocoumarins-Specific Inhibitors. We have also 
synthesized a number of isocoumarin inhibitors which are more 
specific for the active sites of chymases or tryptases. 
Page 14 
Inhibitors targeted for chymase should contain an aromatic side 
chain which resembles the side chain of Phe, Tyr or Trp, while 
those inhibitors targeted for tryptase should containing a charged 
group which resembles the side chain of Arg or Lys. Several of 
the more specific isocoumarin inhibitors are shown below. 
Inhibitors with the benzyloxy (such as WR268387) or phenylethoxy 
groups (WR259666) were targeted at the chymases, while those with 







The mechanism of inhibition of serine proteases by 3~alkoxy-
4-chloroisocoumarins involves acylat.ion of the active site serine-
195 to form acyl enzymes with varying stabilities (tl/2 = hrs to 
days) depending on the nature of the alkoxy group (Harper and 
Powers, 1985). 
0 0 
c¢ ,.......ser19s 0 C02R OR 
Cl Cl 
Analogous isocoumarins ·with electron donating substituents in 
the 7-position such as 3-alkoxy-7-amino-4-chloroisocoumarins 
(below) are mechanism-based or suicide inhibitors of serine 
proteases (Powers et al., 1989). These inhibitors also acylate 
serine proteases, but form stable acyl enzymes which are not 
reactivated upon long standing or upon treatment with 
hydroxylamine. The inhibition mechanism involves formation of an 
acyl enzyme which can then eliminate chloride to form a quinone 
imine methide (center) . This intermediate then irreversibly 
alkylates His-57 with the formation of a stable covalent bond 
between enzyme and inhibitor. This mechanism is supported by x-
ray crystallographic studies of complexes of isocoumarin 
inhibitors bound to the active site of porcine pancreatic elastase 
{Bode et al., 1989). Thus far, five separate isocoumarins have 
been studied crystallographically, t,N'o give simple acyl enzyme 
structures (above), two give acyl enzyme structures where His-57 
has been alkylated, and one gives a mixture of both structures. 
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Isocoumarins which have been submitted and should inhibit 
serine proteases by the above mechanism include 7-amino-4-chloro-
3-(cyclohexylmethoxy)isocoumarin (WR268693) and 4-chloro-7-(N-
phenylcarbamoyl)amino-3-propoxyisocoumarin (WR268440). 
Two analogs of 3,4-dichloroisocoumarin are shown below. 
These two compounds were synthesized with the expectation that any 
isocoumarins with two small electronegative functional groups 




a-Aminoalkylphospholt'tates Diphenyl Esters. Peptidyl 
derivatives of a-aminoalkylphosphoriate diphenyl ester are 
effective and specific inhibitors of serine proteases at low 
concentrations (Oleksyszyn and Powers, 1989; 1991) . These peptide 
derivatives phosphonylate the active site serine to form stable 
phosphonyl derivatives. Good interactions with the S1 pocket of 
the target serine protease are necessary before nucleophilic 
substitution on phosphorus atom occurs to give a stable phosphonyl 
derivative. 
Active Site 
S b s1 u strate Ser195 
Binding Site II 0-H ---His 
____J R I 57 
R-CO-NH-C
1




R I H H' I ,..0 - IS57 
R-CO-NH-CH-ft'OPh 
0 0, , ~ 
H' ~H oxyanion 
I I 
N N hole 
Phosphonate diphenyl ester inhibitors are chemically stable, 
relatively easy to synthesize, do not react with 
acetylcholinesterase, form vE~ry stable derivatives possibly due to 
their resemblance to the tetrahedral intermediate involved in 
peptide bond hydrolysis, and have considerable potential utility 
as therapeutic agents. 
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We have submitted a nurmer of simple amino acid and peptide 
derivatives of phosphonate diphenyl esters including Z-MetP(OPh)2 
(WR268143), Z-ValP(OPh)2 (WR268144), Z-PheP(OPh)2 (WR259858), Z-
Phe-PheP(OPh)2 (WR268132), and Suc-Val-Pro-PheP(OPh)2 (WR268241). 
More recently, we have accomplished the synthesis of the 
amidinophenyl phosphonate derivative (WR268694) shown below. The 
benzyloxycarbonyl (Z) derivative has been submitted recently for 
testing. We have also synthesized a few peptide derivatives of 
the amidinophenyl phosphonate, but not in sufficient quantities 
for submission. 
Benzoxazin-4-ones. Substituted benzoxazin-4-ones were 
discovered to be potent inhibitors of human leukocyte (HL) 
elastase, porcine pancreatic (PP) elastase, cathepsin G, and 
chymotrypsin by the PI (Teshima et al., 1982). Mechanistic 
studies by Abeles showed that these compounds were forming stable 
acyl enzyme derivatives (shown below) with chymotrypsin (Hedstrom 
et al., 1984) and this has been confirmed by x-ray 
crystallographic studies with two benzoxazinones bound to PP 
elastase (Radhakrishnan et al., 1987). Due to the potential of 
benzoxazinone inhibitors of HL elastase for treatment of 
emphysema, a group at Syntex Canada has synthesized over 100 new 
benzoxazinones, carried out a structure-function study as 
substituents were varied on the ring system, and studied the 
plasma stability of these compounds (Spencer et al., 1986; Krantz 
et al., 1987; Krantz et al., 1990). This year we have submitted 
two benzoxazinones (BM05441 and BM05807) as elastase inhibitors. 
Guanidinobenzoic Acid Inhibitors. Esters of p-
guanidinobenzoic acid have been reported to be potent inhibitors 
for various trypsin-like enzymes (Okutome et al., 1984; Fujii et 
al., 1977) and p'-nitrophenyl-p-guanidinobenzoate is widely used 
as an active-site titrant for these enzymes (Chase and Shaw, 
1970) . An active-site titrant for trypsin-like enzymes developed 
in the laboratories of the PI is benzyl p-guanidinothiobenzoate 
(Cook and Powers, 1983) . We have submitted samples of five p-
guanidinobenzoic acid derivatives for testing. 
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Saccharin Inhibitors. N-Acyl and N-aryl saccharins are 
potent -acylating agents of HL elastase, cathepsin G, and 
chymotrypsin (Zimmerman et al., 1980; Ashe et al., 1981). A few 
of the N-acyl derivatives such as N-furoyl, N-thienoyl, and N-
benzoylsaccharin inhibit t.rypsin with ICso values of 0. 7-2.4 J.LM. 
These structures were initially designed as acyl transfer 
reagents, but studies using 35s-labeled N-furoylsaccharin 
indicated that the saccharin portion of the inhibitor becomes 
covalently and stoichiometrically bound to both HL elastase and 





A ==acyl or aryl with oc 
electronegative group: 0 
NH-R 
so~ 
Two of the saccharins which we have submitted are shown 
below. 
WR26814Ei 
Miscellaneous Inhibitors. Two heterocyclic general serine 
protease inhibitors have been submitted. They are isatoic 
anhydride which has been shown to acylate the active site of 
chymotrypsin and form a stable acyl enzyme (Moorman and Abeles, 
1982) and 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide which forms a 








0 2N 'CC)so2 
5-Nitro-3H-1 ,2-benzoxathiole .. 2,2-dioxide 
WR099874 
The sulfide shown below is an ~ffective inhibitor of elastase 
which was discovered in the laboratory of the PI. 
The following phthalimide derivative was designed as a 
trypsin inhibitor. 
~ NH 
~N~S----{ • HBr 
0 NH2 




Benzamidine Inhibitor~'. Five benzamidine inhibitors have 
been submitted as reversible inhibitors for trypsin-like enzymes. 
These compounds interact with the 81 pocket as well as other 
portions of the active site. 
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-o- -Q--t<NH2 Cl NHCO-NH f ' + - NH2 BM06840 
BM07481 
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Biological Test Data. 
All the inhibitors which we have synthesized have been tested 
for inhibitory potency against a variety of serine proteases. 
Kinetic data obtained with the various inhibitors are shown in 
Tables I-III. Most of the inhibitors are irreversible or slowly 
reversible inhibitors and we report the second order inhibition 
rate constants kobs/[I]. Several of the inhibitors reported in the 
tables have kobs/[I] values of 100,000 M-1s-1 or greater. A 
second order inhibition rate constant of this magnitude indicates 
that the reaction between equimolar concentrations of enzyme and 
the inhibitor is over in less than 0.2 min. (the time required for 
mixing the enzyme and inhibitor in the assays) . The half-life of 
the inhibition reaction can be calculated from the equation t1;2 = 
0.693/{ [I]*kobs/[I]}. Thus, an inhibitor with a kobs/[I] value of 
100,000 M-1s-I would have an inhibition half-life of 6.93 sec. at 
an inhibitor concentration of 1 ~M, while an inhibitor with 
kobs/[I] = 10,000 would have a half-life of 69 sec. For the few 
reversible inhibitors investigated, KI values (dissociation 
constant of the enzyme-inhibitor complex) or IC5o values ·are 
given. 
The data with bovine chymotrypsin, cathepsin G, rat mast cell 
protease II, human skin chymase, and dog skin chymase is given in 
Table I. The best isocoumarin inhibitor in this table is 3-
benzyloxy-,4-chloroisocoumarin (WR268387) with a kobsdl [I] = 12,000 
M-1s-1 for the human skin chymase. Increasing the length of the 
side chain at position 3 by one methylene group [4-chloro-3-(2-
phenylethoxy)isocoumarin, WR259666] reduces the activity by a 
factor of 35. 
The best phosFhonate inhibitor for chymotrypsin-like enzymes 
is Suc-Val-Pro-Phe (0Ph)2, which corresponds to the sequence of an 
excellent 4·-nitroanilide substrate for these enzymes. NMR studies 
with chymotrypsin indicate that only one of the two stereoisomers 
reacts with the enzyme (kobsd/[I] = 146,000 M-1s-1 calculated for 
the single :Lsomer, the value in the table is for the DL mixture) . 
The 31p NMR of chymotrypsin inhibited by this peptide phosphonate 
shows one broad signal at 25.98 ppm corresponding to the Ser-195 
phosphonylated enzyme derivative (Oleksyszpn and Powers, 1991) . 
The tripeptide phosphonate Suc-Val-Pro-Phe (0Ph}2 makes better 
interactions with the extended substrate binding site of the 
enzyme than is possible with the shorter dipeptide or amino acid 
phosphonate derivatives. 
All of the saccharins submitted so far have high kobsd/[I] 
values with the various chymotrypsin-like enzymes and low IC50 
values with the elastases tested. One of the better inhibitors in 
this family is N-furoylsaccharin. The acyl enzymes formed upon 
acylation of serine proteases by acyl saccharins have variable 
stabilities. Furoyl saccharin and benzoyl saccharin form 
inhibited elastase derivatives which are very stable and have 
half-lives for deacylation of 80-160 hrs. In contrast the 
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chymotrypsin derivatives have much shorter half-lives in the range 
of 1.9 hrs. One disadvantage of some acyl saccharins is their 
fairly rapid hydrolysis at neutral pH values. 
The data with porcine pancreatic elastase (PPE) and human 
leukocyte elastase (HLE) is given in Table ii. All the 
isocoumarin derivatives reported in this table are excellent 
inhibitors of HLE, the best one being the 7-ureido derivative 
WR268440 with a kobsd/[I] = 140,000 M-1s-1 for HLE. It is also 
highly selective compared with 3,4-dichloroisocoumarin and 3-
chloroisocoumarin which is a logical consequence of the 
improvement in binding resulting from substitution at the ?-amino 
group. We have also submitted an excellent benzoxazinone 
inhibitor. for HLE (WR268398). Two analogs of this compound were 
poor inhibitors of the elastases, and were only moderate 
inhibitors of chymotrypsin-like enzymes. 
The phosphonate derivatives which we have submitted thus far 
are not good inhibitors for PPE or HLE. This is not surprising 
since the sequence of the tripeptide was chosen for chymase 
inhibition and this sequence is very specific for the chymases as 
discussed earlier. An excellent phosphonate inhibitor for the 
elastases has been synthesized only in a small scale. This 
inhibitor, Boc-Val-Pro-ValP(OPh)2, has kobsd/[I] value of 27,000 
M-1s-1 for human leukocyte elastase (HLE) and 11,000 M-1s-1 for 
porcine pancreatic elastase (PPE) . Again this sequence 
corresponds to a good HLE substrate sequence and at low 
concentrations this peptide did not react with chymotrypsin. 
The inhibition data obtained with bovine trypsin, human lung 
tryptase, rat skin tryptase, human skin tryptase, anq human 
recombinant tissue plasminogen activator is given in Table III. 
The best tryptase inhibitor submitted is the 3-
(isothioureidopropoxy)isocou~narin WR268397 with a kobs/[I] 
650,000 M-1s-1 for the rat skin tryptase, an extremely rapid 
inhibition rate. However, the acyl-enzyme formed with this 
inhibitor is unstable and the enzyme regains its activity within 5 
min. 
Several p-guanidinobenzoic acid derivatives have been tested 
as inhibitors for the various tryptases. One of these 
derivatives, 0-(p-guanidinobenzoyl)glycolamide is an excellent 
inhibitor of the rat skin tryptase, but is a much poorer inhibitor 
of human skin tryptase. In contrast to the isocoumarin WR268397, 
the inhibited derivative did not regain enzyme activity upon 
standing. We pursued this lead and synthesized additional 
derivatives. The 4-cyanophenyl p-guanidinobenzoate was also a 
very potent inhibitor of trypsin and human lung tryptase. However 
it is probably not very stable in solution. 
We then shifted our emphasis away from guanidine compounds to 
amidines when we learned that amidines are likely to be less toxic 
than guanidine derivatives. In the last few months of this 
contract we have been concentrating only on inhibitors for 
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tryptases since this may be the more important enzyme in blister 
formation. Aromatic benzamidine derivatives are reversible 
inhibitors for trypsin-like enzymes and we have been preparing a 
series of derivatives to see if we can increase their inhibitory 
potency for tryptases. The most potent inhibitor thus far for 
both trypsin and the human lung tryptase is 1-(amidinophenyl)-3-
(4-phenoxyphenyl)urea (GP8) which has a Kr value of 1.6 J..LM with 
bovine trypsin and inhibits 71% of the activity of human lung 
tryptase at 226 J.LM. 
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Table I. Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and Dog Skin 








259666 4-chloro-3-(2-pheny lethoxy )IC 
268387 4-chloro-3-benzyloxyiC 
268693 7 -amino-4-chloro-3-
cyclohexy lmethoxy IC 
268715 4-chloro-3-methyl IC 






























Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 









268142 di( 4-isovaleroylpheny l)sulfide 
268143 Z-MetP(OPh)2 
268144 Z-ValP(OPh)2 
259858 Z-PheP (0Ph)2 
268132 Z-Phe-PheP(OPh)2 


























Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 































ainactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, containing 9 % Me2SO at 25 
°C. Enzyme concentrations were: chymotrypsin, 1.6 JlM; cathepsin G, 0.8-1.6 JlM; RMCP II, 38 nM; human skin chymase, 0.07 
J..LM. Chymotrypsin and cathepsin G were assayed with Suc-Val-Pro-Phe-NA (0.5 J..LM), human skin chymase and RMCP II were 
assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 JlM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
binhibitor concentrations were in the range 5.2 J.!M-1000 JlM. N-Cyanomethyl saccharin was inactive at 1 mM. 
CJnhibitor concentrations were in the range: 4.8 JlM-1000 JlM. 
dJnhibitor concentrations were in the range: 3-148 JlM. 
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Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 
Dog Skin Chymase by V arlo us Serine Protease Inhibitors.fl 
elnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 45 tJM; 7-amino-4-chloro-3-cyclohexylmethoxyiC, 0.44 
mM; Suc-Val-Pro-PheP(QPh)2, 0.54 J!M. 
fJnhibitor concentrations were as follows: 3,4-dichloroisocoumarin, 540 J!M; 3-benzyloxy-4-chloroiC, 1.0 tJM. 
&Data was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841. 
hNo inhibition. 
iJnhibition was not time dependent, and the % inhibition was measured at 92 f.1M 
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Table IT. Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte Elastase (HLE) 
by Various Serine Protease Inhibitors. a 
WR Compound No. Inhibitor HLEC 
Isocoumarin Inhibitors 
268195 3,4-dichloroiCd 2,500 9,000 
268119 3-chloroicd 510 3,900 
~ 
259666 4-chloro-3-(2-pheny lethoxy )IC 
268440 4-chloro-7 -(N -phenylcarbamoyl)amino-
3-propoxy IC 59 140,000 
268715 4-chloro-3-methyl IC Nle 72%f 
BM06288 4-chloro-3-methoxy IC 601 87 
Misc·ellaneous Inhibitors 
015392 isatoic anhydride 
268142 di( 4-isovaleroy lpheny 1 )sulfide 2J.!Mg 
099874 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide 50 
Benzoxazinones 
268398 2-ethoxy-4H-3, 1-benzoxazin-4-one 110,000 
BM05441 2··phenylamino-
4H-3, 1-benzoxazin -4-one 216 NI 
BM05807 2·-benzy lamino-
4H-3, 1-ben:zoxazin-4-one NI NI 
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Table II (Continued). Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte 
Elastase (HLE) by Various Serine Protease Inhibitors. a 
kobsi[I] (M-1 s-1) 
WR Compound No. Inhibitor 
Saccharin Inhibitors 
268145 N-benzoy !saccharin 5.2 JlMh 2.4j.tMh 
268147 N -pheny lacetylsaccharin 
268146 N-dipheny lacety !saccharin 
268141 N-furoy !saccharin 0.58 JlMh 0.36j.tMh 
268385 N -cyanon1ethy I saccharin 
Plttosphonate Inhibitors 
268143 Z-MetP(QPh)2 Nie 0.8 
268144 Z-V alp (OPh)2 2.5 90 
259858 Z-PheP(QPh)2 NI 6 
268132 Z-Phe-PheP(QPh)2 NI NI 
268241 Sue-Val-Pro-PheP(QPh)2 NI NI 
alnactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M N aCl, pH 7.5 
buffer, containing 8-12% Me2SO at 25 °C. Enzyme concentrations were: PPE, 1.6 J.!M; HLE, 
0.3 j.LM. PPE was assayed with Sue-Ala-Ala-Ala-N A (0.75 mM), and HLE was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA (0.5 mM). 
binhibitor concentrations were in the range: 3-1000 JlM. 
Cfuhibitor concentrations were in the range: 1.2-1000 J.l.M. 
dnata was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 
1831-1841. 
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Table II (Continued). Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte 
Elastase (HLE) by Various Serine Protease Inhibitors. a 
eNo inhibition. 
finhibition was not time dependent. 
ginhibition was not time dependent and the ICso was obtained. 
hiCso values obtained from Zimmerman, M., Morman, H., Mulvey, D., Jones, H, Frankshun, 
R. and Ashe, B. M. (1980) J. Bioi. Chern. 255, 9848-9851. 
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Table Ill. Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human Recombinant 
Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, Benzamidines, and 
Miscellaneous Inhibitors. 
WR Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Isocouinarin Derivatives 
268195 3,4-dichloroisocoumarin 200 190 610 70 
268397 4-chloro-3-(3-isothioureido-
propoxy )isocoumarin 46,000 260,000 650,000 83,000 13,000 
Guanidinobenzoic Acid Derivatives 
268476 p-guanidinobenzoic acid Nig 
184335 ethyl p-guanidinobenzoate 4.3 1.7 0.7 Nlg 
268570 N-(p-guanidinobenzoy 1) 
valine amide 4.4 4.7 1.3 2,000 
268596 0-(p-guanidinobenzoy 1) 
glycolamide 100 19%h 130,000 5.8 Nlg 
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Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, 
Benzamidines, and Miscellaneous Inhibitors. 
WR Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
BM06304 4-cyanopheny 1 
p-guanidinobenzoate 150,000 91,000 
Phosphonate Inhibitors 
268694 Z-NHCH(AmPh)P03Ph2i ? (\()(\ .. , •. , ... v 16 
Benzamidine Derivatives K1 (J!M) % Inhibitioni 
BM06804 1-(amidinophenyl)-3-phenylurea 23 41 
BM06840 1-(amidinophenyl)-
3-( 4-chloropheny 1 )urea 18 51 
BM07481 1-(amidinophenyl)-3-benzylurea 19 49 
GP8 1-(amidinophenyl)-
3-(4-phenoxyphenyl)urea 1.6 71 
GP9 (4-amidinobenzyl)benzyl ether 47 31 
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Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, 
Benzamidines, and Miscellaneous Inhibitors. 
WR Compound No. Inhibitor 
Miscellaneous Inhibitors 
BM07490 1-( 4-(pheny lureido) benzoy loxy )-
1 ,2,3-benzotriazole 
l\1A-76 1 b 1 11 "' "' 1 • • .. 1- enzoytoxy-I,.£.,.J-oenzomazote 















ainactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 J!M; rat skin tryptase, 0.015 
JlM; human skin tryptase, 0.12 JlM and 0.02 J..LM; human r-t-PA, 0.017 JlM Bovine trypsin was assayed with Z-Phe~Gly-Arg­
NA·HCI (0.07 mM). Human lung tryptase, human skin tryptase and rat skin tryptase were assayed with Z-Arg-SBzl·HCl (0.07 
mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCI2, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as 
follows: 4-chloro-3-(3-isothioureidopro}Xlxy )isocoumarin, 1 J!M; p-guanidinobenzoic acid, 0.44 mM; ethy 1 p-guanidinobenzoate, 
0.43 mM; p-guanidinobenzoyl valine amide,0.44 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.44 mM; 4-cyanophenyl p-
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Table III (Continued). 
guanidinobenzoate, 0.46 JlM; 1-( 4-(phenylureido )benzoy loxy )-1 ,2,3-benzotriazole, 1.22 JlM; 1-be~zoyloxy -1 ,2,3-benzotriazole, 22 
J!M. 
cconditions were as follows: 0.1M Hepes, 0.5M NaCl, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 4-
chloro-3-(3-isothioureido-propoxy)isocoumarin, 0.42 JlM; ethyl p-guanidinobenzoate, 0.42 mM; p-guanidinobenzoyl valine amide, 
0.42 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.42 mM; 4-cyanophenylp-guanidinobenzoate, 0.22 J!M; 1-(4-
(phenylureido)benzoyloxy)-1,2,3-benzotriazole, 11.6 JlM. 
d.Conditions were as follows: 25 rn1vt phosphate, 0.5M NaCi, 1mM EDTA, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations 
were as follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.44 JlM; ethyl p-guanidinobenzoate, 0.45 mM ; p-
guanidinobenzoyl valine amide, 0.42 mM; 0-(p-guanidinobenzoyl)glycolarnide, 0.44 JL'vf. 
econditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.35 JlM; p-guanidinobenzoyl valine amide, 3.5 J.!M; 0-(p-
guanidinobenzoyl)glycolamide, 1. 7 mM. 
fConditions were as follows: 0.1 M Hepes, 0.5 M NaCl, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 4.3 JlM; ethyl p-guanidinobenzoate, 0.44 mM; 0-(p-
guanidinobenzoyl)glycolamide, 0.43 mM. 
gNo inhibition. 
hinhibition was not time dependent and the % inhibition was measured at 0.42 mM. 
I AmPh = 4-amidinophenyl 
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Table III (Continued). 
jlnhbitior concentrations were 226 J.LM. 
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Animal Testing Priorities 
The various compounds which we have submitted have been 
prioritized for animal testing and the following table lists the 
priority which we have assigned to each compound and the reasons 
for that priority. 
High-1 WR268195 3,4-dichloroisocoumarin 
This isocoumarin is a general serine protease inhibitor and 
effectively inhibits most of the enzymes tested. 
High-2 GP8 1-(amidinophenyl)-3-(4-phenoxyphenyl)urea 
This benzamidine should be very stable ·in solution and is an 
excellant competitive inhibitor of 1:rypsin-like enzymes. 
High-3 WR268241 Suc-Val-Pro-PheP(QPh)2 
This peptide phosphonate is a reactive and specific inhibitor 
for chymotrypsin-like enzymes including chymases. 
High-4 ~~268397 4-chloro-3-(3-isothioureidopropoxy)isocoumarin 
This isocoumarin is a very reactive inhibitor for the rat 
skin tryptase. 
High-S WR268398 2-ethoxy-4H-3,1-benzoxazin-4-one 
This benzoxazinone inhibitor is an effective inhibitor for 
elastase. 
High-6 WR268141 N-furoylsaccharin 
This saccharin is a general protease inhibitor and inhibits 
elastases and chymotrypsin--like enzyme quite effectively and is 
probably a moderate inhibitor for trypsin-like enzymes. 
High-7 BM06304 4-cyanophenyl p-guanidinobenzoate 
This guanidinium substituted derivative is an effective 
inhibitor for trypsin-like enzymes 
High-8 WR268440 4-chloro-7-(N-phenylcarbamoyl)amino-3-
propoxyisocoumarin 
This isocoumarin is an effective elastase inhibitor. 
High-9 WR268142 di(4-isovaleroylphenyl)sulfide 
This aromatic derivative is an effective elastase inhibitor. 
High-10 WR268387 4-chloro-3-benzyloxyisocoumarin 




Isocoumarins. Three new isocoumarins have been synthesized 
this year and submitted for testing as antivesicants. The 
compounds are 4-chloro-3-methylisocoumarin (WR268715), and 4-








4-Chloro-3-methylisocoumarin was prepared by reaction of 
homophthalic acid with acetic anhydride in pyridine to obtain 4-
acetyl homophthalic anhydride which was then treated with cone. 
H2S04 to yield 3-methylisocoumarin. The latter compound gave the 





7-Amino-4-chloro-3-cyclohexylmethoxyisocoumarin was obtained 
by a multistep procedure involving nitration of homophthalic acid, 
esterification of the resulting nitrohomophthalic acid with 
cyclohexanemethanol to the monoester and cyclization of the latter 
to the 3-alkoxy-4-chloro-7-nitroisocoumarin using phosphorus 
pentachloride. The last step, reduction of the nitro group to the 
amino group can only be done on a small scale (about 1 g), 
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2. H2; Pd/C 0-CH~ 
Cl 








amidinophenyl)methane phosphonate was obtained by a-
amidoalkylation of triphenyl phosphite using 4-cyanobenzaldehyde 
and benzyl carbamate to give diphenyl N-benzyloxycarbonylamino(4-
cyanophenyl)methane phosphonate. The cyano group was then 
converted to an imino ester by reaction with HCl in ethanol and 
finally to an amidino moiety by reaction with ethanolic ammonia. 
-o- P(OPh)3 AcOH -o- ,P03Ph2 HCI/EtOH NC ·CHO + ,... NC ~ ~ CH CHCI3 24 hrs H N-Z \.\ 11 ' lJI-
2 60-90°C, 2hrs NH-Z 
Benzoxazinones. Two new compounds have been synthesized 
this year and submitted for testing as antivesicants. The 
compounds are 2-phenylamino-4H-3,1-benzoxazin-4-one and 2-
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2-Phenylamino benzoxazin-4-one was prepared by the 
cyclodehydi~ation of 2-(3-phenylureido)benzoic acid. The latter was 
prepared by the reaction of phenyl isocyanate with anthranilic 




N ~ ~ D 
2-Benzylamino-4H-3,1-benzoxazin-4-one was also prepared by a 
cyclodehydration reaction using H2S04 as the dehydrating agent. 
The starting compound for this reaction was methyl 2-(3-
benzylureido)benzoate. This in turn was prepared by the reaction 
of 2-carbomethoxy phenylisocyanate with benzyl amine in THF at 
room temperature. 
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p-Guanidinobenzoic Acid Derivatives. 4-Cyanophenyl p-
guanidinobenzoate was prepared from p-guanidinobenzoic acid and 4-
cyanophenol using DCC as the coupling agent. 
Benz~nidines. The synthesis of p-guanidino benzoic acid 
derivatives was discontinued due to numerous problems in the 
synthetic/purification procedures when the substituents on the 
carboxyl.group were more complex aromatic structures than a single 
phenyl group. We are presently concentrating on derivatives of 
benzamidine as inhibitors for trypsin-like enzymes. Although the 
synthesis and purification procedures are still difficult, better 
results are being obtained with more complex aromatic structures 
containing benzamidine-like moieties. Thus far five benzamidines 
have been prepared as inhibitors for trypsin-like enzymes. Two 
representative compounds are 1- ( 4-amidinophenyl) ·-3-phenylurea 
hydrochloride (1, BM06804) and 1-(4-amidinophenyl)-3-(4-
chlorophenyl)urea hydrochloride (2, BM06840). 
cr 
2 R=CI 
Numerous attempts to make 1-(4-amidinophenyl)-3-phenylurea 
(1) and its 4-chloro analog (2) by condensing 4-aminobenzamidine 
with phenylisocyanate and 4-chlorophenylisocyanate failed. These 
compounds W4ere finally made by a different route. 1- ( 4-
Amidinophenyl)-3-phenylurea (1) was finally prepared starting from 
4-aminobenzonitrile. Phenylisocyanate and 4-aminobenzonitrile 
were condensed in refluxing benzene and the resulting urea was 
converted to the imidate ester by treatment with dry methanol in 
the presence of dry HCl. The final amidino compound was obtained 
by refluxing the imidate ester in isopropanol saturated with dry 
ammonia. The product was isolated as its hydrochloride salt and 











1-(4-Amidinophenyl)-3-(4-chlorophenyl)urea (2) was prepared 
using the same reaction scheme except that phenylisocyanate was 
replaced by 4-chlorophenylisocyanate. 
1-(4-Amidinophenyl)-3-benzylurea (BM07481) and 1-(4-
amidinophenyl)-3-(4-phenoxyphenyl)urea (GP8, below) were made 
using essentially the same set of reactions. Any modifications 
which were required in going from one product to the other are 
clearly noted in the Experimental Section. 
Micellaneous Compounds. Several new compounds with a 
variety of structures were synthesized this year and submitted for 
testing as antivesicants. 
One structure was N-(2-isothiureido)ethyl phtalimide 
hydrobromide which was prepared by alkylation of thiourea with N-
(2-bromoethyl)phtalimide in THF. This compound was modeled after 
the isothiureido isocoumarins prepa:r:ed in our laboratories which 





Two N-hydroxybenzotriazole derivatives were synthesized. 
They are 1-(4-(phenylureido)benzoyloxy)-1,2,3-benzotriazole 
(BM07490) and 1-benzoyloxy-1,2,3-benzotriazole (MA-76). Their 
structures are shown below. 
The first derivative was reported as N-(4-amidinophenyl)-4-
(phenylcarbamoylamino)benzamide in one of the quarterly reports. 
The synthesis involved a DCC coupling of 4-
(phenylcarbamoylamino)benzoic acid with 4-aminobenzamidine using 
1-hydroxybenzotriazole in DMF. The acid was prepared from 4-
aminobenzoic acid and phenyl isocyanate as depicted below. 
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At that time the compound was reported as a mixture of salts 
because the elemental analysis could not be matched with the 
expected structure (3) . The fact that it was a good trypsin and 
human lung tryptase inhibitor further suggested that it must 
contain the amidino moiety in its structure. On the other hand, 
all the analytical data could be explained by a compound with the 
structure corresponding to an acylated benzotriazole, namely 1-(4~ 
{phenylureido)benzoyloxy)-1,2,3-benzotriazole (4). The compound 
is therefore reported as such in the Experimental Section. A 
spectrophotometric study of the hydrolysis of this compound in the 
buffer used to assay inhibition of trypsin shows at least two 
isosbestic points over a 5 h period. However, no significant 
hydrolysis was observed during the short time periods used in the 
inhibition assays and therefore the inhibition constants reported 
are accurate values. Kinetic studies are being performed to 
elucidate a mechanism for the inhibition of trypsin by this 
compound. The benzoyl derivative was made in order to compare its 
inhibition of trypsin with that of the more complex derivative 
discussed above. It was also made in order to ascertain if an 
acyl derivative of 1-hydroxy-1,2,3-benzotriazole could indeed 
inhibit trypsin. We found this to be the case, and 1,2,3-
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benzotriazole-1-benzoate had a kobs/[I] value of 1,100 M-1s-1 
towards trypsin. It was made by acylation of 1-hydroxy-1,2,3-
benzotriazole with benzoyl chloride in THF/pyridine. This type of 
inhibitors are a new and interesting class of trypsin inhibitors 




Cyclohexanemethyl 4-nitro-2-carboxyphenylacetate. A 
solution containing 10 g (44: mmol) of 5-nitro homophtalic acid 
[prepared according to H. E. Ungnade, D.V. Nightingale and H. E. 
French (1945) J. Org. Chem. 10, 533], cyclohexanemethanol (14 mL, 
111 mmol) and 6 drops of cone. H2S04 in 150 mL of benzene was heated 
to reflux temperature with a.zeotrop:Lc removal of water for 4.5 h. 
The reaction mixture was cooled to J::-oom temperature and then 
extracted with a saturated solution of NaHC03 (5 x 25 mL) and water 
(2 x 25 rnL) . Excess concentrated HCl was added to the aqueous 
extract and the white solid which precipitated was collected by 
filtration and dried to yield 8.58 9 (61%) of product that was pure 
enough to be used in the next step; m.p. 141-2 °C. 
4-Chloro-3-cyclohexylmethoxy-7-nitroisocoumarin. A 
solution of cyclohexanemethyl 4-nitro-2-carboxyphenylacetate (8.58 
g, 27 mmol) and PCl5 (13.9 g, 67 mmol) in 100 mL of benzene was 
heated to reflux temperature for 4 h and then the solvent was 
removed in vacuo. The residue was recrystallized from 95% EtOH to 
yield the product as bright yellow needles (5.13 g, 56%); m.p. 102-
104 °C. 
7-Amino-4-chloro-3-cyclohell:ylmethoxyisocoumarin. 
Palladium on charcoal (150 mg, 5% catalyst) was added to a solution 
of 4-chloro·-3-cyclohexylmethoxy-7-nitroisocoumarin (1.24 g, 3.7 
mmol) in 200 mL of EtOAc and the resulting mixture was stirred under 
a hydrogen atmosphere for 6 h at atmospheric pressure. The catalyst 
was then removed by filtratic:>n through a bed of Celite and the 
filtrate was concentrated to dryness in vacuo. The residue was 
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recrystallized from ethanol/water to yield the product as bright 
yellow needles (801 mg, 71%); m.p. darkens >180 °C. 1H NMR (d6-
MeS04) 0: 7.4 (d, 1H), 7.25 (d, 1H), 7.14 (d of d, 1H), 5.76 (br. s, 
2H), 4.05 (d, 2H), 1.76-1.58 (m, 6H), 1.30-0.98 (m, SH). Anal 
Calcd. for C16H19ClN03: C, 62.44; H, 5.89; N, 4.55; Cl, 11.52. 
Found: C, 62.50; H, 5.93; N, 4.51; Cl, 11.42. 
Diphenyl N-benzyloxycarbonylamino(4-cyanophenyl)-
methanephosphonate. Obtained from 9.75 g 4-cyano-benzaldehyde, 
7.65 g benzyl carbamate and 13.5 ml of triphenyl phosphite in 20 ml 
of glacial acetic acid, according to procedure described earlier 
[Oleksyszyn, J., Subotkowska, L., Mastalerz, P. (1979) Synthesis, 
985]. Yield 70%; mp. 135-138 °C; Anal. Calcd. for C29H2305N2P . 1;2 
H20: C, 66.27; H, 4.73; N, 5.52. Found; C, 66.03; H, 4.51; N, 5.49. 
Diphenyl N-benzyloxycarbonylamino(4-amidinophenyl)-
methanephosphonate hydrochloride. A solution of 7 g diphenyl z-
benzyloxycarbonylamino(4-cyanophenyl)-methanephosphonate in 150 mL 
of dry chloroform and 15 mL of absolute ethanol was saturated with 
dry HCl at 0 °C. The reaction mixture was kept in the refr~gerator 
until TLC showed no presence of starting material 1(about 24 h) . An 
excess of pentane was added and the precipitate was removed by 
filtration and dried under high vacuum. The solid was dissolved in 
200 ml of dry methanol and gaseous dry ammonia was bubbled through 
the solution (one equivalent is required) for approximately 20 min. 
Methanol and excess ammonia r111ere removed as fast as possible in the 
rotary evaporator. A portion of fresh methanol (100 mL) was added 
and the solution was heated at 50 °C by about 8 h, until TLC shows 
no presence of imino ether. The solvent was evaporated and the 
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resulting oil was dissolved in chloroform. Addition of ether caused 
separation of an oil which solidified after a while. The solid that 
resulted was again dissolved in chloroform, the solution was 
filtered and the solid product was precipitated using ether. In 
several experiments the yields were 70-80%; mp. 154-158 °C 
{decamp); 31p NMR 14,87 ppm. Anal. Calcd. for 
c28H27o5N3ClP·0.3NH4Cl·H20; C, 57.41; H, 5.16; N, 7.52; Cl, 7.31. 
Found; C, 57.75; H, 5.00; N, 8.86; Cl, 7.43. 
Diphenyl amino(4-amidinophenyl)methanephosphonate 
dihydrochloride. A sample of 1.8 g of diphenyl N-benzyloxy-
carbonylamino{4-amidinophenyl)methanephosphonate hydrochloride was 
dissolved in 150 mL of 2N HCl/methanol solution and after addition 
of 5% Pd/C catalyst the resulting mixture was stirred under an 
atmosphere of hydrogen until the theoretical amount of hydrogen was 
consumed. The catalyst was removed by filtration and after 
evaporation of methanol a residue was crystallized from ethanol-
ether. In several experiments the yields were 60-80%; mp. 213-215 
°C; Anal. Calcd. for C20H22N3ClP·1/2H20: C, 51.85; H, 4.97; N, 
9.08; Cl, 15.34. Found: C, 51.73; H, 5.02; N, 9.10; Cl, 15.36. 
4-Chloro-3-methylisocoumarin. To a stirred solution of 10 
g (0.06 mol) of 3-methylisocoumarin [Tirodkar, R.B. and Usgaonkar, 
R. N. {1969) J. Ind. Chern. Soc. 46, 935) in 25 mL of DMF was added 
11.16 g {0.08 moles) of N-chlorosuccinimide and the reaction mixture 
stirred at room temperature overnight. The reaction mixture was 
then diluted with ether and the ether layer was washed successively 
with 10 % HCl, 5 % NaHC03, water and finally dried over anhydrous 
MgS04. Ether was evaporated and the solid obtained was 
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recrystallized from hexane 1:o give 3.5 g (29 %) of the title 
compound as yellowish needles; m.p. 91-93 °C; H1 NMR (CDCl3) 0: 2.48 
(s, 3H), 7. 55 (m, 1H), 7. 80 (rn, 2H), 8. 31 (d, 1H). Anal. Calcd. for 
c1 oH7Cl02 0.2 H20 : C, 60.54; H, 3.53; Cl, 17.91. Found : C, 60.68; 
H, 3.66; Cl, 17.98. 
2-Phenylamino-4H-3, 1-~benzoxazin-4-one. Phenyl isocyanate 
(3.57 g, 0.03 mol) was dissc,lved in 10 mL THF and to this stirred 
solution was added anthranilic acid (4.1 g, 0.03 mol) and the 
reaction stirred overnight at room temperature. The solvent was then 
removed under reduced pressure to get 2-(3-phenylureido) benzoic 
acid as a white solid. 
The product from the above reaction (3.84 g) was dissolved in 
10 mL cone. H2S04 and kept at room temperature for 1 h. The 
reaction was then poured over ice, neutralized with saturated NaHC03 
solution, the precipitated white solid filtered and dried in air and 
recrystallized from benzene to get the title compound as white 
crystals; m.p. 191-192 °C. 1H NMR (DMSO-d6) 0: 7.1-8.0 (aromatic). 
Anal. Calcd.for C14H10N202 0.27 H20 : C, 69.13; H, 4.12; N, 11.52. 
Found: C, 69.10; H, 4.32; N, 10.71. 
2-Benzylamino-4H-3,1-benzoxazin-4-one. To a stirred 
solution of benzylamine (634 mg, 0.0059 mol) in dry THF (40 mL) was 
added 2-carbomethoxy phenylisocyanat:e (1 g, 0. 0056 mol) and the 
reaction stirred at room temperature overnight. The solvent was 
removed under reduced pressure to obtain methyl 2-(3-benzylureido) 
benzoate as a white solid. 
The product (1.13 g) from the reaction above was dissolved in 2 
mL cone. H2S04 and left at room temperature for 1 h. The re~ction 
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was worked up as in the previous experiment and the product 
recrystallized from ethyl acetate-benzene to get the title compound 
as a white solid; m.p. 177-178 °C. lH NMR (DMSO-d6) 0: 4. 3 (d, 2H, -
CH2-), 6.9-8.4 (aromatic), 10.2 (s, 1H, NH). Anal. Calcd. for 
C15H12N202 x 1.1 H20: C, 66.17; H, 5.22; N, 10.29. Found: C, 66.20; 
H, 5.24; N, 10.15. 
4-CyallOphenyl p-Guanidino B~enzoate. Dicyclohexyl 
carbodiimide (2.33 g, 11.3 rnmol) was added to a solution of p-
guanidinobenzoic acid hydrochloride (2.43 g, 11.3 mmol) in 50 mL 
pyridine. 4-Cyanophenol (1.34 g, 11.3 mmol) was added to this 
solution and the resulting mixture l.vas stirred at room temperature 
for 14 h with protection from moisture. Dicyclohexylurea was 
removed from the reaction mixture by filtration and the filtrate was 
concentrated in vacuo to a foam which was triturated with 30 mL 
EtOAc. The beige solid that resulted was collected by filtration 
and washed throughly with EtOAc. ~rhe crude product (2.5 g) is 
taken up in approx. 3 L of water and the solid remaining is removed 
by filtration through a bed of Celite. The filtrate was lyophilized 
to obtain 1.75 g (70 %) of pure product; m.p. 160-62 °C. 1H NMR 
(d6-Me2SO) 0: 10.58 (s, 1H), 8.18 (d, 2H), 7.99 {d, 2H), 7.88 (br.s., 
3H), 7.52 (d, 2H), 7.42 (d, 2H). Anal. Calcd. for C1sH13ClN402 x 
1.98 H20: C, 51.13; H, 4.85; N, 15.90. Found: C, 51.13; H, 4.70; N, 
15.79. 
1-(4-(phenylureido)benzoyloxy)-1,2,3-benzotriazole. 
Triethylamine (0 .19 mL, 1. 4 :mmol) wa.s added to a solution of 4-
aminobenzamidine dihydrochloride (28.4 mg, 1.4 mmol) in 6 mL DMF. 
1,3-Dicyclohexylcarbodiimide (311 mg, 1.5 mmol) was then added, 
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followed by 1-hydroxy-1,2,3--benzotriazole (185 mg, 1.4 mmol). This 
mixture was cooled to 10 °C and 4-phenylaminocarbamoyl benzoic acid 
was then added (350 mg, 1.4 mmol). The reaction mixture was stirred 
at 5-10 °C for 14 h and dicyclohexylurea was removed by filtration. 
It was washed with fresh DMF, and the filtrate was concentrated to 
I 
dryness and coevaporated with acetone to obtain an amorphous white 
solid that was washed with CHCl3:EtOH 4:1 to obtain 225 mg (40 %) of 
pure product as a white solid; mp 217-8 °C (dec). The product can 
be recrystallized from CHCl3/DMF/hexane. 1H NMR (DMSO-d6) 0: 9.45 
(br s, 1H); 8.96 (br s, 1H); 8.22 (d, 2H); 8.18 (d, 1H); 7.85 (d, 
1H); 7.78 (d, 2H); 7.67 (t., 1H); 7.54 (t, 1H); 7.49 (d, 2H); 7.32 
(t, 2H); 7.02 (t, 1H). Anal Calcd. for C20H15N503·0.2 H20: C, 
63.71; H, 4.12; N, 18.58. Found: C, 63.71; H, 4.36; N, 18.80. 
N-(2-Isothiureido)ethyl phtalimide hydrobromide. N-(2-
Bromoethyl)phtalimide (4.6 g, 18 mmol) was dissolved in 50 mL THF 
and then thiourea (1.52 g, 20 mmol) was added in one portion. The 
resulting mixture was heated to reflux temperature for 2 days and 
then allowed to cool to 5-10 °C in an ice bath. The white solid in 
suspension was filtered and washed with THF and hexane to yield 3.21 
g (54%) of pure product; mp 245-6 °C (dec). 1H NMR (DMSO-d6) 0: 9.04 
( b r s , 4 H ) ; 7 . 8 6-7 . 91 ( m, 4 H) ; 3 . 8 7 ( t , 2 H) ; 3 . 4 9 ( t , 2 H) . An a 1 . 
Calcd. for C11H12BrN302S: C, 40.01; H, 3.66; N, 12.73; Br, 24.20. 
Found: C, 40.10; H, 3.71; N, 12.72; Br, 24.14. 
1-Benzoyloxy-1,2,3-benzotriazole. A solution of benzoyl 
chloride (6.2 mL, 53 mmol) in 30 mL of THF was added dropwise to a 
solution of 1-hydroxy-1,2,3-benzotriazole (6.5 g, 48 mmol) and 
pyridine (4.3 mL, 53 mmol} in 65 mL THF. The resulting mixture was 
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stirred at room temperature for 24 h under protection from moisture, 
and the solvent was then removed under vacuum. The white solid 
obtained was purified by lOliiT temperature recrystallization from 
CHCl3/hexane and cooling at 0-5 °C for 2 days. The pure product was 
obtained as a white solid (5.15 g, 47 %); mp 78-9 °C. A second crop 
can be obtained from the mot:her liquor by concentration to 2/3 of 
the volume, addition of hexane, and further cooling at 0-5 °C for 2 
days. 1H NMR (DMSO-d6) 0: 7.98-7.92 (m, 3H); 7.72 (d, 1H); 7.64-
7.38 (m, SH). Anal. Calcd. for C13H9N302: C, 65.26; H, 3.79; N, 
17.56. Found: C, 65.36; H, 3.81; N, 17.61. 
1-(4-Amidinophenyl)-3-phenylurea. To a stirred solution 
of 4-aminobenzonitrile (4.72 g, 0.04 mol) in dry benzene (200 mL) 
was added phenylisocyanate (9.52 g, 0.08 mol) and the resulting 
solution refluxed for 5 h and further stirred at room temperature 
overnight. The precipitated solid was filtered and recrystallized 
from methanol to get the urea as a white crystalline solid (8.3 g). 
Dry HCl gas was passed through a solution of the urea (4.74 g, 
0.02 mol) in dry dimethoxyethane (100 mL) for 1 h. The reaction 
mixture was then stirred a.t room temperature for 24 h. The 
precipitated imidate ester was filtered and stored over KOH in a 
vacuum desiccator (3.5 g) for 24 h. 
The imidate ester (2 g, 0.006 mol) was dissolved in isopropanol 
saturated with ammonia (100 mL) and the reaction mixture was 
refluxed for 6 h and further stirred at room temperature overnight. 
The solvent was then evaporated under reduced pressure, a white 
solid that was obtained, and this was recrystallized from 2N HCl to 
get the title compound as its HCl salt (1.5 g); m. p. 240 °C 
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(decamp.). lH NMR (DMSO-d6) 0: 7.00 (t, lH), 7.30 (t, 2H), 7.45 (d, 
2H), 7.65 (d, 2H), 7.80 (d, 2H), 8.80 (s, 2H), 9.15 (s, 2H), 9.40 
(bs, lH), 9.80 (bs, lH). Anal. Calcd. for C14H15ClN40·H20: C, 
54.53; H, 5.56; Cl, 11.35; N, 18.18. Found: C, 54.53; H, 5.46; Cl, 
11.42; N, 18.13. 
1-(4-Amidinophenyl)-3-(4-chlorophenyl)urea 
hydrochloride. To a stir rE=d solution of 4 -aminobenzoni tr ile ( 4 . 7 2 
g, 0.04 mol) in dry THF (50 mL) was added 4-chlorophenylisocyanate 
(6.12 g, 0.04 mol) in one portion and the reaction stirred 
magnetically overnight. The separated white solid was filtered out 
and recrystallized from methanol to get the cyano urea as a white 
crystalline solid (9.2 g, 85 %) . 
Dry HCl was passed through a cooled solution of the cyano urea 
(5.43 g, 0.02 mol) and dry methanol (3.2 g, 0.10 mol) in dry 
dimethoxyet.hane (100 mL) for 2 h and the reaction further stirred at 
room t'empe:r:·ature for 36 h.. Solvent was then evaporated under 
reduced pressure and the imidate ester obtained as a yellow solid 
was stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (6 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl to 
get white crystals of the title compound (4.8 g, 84 %); mp 275 °C 
(dec.) . lH NMR (DMSO-d6) 0: 7. 32 (d,. 2H); 7. 50 (d, 2H); 7. 66 (d, 2H); 
7.80 (d, 2H); 8.85 (s, 2H); 9.18 (s, 2H); 9.70 (s, lH); 9.98 (s, 
lH). Anal. Calcd. for C14H14Cl2N40·0.69 H20: C, 49.80; H, 4.58; Cl, 
21.01; N, 16.59. Found: C, 50.21; H, 4.62; Cl, 20.73; N, 16.19. 
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1- (4-Amidinophenyl) -:~-benzy:Lurea hydrochloride. To a 
stirred solution of 4-aminobenzonit:~ile (3.9 g, 0.03 mol) in dry 
benzene (100 mL) was added benzylisocyanate (4.5 g, 0.03 mol) in one 
portion and the reaction heated under reflux for 6 h and stirred 
magnetically at room temperature overnight. The separated white 
solid was filtered out and recrystallized from methanol to get the 
cyano urea as a white crystalline solid (6.1 g, 72 %) . 
Dry HCl was passed through a cooled solution of the cyano urea 
(3 g, 0.012 mol) and dry methanol (1.92 g, 0.060 mol) in dry 
dimethoxyethane (150 mL) fo:r· 2 h and the reaction further stirred at 
room temperature for 24 h. Solvent was then evaporated under 
reduced pressure and the imidate ester obtained as a yellow solid 
was stored in a vacuum desiccator over KOH for 24 h (3.2 g). 
The imidate ester (3.2 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained recrystallized from 2N HCl to get 
white crystals of the title compound (3 g, 84 %); mp 292 °C (dec.). 
1H NMR (DMSO-d6) 8: 4. 31 (d, 2H); 7.17 (t, 1H); 7. 20-7.38 (m, 5H); 
8. 82 (s, 2H); 9.12 (s, 2H); 9. 66 (s, 1H) . Anal. Calcd. for 
C15H17Cl2N40: C, 59.11; H, 5.62; Cl, 11.63; N, 18.38. Found: C, 
59.23; H, 5.64; Cl, 11.63; N, 18.28. 
1-(4-Amidinophenyl)-3-(4-phenoxyphenyl)urea 
hydrochloride. To a stirred solution of 4-aminobenzonitrile (2.95 
g, 0.025 mol) in dry benzene (50 mL) was added 4-
phenoxyphenylisocyanate (5.25 g, 0.025 mol) in one portion and the 
reaction heated under reflux for 10 h and stirred at room 
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temperature overnight. The separated white solid was filtered out 
and recrystallized from methanol to get the cyano urea as a white 
crystalline solid (6.5 g, 79 %) . 
Dry HCl was passed through a cooled solution of the cyano urea 
(5 g, 0.015 mol) and dry methanol (2.43 g, 0.075 mol) in dry 
dimethoxyethane (100 mL) for 2 h and the reaction stored in the 
refrigerator for 48 h. Solvent was then evaporated under reduced 
pressure and the solid obtained stored in a vacuum desiccator over 
KOH for 24 h. 
The imidate ester (5 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 7 h 
and further stirred at room temperature for 24 h. Solvent was 
evaporated and the solid obtained recrystallized from 2N HCl to get 
white crystals of the title compound (4.6 g, 95 %); mp 202-205 °C. 
1 H NMR ( D MSO-d 6 ) 0 : 6 . 9 0 -7 . 0 1 ( m, 4 H) ; 7 . 0 9 ( t , 1 H ) ; 7 . 3 5 ( m, 2 H) ; 
7.47 (m, 2H); 7.65(d, 2H); 7.80 (d, 2H); 8.80 (s, 2H); 9.15 (s, 2H); 
9.39 (s, 1H); 9.75 (s, 1H). Anal. Calcd. for C20H19Cl1N402·0.7 H20: 
C, 60.74; H~" 5.16; Cl, 8_.98; N, 14.17. Found: C, 60.36; H, 5.05; 
Cl, 9.00; N, 14.08. 
4-Chl.oro-3-methoxyisoc:oumarir.L. This compound was prepared 
according to the procedure of Tirodkar, R. B., and Usgaonkar, R.N. 
(1969) Indian J. Chern. 7, 1114; m.p. 91-93 °C. Anal. Calcd.for 
C1oH7Cl103. 0.1 H20: C, 56.65; H, 3.31; Cl, 16.76; Found: C, 56.45; 
H, 3.46; Cl, 16.61. 
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FOR:E:WORD 
Opinions, interpretations, conclusions and recommendations 
are those of the author and are not necessarily endorsed by 
the U .. S. Army. 
Where copyrighted material is quoted, permission has been 
obtained to use such material. 
Where material from documents designated for limited 
distribution is quoted, permission has been obtained to use 
the material. 
Citations of commercial organizations and trade names in 
this report do not constitute an official Department of Army 
endorsement or approval of the products or services of these 
organizations. 
In conducting the research described in this report, the 
investigator(s) adhered to the "Guide for the Care and Use of 
Laboratory Animals," prepared by the Committee on Care and 
·Use of Laboratory Animals of the Institute of Laboratory 
Animal Resources, National Research Council (DHEW Publication 
No. (NIH) 8 6-23, Revised 1985) . 
For the protection of human subjects, the investigator(s) 
adhered to policies of applicable Federal Law 45 CFR 46. 
In conducting research utilizing recombinant DNA 
technology, the investigator adhered to current guidelines 
promulgqted by the National Institutes of Health. 
PROTEASE INHIBITORS AS ANTIVESICANTS 
Keywords: Antivesicants, Protease Inhibitors, Serine Protease, 
Sulfur Mustard 
ABST:RACT 
Bis-(2-chloroethyl)sulfide (HD, sulfur mustard) is a potent 
vesicant which was used in the Iran-Iraq conflict. Sulfur 
mustard penetrates the skin rapidly and after a latent period of 
several hours under temperate climatic conditions, causes 
extensive blistering of the skin. The mustard is thought to 
alkylate DNA which eventually results in the release of potent 
proteolytic (protein degrading) enzymes, particularly serine 
proteases. These serine proteases are capable of destroying a 
number of connective tissue proteins and several of the enzymes 
seem to be able to specifically cleave proteins at the junction 
of the dermis and epidermis (outer non-vascular layer of skin) . 
The destruction of these basement. membrane and connective tissue 
proteins results in an epidermal-dermal separation, fluid 
accumulation, and formation of a blister. 
A total of 45 serine protease inhibitors have been 
submitted in 3-5 g quantities for animal testing. The 
structural classes include 9 isocoumarins, 5 saccharins, 6 
peptide phosphonates, 3 benzoxazinones, 11 benzamidines, 5 
derivative of p-guanidino benzoic acid and 6 miscellaneous 
compounds. The inhibitors have been surveyed for inhibitory 
potency against human neutrophil elastase, human neutrophil 
cathepsin G, rat skin tryptase, human skin tryptase, human skin 
chymase,. human plasminogen activator, porcine pancreatic 
elastase, rat mast cell protease II, dog skin chymase, human 
lung tryptase and bovine chymotrypsin. 
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BACKGROUND 
Sulfur Mustard. Bis-(2-chloroethyl)sulfide (HD, sulfur 
mustard) is a potent vesicant which was used in the Iran-Iraq 
conflict. Sulfur mustard penetrates the skin rapidly and after a 
latent period of several hours under temperate climatic 
conditions, causes extensive blistering of the skin. Antimustard 
ointments which attempt to inactivate the free mustard are 
ineffective since the mustard quickly reacts with components in 
the skin and other tissues. Therefore, an effective therapy for 
sulfur mustard exposure must be based on reversing the 
physiological processes that result upon contact with this potent 
vesicant (Cullumbine, 1947). 
Bis-(2-chloroethyl)sulfide is a potent alkylating agent which 
can react with the heterocyclic bases in nucleic acids (Ludlum et 
al., 1984) and with a wide variety of the side chain functional 
groups (thiols, thioethers, carboxyl groups, amino groups, 
imidazole rings, etc.) found in proteins. The majority of the 
sulfur mustard is secreted in the form of various metabolites such 
as thiodiglycol, but some is carried by the circulation to other 
organs, and a significant portion is stored in skin reservoirs 
(Klain and Bonner, 1987) . While the most significant mustard 
induced injury occurs in the skin (vesication and inflammation), 
significant numbers of mustard casualties have ocular injuries and 
cornea impairment for 2-4 months. In cases of severe exposure, 
there is serious lung and bone marrow damage which results in 
death. 
Mechanism of Sulfur Mustard :Induced Blistering. The 
molecular mechanisms by which sulfur mustard causes toxicity are 
unknown but mustard is a powerful alkylating agent of DNA and RNA. 
Papirmeister has suggested that the alkylated purine bases in DNA 
are unstable and undergo both spontaneous and enzymatic 
depurination (Papirmeister et al., 1985). This results in DNA 
strand breaks, and activation of nucleases and other DNA repair 
mechanisms. As a result, poly(ADP-ribose)polymerase is activated, 
NAD+ is depleted, glycolysis is inhibited, and the hexose 
monophosphate shunt is stimulated (Meier et al., 1987). This 
causes the release of potent proteolytic enzymes which produces 
the observed pathology of basal cell necrosis and vesication. 
Evidence for the Papirmeister hypothesis includes the 
~solation and structural characterization of several DNA 
alkylation products upon treatment of DNA with sulfur mustard 
(Benschop et al., 1989) and the demonstration of single strand 
breaks in the DNA after exposure of keratinocyte cultures to low 
levels of sulfur mustard (Bernstein et al., 1989). In addition, 
other agents which result in DNA damage such as UV light and 
radiation have been shown to stimulate the synthesis or release of 
proteases in fibroblast cultures (Miskin and Reich, 1980) . 
Proteases are normally controlled by natural plasma protein 
protease inhibitors such as a1-protease inhibitor, a1-
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antichymotrypsin, and a2-macroglobulin. If this antiprotease 
screen is destroyed, tissue destruction results. Several of the 
plasma serpins (serine protease inhibitors) including a1-protease 
inhibitor and a1-antichymotrypsin have essential methionine 
residues and are susceptible to inactivation by oxidizing agents 
or alkylating agents. A single dose of sulfur mustard in the 
mouse brain has recently been shown to cause a burst of oxidants 
(Elsayed et al., 1989). The serpin screen could then be removed 
directly by sulfur mustard alkylation or indirectly by oxidation 
as a result of this oxidative burst. Thus, sulfur mustard 
exposure probably results both in the release of powerful 
proteolytic enzymes and in the partial destruction of the protease 
inhibitor screen which would normally protect the organism from 
proteolysis. 
Other Blistering lDisease States Involve Proteases. 
Blistering disease states which have been described include 
dermatitis herpetiformis (DH), bullous pemphigoid (BP), chronic 
bullous disease of childhood, and pemphigus vulgaris. These 
diseases are characterized by destruction of various connective 
tissue components of the epidermis or dermis followed by tissue 
separation and the formation of fluid-filled blisters. Blister 
fluids from patients with all of these diseases have been shown to 
contain proteases including elastase and collagenase (Oikarinen et 
al., 1983). Human polymorphonuclear leukocyte elastase is the 
major enzyme in DR fluid, while BP fluid predominantly contains 
the metalloprotease collagenase. A trypsin-like enzyme and a 
thiol protease have also been implicated in blister formation 
respectively in recessive dystrophic epidermolysis bullosa and 
epidermolysis bullosa simplex (Takamori et al., 1985). Incubation 
of normal human skin with the blister fluid from patients with 
epidermolysis bullosa letalis, a severe and usually fatal 
congenital blister disease, results in dermal-epidermal 
separation. A number of common serine protease inhibitors 
prevented the separation (Matsumoto and Hashimoto, 1986) . 
Proteases are Associated with Inflammation. Proteases 
are important mediators and modulators of inflammation and have 
been demonstrated in non-blistering inflammatory disease states 
such as psoriasis and arthritis. The most abundant enzymes are 
the serine proteases elastase and cathepsin G (a chymotrypsin-like 
enzyme) from leukocytes; chymases (chymotrypsin-like enzymes), and 
tryptases (trypsin-like) enzymes from mast cells; plasminogen 
activator; and the metalloprotease collagenase from leukocytes. 
These enzymes are capable of cleaving a variety of connective 
tissue proteins including elastin, collagen, proteoglycans, and 
other basement membra~e components. 
Sulfur Mustard Induced Inflammatory Lesions Contain 
Proteases and Protease-Inhibitor Complexes. The proteolytic 
enzymes released upon exposure to sulfur mustard have not yet been 
isolated or characterized, but likely candidates include chymases 
and tryptases from mast cells, elastase and cathepsin G from 
leukocytes, plasminogen activator, and collagenase. Culture 
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fluids frorn mustard-induced inflammatory lesions in rabbit skin 
show 3 to 6 fold increased levels of proteases both in developing 
and healing lesions (Higuchi et al., 1987). These fluids will 
hydrolyze two synthetic peptide substrates, Boc-Leu-Gly-Arg-AFC 
(Boc = t-butyloxycarbonyl, AFC = 7-amino-4-trifluoromethyl 
coumarin) and Bz-Phe-~-naphthyl ester (Bz = benzoyl) . The first 
peptide is a substrate for trypsin, tryptases, plasmin, 
plasminogen activator and other trypsin-like enzymes, while the 
latter is a substrate for chymotrypsin-like enzymes including 
chymases and cathepsin G. The rabbit skin culture fluids did not 
consistently hydrolyze four other synthetic peptide substrates 
(two for elastase and two for cathepsin G) or the protein elastin 
(elastase's natural substrate). Exposure of human skin in culture 
to sulfur mustard results in a 41 % increase in plasminogen 
activator activity (Dannenberg et al., 1989), an enzyme which is 
known to be associated with blister formation (Hashimoto et al., 
1983). The enzymatic activity of chymases, tryptases, and 
angiotensin converting enzyme toward small synthetic substrates 
were not elevated. 
The proteases found in the cul·ture fluids from mustard-
induced inflammatory lesions in rabbit skin are not present as 
free active enzymes, but arE~ found as inactive complexes with 
their natural plasma protease inhibitors a1-protease inhibitor and 
a2-macroglobulin (Harada et al., 1987; Dannenberg et al., 1987; 
Higuchi et al., 1987). These complexes are formed as natural 
protein protease inhibitors from the plasma react with the 
proteases being released at the site of inflammation. The 
protease-inhibitor complexes are incapable of hydrolyzing protein 
substrates and complex formation thus protects the.organism from 
further damage. The natural plasma protease inhibitors are 
probably not completely destroyed by exposure to low levels of 
sulfur mustard and are still available to react with some of the 
proteases released in the blister. 
Protease-inhibitor complex formation hinders the 
identification of the proteases present in sulfur mustard induced 
culture fluid. Complexes of elastase and cathepsin G respectively 
with a1-protease inhibitor and a1-antichymotrypsin are inactive 
toward both synthetic peptide substrates and natural protein 
substrates. Thus the lack of hydrolysis of elastin or elastase 
substrates does not preclude the presence of inactivated elastase 
in the culture fluids. Similarly the lack of hydrolysis of the 
protein fibrin by the culture fluids doesn't exclude the presence 
of plasmin or plasminogen activator. In summary, it is now clear 
that there is a chymotrypsin-like enzyme (chymase), a trypsin-like 
enzyme (tryptase), and plasminogen activator in the sulfur mustard 
induced inflammatory lesions, but the presence of other enzymes 
has not been excluded. 
Skin Serine Proteases Have Been Isolated and 
Characterized. The dermis of human skin is a rich source of 
mast cells and salt extraction of human skin has yielded two 
serine proteases, a chymase and a tryptase. These serine 
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proteases are localized in the granule fraction of mast cells, a 
cell type which is located predominantly in connective tissue. 
The chymase has been demonstrated immunocytochemically to bind to 
the derma-epidermal junction in skin (Sayama et al., 1987). Both 
the mast cell chymase and tryptase are able to specifically cleave 
proteins found in the dermal-epidermal boundary and cause 
vesication. The chymase is incompletely inhibited by plasma due 
to a 650 fold slower rate of reaction with the serpins a1-protease 
inhibitor and a1-antichymotrypsin (Schechter et al., 1989), while 
the tryptase appears not to be inhibited by most protein protease 
inhibitors (Schechter et al., 1983). This may explain the ready 
detection of chymase and tryptase activity in culture fluids from 
mustard-induced lesions in 1::-abbit skin. 
Rat mast cells contain two chymases (RMCP I and RMCP II) 
which have been more extensively characterized than the chymase 
from human skin. Both of these serine proteases are highly 
homologous to human mast chymase and human leukocyte cathepsin G. 
RMCP I and RMCP II have both been sequenced and.the x-ray crystal 
structure of RMCP II has been determined, while the x-ray 
structure of RMCP I is underway (Woodbury and Neurath, 1980; 
Remington et al., 1988). The sequence of dog mast cell tryptase 
and a related dog mast cell protease have been determined by gene 
sequencing tecl).niques (Vanderslice et al., 1989) and it is likely 
that the sequences for human skin tryptase and chymase will be 
available in the next few years. 
The substrate specificity and inhibition profile of human 
skin chymase, human skin tryptase, RMCP I, RMCP II, and related 
enzymes have been studied in the laboratory of the principle 
investigator (Powers et al., 1985). Human skin chymase hydrolyzes 
peptide substrates containing aromatic amino acid residues and 
prefers Phe-AA and Tyr-AA bonds over Trp-AA bonds (AA = any amino 
acid residue) in contrast to chymotrypsin which prefers Trp over 
Phe and Tyr. One of the best peptide substrates is Suc-Phe-Val-
Pro-Phe-NA (Sue = succinyl, NA = 4-nitroanilide) . Human skin 
tryptase is a trypsin-like e~nzyme, but seems to prefer double 
basic residues in its substrates (Tanaka et al., 1983). For 
example, the thioester substrate Z-Lys-Arg-SBu-i (Z = 
benzyloxycarbonyl, SBu-i = thioisobutyl ester) is hydrolyzed by 
human skin tryptase with a kcatiKM == 59,000,000 M-ls-1, a second 
order rate constant which is close to the diffusion controlled 
rate. 
Serine Protease Specificity. The specificity of serine 
proteases toward natural peptide substrates or synthetic 
inhibitors is determined by the nature of the primary substrate 
specificity pocket (51) and secondary subsites (S2, S3, etc.) on 
the surface of each individual enzyme. Trypsin's primary 
specificity site contains an Asp residue in the back of the S1 
pocket so that trypsin will only bind to and hydrolyze peptide 
substrates containing lysine or arginine residues (a schematic 
model of trypsin with a bound substrate is shown below) . The 
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three-dimensional structure of chymotrypsin is quite similar 
except that the Asp-189 in trypsin is replaced by Gly-189 in 
chymotrypsin. As a result the S1 pocket of chymotrypsin in very 
hydrophobic and chymotrypsin prefers substrates containing 
aromatic amino acid residues such as Trp, Tyr, and Phe. With many 
serine proteases, interactions of inhibitors with the extended 
substrate binding site (S2, S3, etc:.) are important to increase 
the specificity and reactivity of the inhibitor. This is clearly 
the case with human slc:ln chymase and tryptase. For example, 
interaction of the Lys in the substrate Z-Lys-Arg-SBu-i with the 
S2 subsite of human tryptase results in an accelerated rate of 
hydrolysis, while little change in hydrolysis rate is observed 
with trypsin. 




























It is clear-no matter the exact mechanism of their release or 
their source-:that proteases are major factors in the tissue 
destruction that accompanies mustard induced vesication. We 
propose that protease inhibitors will be effective antivesicants 
and should be useful both in preventing blistering and in the 
treatment of blisters. Appropriate target proteases are the mast 
cell chymase and tryptase, serine proteases which are localized in 
the skin and have the ability to cleave proteins at the dermal-
epidermal junction. However other serine protease such as 
elastase and cathepsin G from leukocytes, and plasminogen 
activator may also be involved. Evidence for the involvement of 
other classes of proteases .such as the metalloprotease collagenase 
or the thiolprotease cathepsin B is incomplete or lacking at 
present, although the mast cell tryptase is able to activate 
latent collagenase (Gruber et al., 1989). 
Research Strategy. Since the exact target enzyme (or 
enzymes) is not known with certainty, we decided to synthesize 
general serine protease inhibitors, specific chymase inhibitors, 
specific tryptase inhibitors, specific plasminogen activator 
inhibitors, and specific inhibitors for other important serine 
proteases. During the last portion of this contract, we focused 
on inhibitors for trypsin-like enzymes since Smith et al. (1991) 
have recently reported increased hydrolysis rates for substrates 
of trypsin-like enzymes by mustard stimulated lymphocytes. Thus, 




1. Prepare and submit for animal testing 3-5 inhibitors of 
serine proteases such as 3,4-dichlo:roisocoumarin and saccharins 
each year. 
2. Prepare and submit for testing 3-5 inhibitors of human skin 
chymase each year. 
3. Prepare and submit for testing 3-5 inhibitors of h~man skin 
tryptase each year. 
4. Prepare and submit for testing each year 3-5 inhibitors for 
other human serine proteases-such as human leukocyte elastase, 
cathepsin G, and plasminogen activator-which may have a role in 
vesication. 
5. Assay all inhibitors with human skin serine proteases and 
related enzymes for in vitro effectiveness. 
Research Progress-Summary 
1. A total of 45 serine protease inhibitors have been submitted 
in 3-5 g quantities for animal testing during the first two years 
of this contract. The structural classes include 9 isocoumarins, 
5 saccharins, 6 peptide phosphonates, 3 benzoxazinones, 11 
benzamidines, 5 derivative of p-guanidino benzoic acid and 6 
miscellaneous compounds. All the inhibitors which were submitted 
are listed in the following table along with their sample numbers. 
2. Various inhibitors have been surveyed for inhibitory potency 
against human neutrophil elastase, human neutrophil cathepsin G, 
rat skin tryptase, human skin tryptase, human skin chymase, human 
plasminogen activator, porcine pancreatic elastase, rat mast cell 
protease II, dog skin chymase, human lung tryptase and bovine 
chymotrypsin. 
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SAMPLES SUBMITTED: DMADl?-89-C-9008 
BOT-NUM WR-NUM SUB-ID RCHD COMPOUND 
ISOCOUMARINS (9 submitted) 
BL58572 268195 II-148 89/05/15 3,4-dichloroisocoumarin 
BL57637 268119 II-134 89/03/20 3-chloroisocoumarin 
BL57413 259666 II-137 89/03/13 4-chloro-3(2-phenylethoxy)isocoumarin 
BM00482 268387 II-151 89/08/08 4-chloro-3-benzyloxyisocoumarin 
BM04319 268693 MA-134 90/04/17 7-amino-4-chloro-3-cyclohexylmethoxyisocoumarin 
BM04668 268715 GP1 90/05/17 4-chloro-3-methylisocoumarin 
BM01096 268440 J0-138 89/09/12 4-chloro-7-(N-phenylcarbamoyl)amino-3-propoxy 
isocoumarin 
BM00642 268397 II-152 89/08/21 4-chloro-3-(3-S-isothiureidopropoxy)isocoumarin 
BM06288 GP2 90/09/05 4-chloro-3-methoxyisocoumarin 
"'0 
PJ SACCHARINS (5 submitted) 
I.Q 
(!) 
BL57977 268145 MA-84 89/04/19 N-benzoyl saccharin 
J-1 BL57995 268147 MA-89 89/04/19 N-phenylacetyl saccharin 1\.) 
BL57986 268146 MA-87 89/04/19 N-diphenylacetyl saccharin 
BL57931 268141 MA-86 89/04/19 N-furoyl saccharin 
BM00464 268385 MA-96 89/08/01 N-cyanomethyl saccharin 
PHOSPHONATES (6 submitted) 
BL57959 268143 II-22 89/04/19 Z-MetP(OPh)2 
BL57968 268144 II-138A 89/04/19 Z-ValP(OPh)2 
BL57422 259858 II-137A 89/03/13 Z-PheP(OPh)2 
BL57842 268132 II-139 89/04/10 Z-Phe-PheP(OPh)2 
BL59382 268241 II-147 89/06/14 Suc-Val-Pro-PheP(OPh) 2 






















































MISC. (6 submitted) 
BL57646 015392 II-137B 
BL57940 268142 II-145 

























































Isocoumarins-General Inhibitors. Dichloroisocoumarin 
(WR268195) is an excellent 9eneral inhibitor of serine proteases 
and was discovered in the laboratory of the principal investigator 
(Harper et al., 1985). With the exception of the bacterial enzyme 
subtilisin, 3,4-dichloroisocoumarin is an inactivator of all 
serine proteases which have been tested, including human leukocyte 
elastase, human skin chymase, dog skin chymase, rat mast cell 
protease I, and rat mast cell protease II. 
The dichloroisocoumarin ring system contains a masked acid 
chloride (or ketene) functional group which is exposed when an 
acyl enzyme is formed upon reaction with the active site serine of 
a serine protease (Harper et al., 1985). The acyl enzyme (top 
right of figure) which is formed initially can react further by 
acylating the active site histidine to form a doubly acylated 
enzyme derivative (bottom left) or can hydrolyze to form an acyl 
enzyme stabilized by a salt link between the protonated histidine 
and the inhibitor carboxyl group (bottom right) . The monochloro 
derivative, 3-chloroisocoumarin (WR268119), inhibits chymotrypsin-
like enzymes at slower rates than 3,4-dichloroisocoumarin and does 
not touch trypsin. The acyl enzymes formed upon reaction with 
dichloroisocoumarin have variable stabilities, but in general the 
half-lives for reactivation (deacylation) are greater than 8 hrs 





o¢ /Ser195 0 FN CO-N~ 
Cl His-57 
Dichloroisocoumarin and 3-chloroisocoumarin are formed by 
reaction of homophthalic acid with PCl5. 
Isocoumarins-Specific Inhibitors. We have also 
synthesized a number of isocoumarin inhibitors which are more 
specific for the active sites of chymases or tryptases. 
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Inhibitors targeted for chymase should contain an aromatic side 
chain which resembles the side chain of Phe, Tyr or Trp, while 
those inhibitors targeted for tryptase should containing a charged 
group which resembles the side chain of Arg or Lys. Several of 
the more specific isocoumarin inhibitors are shown below. 
Inhibitors with the benzyloxy (such as WR268387) or phenylethoxy 
groups (WR259666) were targeted at the chymases, while those with 






The mechanism of inhibition of serine proteases by 3-alkoxy-
4-chloroisocoumarins involves acylation of the active site serine-
195 to form acyl enzymes with varying stabilities (t1/2 = hrs to 
days) depending on the nature of the alkoxy group (Harper and 




Analogous isocoumarins with electron donating substituents in 
the 7-position such as 3-alkoxy-7-amino-4-chloroisocoumarins 
(below) are mechanism-based or suicide inhibitors of serine 
proteases (Powers et al., 1989). These inhibitors also acylate 
serine proteases, but form stable acyl enzymes which are not 
reactivated upon long standing or upon treatment with 
hydroxylamine. The inhibition mechanism involves formation of an 
acyl enzyme which can then leliminate chloride to form a quinone 
imine methide (center) . This intermediate then irreversibly 
alkylates His-57 with the formation of a stable covalent bond 
between enzyme and inhibitor. This mechanism is supported by x-
ray crystallographic studies of complexes of isocoumarin 
inhibitors bound to the·active site of porcine pancreatic elastase 
(Bode et al., 1989). Thus far, five separate isocoumarins have 
been studied crystallographically, two give simple acyl enzyme 
structures (above), twq give acyl enzyme structures where His-57 
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Isocoumarins which have been submitted and should inhibit 
serine proteases by the above mechanism include 7-amino-4-chloro-
3-(cyclohexylmethoxy)isocowmarin (WR268693) and 4-chloro-7-(N-
phenylcarbamoyl)amino-3-propoxyisocoumarin (WR268440). 
Two analogs of 3,4-dichloroisocoumarin are shown below. 
These two compounds were synthesized with the expectation that any 
isocoumarins with two small electronegative functional groups 




a-Aminoalkylphosphonates Dipheny1 Esters. Peptidyl 
derivatives of a-aminoalkylphosphonate diphenyl ester are 
effective and specific inhibitors of serine proteases at low 
concentrations (Oleksyszyn and Powers, 1989; 1991) . These peptide 
derivatives phosphonylate the active site serine to form stable 
phosphonyl derivatives. Good interactions with the S1 pocket of 
the target serine protease are necessary before nucleophilic 
substitution on phosphorus .atom occurs to give a stable phosphonyl 
derivative. 
Active Site 
Substrate S1 Ser195 
Binding Site r-1 6-H .... -His 









0 0 .. , " 
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N N hole 
Phosphonate diphenyl ester inhibitors are chemically stable, 
relatively easy to synthesize, do not react with 
acetylcholinesterase, form very stable derivatives possibly due to 
their resemblance to the tetrahedral intermediate involved in 
peptide bond hydrolysis, and have considerable potential utility 
as therapeutic agents. 
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We have submitted a number of simple amino acid and peptide 
derivatives of phosphonate diphenyl esters including Z-MetP(OPh)2 
(WR268143), Z-ValP(OPh)2 (WR268144), Z-PheP(OPh)2 (WR259858), Z-
Phe-PheP(OPh)2 (WR268132), and Suc-Val-Pro-PheP(OPh)2 (WR268241). 
More recen·tly, we have accomplished the synthesis of the 
amidinophenyl phosphonate derivative (WR268694) shown below. The 
benzyloxycarbonyl (Z) derivative has been submitted recently for 
testing. We have also synthesized a few peptide derivatives of 
the amidinophenyl phosphonate, but not in sufficient quantities 
for submission. · 
Benzoxazin-4-ones. Substituted benzoxazin-4-ones were 
discovered to be potent inhibitors of human leukocyte (HL) 
elastase, porcine pancreatic (PP) elastase, cathepsin G, and 
chymotrypsin by the PI (Teshima et al., 1982). Mechanistic 
studies by Abeles showed that these compounds were forming stable 
acyl enzyme derivatives (.shown below) with chymotrypsin (Hedstrom 
et al., 1984) and this has been confirmed by x-ray 
crystallographic studies with two benzoxazinones bound to PP 
elastase (Radhakrishnan et al., 1987). Due to the potential of 
benzoxazinone inhibitors of HL elastase for treatment of 
emphysema, a group at Syntex Canada has synthesized over 100 new 
benzoxazinones, carried out a structure-function study as 
substituents were varied on the ring system, and studied the 
plasma stability of these compounds (Spencer et al., 1986; Krantz 
et al., 1987; Krantz et al., 1990). We have submitted two 
benzoxazinones (BM05441 and BM05807) as elastase inhibitors. 
Guanidinobenzoic Acid Inhibitors. Esters of p-
guanidinobenzoic acid have been reported to be potent inhibitors 
for various trypsin-like en:~ymes (Okutome et al., 1984; Fujii et 
al., 1977) and p'-nitrophenyl-p-guanidinobenzoate is widely used 
as an active-site titrant for these enzymes (Chase and Shaw, 
1970) . An active-site titrant for trypsin-like enzymes developed 
in the laboratories of the PI is benzyl p-guanidinothiobenzoate 
(Cook and Powers, 1983). We have submitted samples of five p-
guanidinobenzoic acid derivatives for testing. 
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Saccharin Inhibitors. N-Acyl and N-aryl saccharins are 
potent acylating agents of HL elastc1se, cathepsin G, and 
chymotrypsin (Zimmerman et al., 1980; Ashe et al., 1981). A few 
of the N-acyl derivatives such as N-furoyl, N-thienoyl, and N-
benzoylsaccharin inhibit trypsin with ICso values of 0.7-2.4 J.lM. 
These structures were initially designed as acyl transfer 
reagents, but studies using 35s-labeled N-furoylsaccharin 
indicated that the saccharin portion of the inhibitor becomes 
covalently and stoichiometrically bound to both HL elastase and 









Two of the saccharins which we have submitted are shown 
below. 
WR268146 
Miscellaneous Inhibitors. Two heterocyclic general serine 
protease inhibitors have been submitted. They are isatoic 
anhydride which has been shown to acylate the active site of 
chymotrypsin and form a stable acyl enzyme (Moorman and Abeles, 
1982) and 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide which forms a 












The sulfide shown below is an effective inhibitor of elastase 
which was discovered in the laboratory of the PI. 




'V-(N~s---( • HBr 
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The following acyl derivatives of N-hydroxybenzotriazole· 
inhibit trypsin. 
Benzamidine Inhibitors. Eleven benzamidine inhibitors 
have been submitted as reversible inhibitors for trypsin-like 
enzymes. These compounds interact ·w-ith the 81 pocket as well as 
other portions of the active site. Some representative examples 
are shown on the next page. 
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Bio1ogica1 Test Data. 
All the inhibitors which we have synthesized have been tested 
for inhibitory potency against a variety of serine proteases. 
Kinetic data obtained with the various inhibitors are shown in 
Tables I-III. Most of the inhibitors are irreversible or slowly 
reversible inhibitors and we report the second order inhibition 
rate constants kobs/[I]. Several of the inhibitors reported in the 
tables have kobs/[I] values of 100,000 M-1s-1 or greater. A 
second order inhibition ratE~ constant of this magnitude indicates 
that the reaction between equimolar concentrations of enzyme and 
the inhibitor is over in less than 0.2 min. (the time required for 
mixing the enzyme and inhibitor in the assays) . The half-life of 
the inhibition reaction can be calculated from the equation t112 = 
0.693/{[I]*kobs/[I]}. Thus, an inhibitor with a kobs/[I] value of 
100,000 M-1s-I would have an inhibition half-life of 6.93 sec. at 
an inhibitor concentration of 1 ~, while an inhibitor with 
kobs/[I] = 10,000 would have a half-life of 69 sec. For the few 
reversible inhibitors invest:igated, KI values (dissociation 
constant of the enzyme-inhibitor complex) or IC5o values are 
given. 
The data with bovine chymotrypsin, cathepsin G, rat mast cell 
protease II, human skin chyrnase, and dog skin chymase is given in 
Table I. The best isocoumarin inhibitor in this table is 3-
benzyloxy-4-chloroisocoumar:Ln (WR268387) with a kobsd/[I] = 12,000 
M-1s-1 for the .human skin chymase. Increasing the length of the 
side chain at position 3 by one methylene group [4-chloro-3-(2-
phenylethoxy)isocoumarin, m~259666] reduces the activity by a 
factor of 35. 
The hest phosfhonate inhibitor for chymotrypsin-like enzymes 
is Suc-Val-Pro-Phe (0Ph)2 1 which corresponds to the sequence of an 
excellent 4-nitroanilide substrate for these enzymes. NMR studies 
with chymotrypsin indicate 1:hat only one of the two stereoisomers 
reacts with the enzyme (kobsd/[I] = 146,000 M-1s-1 calculated for 
the single isomer, the value in the table is for the DL mixture). 
The 31p NMR of chymotrypsin inhibited by this peptide phosphonate 
shows one broad signal at 25.98 ppm corresponding to the Ser-195 
phosphonylated enzyme derivative (Oleksysz~n and Powers, 1991) . 
The tripeptide phosphonate Suc-Val-Pro-Phe (0Ph)2 makes better 
interactions with the extended substrate binding site of the 
enzyme than is possible with the shorter dipeptide or amino acid 
phosphonate derivatives. 
All of the saccharins submitted so far have high kobsd/[I] 
values with the various chymotrypsin-like enzymes and low IC50 
values with the elastases tested. One of the better inhibitors in 
this family is N-furoylsaccharin. The acyl enzymes formed upon 
acylation of serine proteases by acyl saccharins have variable 
stabilities. Furoyl saccharin and benzoyl saccharin form 
inhibited elastase derivatives which are very stable and have 
half-lives for deacylation of 80-160 hrs. In contrast the 
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chymotrypsin derivatives have much shorter half-lives in the range 
of 1.9 hrs. One disadvantage of some acyl saccharins is their 
fairly rapid hydrolysis at neutral pH values. 
The data with porcine pancreatic elastase (PPE) and human 
leukocyte elastase (HLE) is given in Table II. All the 
isocoumarin derivatives reported in this table are excellent 
inhibitors of HLE, the best one being the 7-ureido derivative 
WR268440 with a kobsd/[I] = 140,000 M-1s-1 for HLE. It is also 
highly selective compared with 3,4-dichloroisocoumarin and 3-
chloroisocoumarin which is a logical consequence of the 
improvement in binding resulting from substitution at the 7-amino 
group. We have also submit·ted an excellent benzoxazinone 
inhibitor for HLE (WR268398) . Two analogs of this compound were 
poor inhibitors of the elastases, and were only moderate 
inhibitors of chymotrypsin-like enzymes. 
The phosphonate derivatives which we have submitted thus far 
are not good inhibitors for PPE or HLE. This is not surprising 
since the sequence of the tripeptide was chosen for chymase 
inhibition and this sequence is very specific for the chymases as 
discussed earlier. An excellent phosphonate inhibitor for the 
elastases has been synthesized only in a small scale. This 
inhibitor, Boc-Val-Pro-ValP(OPh)2, has kobsd/[I] value of 27,000 
M-1s-1 for human leukocyte elastase (HLE) and 11,000 M-1s-1 for 
porcine pancreatic elastase (PPE) . Again this sequence 
corresponds to a good HLE substrate sequence and at low 
concentrations this peptide did not react with chymotrypsin. 
The inhibition data obtained with bovine trypsin, human lung 
tryptase, rat skin tryptase, human skin tryptase, and human 
recombinant tissue plasminogen activator is given in Table III. 
The best tryptase inhibitor submitted is the 3-
(isothioureidopropoxy)isocoumarin WR268397 with a kobs/[I] = 
650,000 M-1s-1 for the rat skin tryptase, an extremely rapid 
inhibition rate. However, the acyl-enzyme formed with this 
inhibitor is unstable and the enzyme regains its activity within 5 
min. 
Several p-guanidinobenzoic acid derivatives have been tested 
as inhibitors for the various tryptases. One of these 
derivatives, 0-(p-guanidinobenzoyl)glycolamide is an excellent 
inhibitor of the rat skin tryptase, but is a much poorer inhibitor 
of human skin tryptase. In contrast to the isocoumarin WR268397, 
the inhibited derivative did not regain enzyme activity upon 
standing. We pursued this lead and synthesized additional 
derivatives. The 4-cyanophenyl p-guanidinobenzoate was also a 
very potent inhibitor· of trypsin and human lung tryptase. However 
it is probably not very stable in solution. 
We then shifted our emphasis away from guanidine compounds to 
amidines when we learned that amidines are likely to be less toxic 
than guanidine derivatives. In the last few months of this 
contract we have been concentrating only on inhibitors for 
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tryptases since this may be the more important enzyme in blister 
formation. Aromatic benzamidine derivatives are reversible 
inhibitors for trypsin-like enzymes and we have been preparing a 
series of derivatives to see if we can increase their inhibitory 
potency for tryptases. The most potent inhibitor thus far for 
both trypsin and the human lung tryptase is 1-(amidinophenyl)-3-
(4-phenoxyphenyl)urea (GP8, BM07829) which has a Kr value of 1.6 
JlM with bovine trypsin and inhibits 71 9o of the activity of human 
lung tryptase at 226 ~M. 
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Table I. Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and Dog Skin 
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Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 
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Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease II, Human Skin Chymase, and 




























alnactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 buffer, containing 9% Me2SO at 25 
°C. Enzyme concentrations were: chymotrypsin, 1.6 JlM; cathepsin G, 0.8-1.6 JlM; RMCP II, 38 nM; human skin chymase, 0.07 
JlM. Chymotrypsin and cathepsin G were assayed with Suc-Val-Pro-Phe-NA (0.5 JlM), human skin chymase and RMCP IT were 
assayed with Suc-Ala-Ala-Pro-Phe-SBzl (88 JlM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
bJnhibitor concentrations were in the range 5.2 Jl.M-1000 JlM. N-Cyanomethyl saccharin was inactive at 1 mM . . 
CJnhibitor concentrations were in the range: 4.8 Jl.M-1000 JlM. 
dJnhibitor concentrations were in the range: 3-148 JlM. 
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Table I (Continued). Inhibition of Bovine Chymotrypsin, Human Cathepsin G, Rat Mast Cell Protease n, Human Skin Chymase, and 
Dog Skin Chymase by Various Serine Protease Inhibitors. a 
elnhibitor concentrations were as follows: 4-chloro-3-(2-phenylethoxy)IC, 45 JlM; 7-amino-4-chloro-3-cyclohexylmethoxyiC, 0.44 
mM; Suc-Val-Pro-PheP(OPh)2, 0.54 JlM. 
finhibitor concentrations were as follows: 3,4-dichloroisocoumarin, 540 JlM; 3-benzyloxy-4-chloroiC, 1.0 J.!M. 
gData was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 1831-1841. 
hNo inhibition. 
iinhibition was not time dependent, and the% inhibition was measured at 92 Jl.M. 
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Table II. Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte Elastase (HLE) 
by Various Serine Protease Inhibitors. a 
WR Compound No. Inhibitor HI.EC 
Isocoumalrin ][nhibitors 
268195 3,4-dichloroiCd 2,500 9,000 
268119 3-chloroiCd 510 3,900 
259666 4-chloro-3-(2·-pheny lethoxy )IC 
268440 4-chloro-7 -(N -phenylcarbarnoyl)amino-
3-propoxy IC 59 140,000 
268715 4-chloro-3-methyl IC Nle 72%f 
BM06288 4-chloro-3-methoxy IC 601 87 
Miscellaneous Inhibitors 
015392 isatoic anhydride 
268142 di(4-isovaleroylphenyl)sulfide 2J,J.Mg 
099874 5-nitro-3H-1,2-benzoxathiole-2,2-dioxide 50 
Benzoxazinones 
268398 2-ethoxy-4H-3,1-benzoxazin-4-one 110,000 
BM05441 2-phenylamino-
4H-3, 1-benzox.azin-4-one 216 NI 
BM05807 2-benzy lamino-
4H-3, 1-benzox.azin-4-one NI Nl 
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Table IT (Continued). Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte 
Elastase (ID..E) by Various Serine Protease Inhibitors. a 
WR Compound No. Inhibitor HLEC 
Saccharin lnhibntors 
268145 N·· benzoylsaccharin 5.2 J.!Mh 2.4~Mh 
268147 N -pheny lacetylsaccharin 
268146 N -diphenylacety I saccharin 
268141 N -furoy !saccharin 0.58 ~Mh 0.36~Mh 
268385 N -cyanontethylsaccharin 
Plltosplllonate Inhibitors 
268143 Z-MetP(QPh)2 Nie 0.8 
268144 Z-ValP(QPh)2 2.5 90 
259858 Z-PheP(QPh)2 NI 6 
268132 Z-Phe-PheP(QPh)2 NI NI 
268241 Sue-V al-Pro-PheP(QPh)2 NI NI 
a Inactivation rates were measured by an incubation method in 0.1 M Hepes, 0.5 M NaCl, pH 7.5 
buffer, containing 8-12% Me2SO at 25 °C. Enzyme concentrations were: PPE, 1.6 ~M; HLE, 
0.3 ~· PPE was assayed with Suc-Ala-Ala-A.la-NA (0.75 mM), and HLE was assayed with 
MeO-Suc-Ala-Ala-Pro-Val-NA (0.5 mM). 
bJnhibitor concentrations were in the range: 3-1000 ~· 
Cfuhibitor concentrations were in the range: 1.2-1000 ~M 
dnata was obtained from Harper, J. W., Hemmi, K., and Powers, J. C. (1985) Biochemistry 24, 
1831-1841. 
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Table IT (Continued). Inhibition of Porcine Pancreatic Elastase (PPE) and Human Leukocyte 
Elastase (ID...E) by Various Serine Protease Inhibitors. a 
eNo inhibition. 
finhibition was not time dependent. 
glnhibition was not time dependent and the ICso was obtained. 
hJCso values obtained from Zimmerman, M., Morman, H., Mulvey, D., Jones, H, Frankshun, 
R. and Ashe, B. M. (1980) J. Bioi. Chern. 255, 9848-9851. 
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Table III. Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human Recombinant 
Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, Benzamidines, and 
Miscellaneous Inhibitors. 
WR Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Isocoumarin Derivatives 
268195 3,4-dichloroisocoumarin 200 190 610 70 
268397 4-chloro-3-(3-isothioureido-
propoxy )isocoumarin 46,000 260,000 650,000 83,000 13,000 
Guanidinobenzoic Acid Derivatives 
268476 p-guanidinobenzoic acid Nlg 
184335 ethyl p-guanidinobenzoate 4.3 1.7 0.7 Nlg 
268570 N-(p-guanidinobenzoyl) 
valine amide 4.4 4.7 1.3 2,000 
268596 0-(p-guanidinobenzoyl) 
glycolamide 100 19%h 130,000 5.8 Nlg 
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Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, 
Benzamidines, and Miscellaneous Inhibitors. 
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Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Pbosphonate Inhibitors, 
Benzamidines, and Miscellaneous Inhibitors. 
WR Compound No. Inhibitor 
BM08308 1 =(3-amidinophenyl)-3-phenyiurea 

























Table III (Continued). Inhibition of Bovine Trypsin, Human Lung Tryptase, Rat Skin Tryptase, Human Skin Tryptase, and Human 
Recombinant Tissue Plasminogen Activator by Isocoumarins, Derivatives of p-Guanidinobenzoic Acid, Phosphonate Inhibitors, 
Benzamidines, and Miscellaneous Inhibitors. 
WR Compound No. Inhibitor Bovine Human Lung Rat Skin Human Skin Human 
Trypsinb Tryptasec Tryptased Tryptasee r-t-PAf 
Miscellaneous Inhibitors 
BM07490 1-( 4-(pheny lureido )benzoy loxy )-
1 ,2,3-benzotriazole 14,000 600 
MA-76 1-benzoy loxy-1 ,2,3-benzotriazole 1,100 
BM07132 N -(2-isothiureidoethy 1 )pthalimide NI 
alnactivation rates were measured by an incubation method. Enzyme concentrations were: trypsin, 0.12 JlM; rat skin tryptase, 0.015 
tJ.M; human skin tryptase, 0.12 J.1M and 0.02 JlM; human r-t-PA, 0.017 JlM Bovine trypsin was assayed with Z-Phe-Gly-Arg-
NA·HCl (0.07 mM). Human lung tryptase, human skin tryptase and rat skin tryptase were assayed with Z-Arg-SBzl·HCl (0.07 
mM) in the presence of 4,4'-dithiodipyridine (0.33 mM). 
bconditions were as follows: 0.01 M Hepes, 0.01 M CaCl2, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as 
follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 1JlM; p-guanidinobenzoic acid, 0.44 mM; ethyl p-guanidinobenwate, 
0.43 mM; p-guanidinobenzoyl valine amide,0.44 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.44 mM; 4-cyanophenyl p-
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Table III (Continued). 
guanidinobenzoate, 0.46 ~; 1-(4-(phenylureido)benzoyloxy)-1,2,3-benzotriazole, 1.22 J.!M; 1-benzoyloxy-1,2,3-benzotriazole, 22 
J.lM. 
cconditions were as follows: 0.1M Hepes, 0.5M NaCl, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 4-
chloro-3-(3-isothioureido-propoxy)isocoumarin, 0.42 J.1M; ethyl p-guanidinobenzoate, 0.42 mM; p-guanidinobenzoyl valine amide, 
0.42 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.42 mM; 4-cyanophenyl p-guanidinobenzoate, 0.22 ~; 1-(4-
(pheny lureido )benzoy loxy )-1 ,2,3-benzotriazole, 11.6 J.lM. 
deonditions were as follows: 25 mM phosphate, 0.5M NaCl, lrnM EDTA, pH 7.5 ~'ld 8-12% Me2SO at 25 °C. Inhibitor concentrations 
were as follows: 4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.44 J.!M; ethyl p-guanidinobenzoate, 0.45 mM; p-
guanidinobenzoyl valine amide, 0.42 mM; 0-(p-guanidinobenzoyl)glycolamide, 0.44 ~-
econditions were as follows: 0.1 M Hepes, 0.5 M NaCi, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 0.35 JlM; p-guanidinobenzoyl valine amide, 3.5 J.!M; 0-(p-
guanidinobenzoyl )glycolamide, 1. 7 mM. 
fConditions were as follows: 0.1 M Hepes, 0.5 M NaCI, pH 7.5 and 8-12% Me2SO at 25 °C. Inhibitor concentrations were as follows: 
4-chloro-3-(3-isothioureidopropoxy)isocoumarin, 4.3 JlM; ethylp-guanidinobenzoate, 0.44 mM; 0-(p-
guanidinobenzoyl)glycolamide, 0.43 mM. 
gN o inhibition. 
hinhibition was. not time dependent and the % inhibition was measured at 0.42 mM. 
. . 
t AmPh = 4-amidinophenyl 
Jlnhbitior concentrations were 226 J.!M. 
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Animal Testing Priorities 
The various compounds which we: have submitted have been 
prioritized for animal testing and the following table lists the 
priority which we have assigned to each compound and the reasons 
for that priority. 
High-1 WR268195 3,4-dichloroisocoumarin 
This isocoumarin is a general serine protease inhibitor and 
effectively inhibits most of the enzymes tested. 
High-2 GP8 1-(amidinophenyl)-3-(4-phenoxyphenyl)urea 
This benzamidine should be very stable in solution and is an 
excellant competitive inhibitor of trypsin-like enzymes. 
High-3 WR268241 Suc-Val-Pro-PheP(OPh)2 
This peptide phosphonate is a reactive and specific inhibitor 
for chymotrypsin-like enzymes including chymases. 
High-4 WR268397 4-chloro-3- (3-:isothioureidopropoxy) isocoumarin 
This isocoumarin is a very reactive inhibitor for the rat 
skin tryptase. 
High-S WR268398. 2-ethoxy-4H-3,1-benzoxazin-4-one 
This benzoxazinone inhibitor is an effective inhibitor for 
elastase. 
High-6 WR268141 N-furoylsaccharin 
This saccharin is a general protease inhibitor and inhibits 
elastases and chymotrypsin-like enzyme quite effectively and is 
probably a moderate inhibitor for trypsin-like enzymes. 
High-7 BM06304 4-cyanophenyl p-guanidinobenzoate 
This guanidinium substituted derivative is an effective 
inhibitor for trypsin-like enzymes 
High-8 WR268440 4-chloro-7-(N-phenylcarbamoyl)amino-3-
propoxyisocoumarin 
This isocoumarin is an effective elastase inhibitor. 
High-9 WR268142 di(4-isovaleroylphenyl)sulfide 
This aromatic derivative is an effective elastase inhibitor. 
High-10 WR268387 4-chlo:ro-3-benzyloxyisocoumarin 




Benzamidines. Six ne~i benzamidines were synthesized in the 
final six months of the project w~e successfully overcame the 
initial difficulties in the synthesis of these class of compounds 
and submitted a total of eleven benzamidines. The last compounds 
submitted are (4-amidinobenzyl) benzyl ether hydrochloride (GP 9), 
bis(4-amidinophenyl)urea dihydrochloride (GP 10), 1-(3-
amidinophenyl)-3-phenylurea hydrochloride (GP 11), (4-
amidinobenzyl)phenylethyl ether hydrochloride (GP 12), 1-(3-
amidinophenyl)-3-(4-phenoxyphenyl)urea hydrochloride (GP 13), (4-
amidinobenzyl) -3-phenylpropyl ether· hydrochloride (GP 14) and (4-
amidinobenzyl)3-phenoxybenzyl ether· hydrochloride (GP 15). The 
structures are shown below. 
GP 9, BM08004 
cr 
GP 10, BM08184 
GP 13, BM08764 
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~0 
Gl, 14, BM09903 
GF1 15, BM09912 
Synthetic Schemes. ( 4-Amidi:nobenzyl) benzyl ether (GP 9) 
was synthesized from the cyano ether obtained by the reaction of 
sodium benzyloxide and cx.-bromo-p-tolunitrile. The cyano ether was 
converted to the imidate ester by treating it with dry methanol in 
the presence of HCl. The imidate ester on reacting with ammonia 
gave the desired amidino compound. 
(4-Amidinobenzyl)phenylethyl ether hydrochloride (GP 12) was 
prepared by replacing benzyl alcohol with phenylethyl alcohol and 
keeping the rest of the procedure as in GP 9. 
ROH + BrCH2-D-' CN ~ ROC H2-o-' CN HCI • __ -- MeOH 
--Q-<NH + ROCH2 2 cr NH2 
(4-Amidinobenzyl)phenylpropyl ether hydrochloride (GP 14) and 
(4-amidinobenzyl)3-phenoxybenzyl ether hydrochloride (GP 15) were 
also synthesized using the same method with ROH being phenylpropyl 
alcohol and 3-phenoxybenzyl alcohol respectively. 
Bis ( 4-amidinophenyl) u:rea dihydrochloride (GP 10) was made by 
conde~sing 4-aminobenzamidine dihydrochloride with urea. 
Page 38 
+ 
1- (3-Amidinophenyl) -3-phenylurea hydrochlo.ride (GP 11) was 
prepared starting from 3-am~nobenzonitrile. Phenyl isocyanate and 
3-aminobenzonitrile were condensed in refluxing benzene and the 
resulting urea was converted to thE~ imidate ester by the treatment 
with dry methanol in presence of dry HCl. Refluxing the imidate 
ester in dry isopropanol saturated with ammonia afforded the 
desired amidino compound. 
1- (3-Amidinopheny·l) -3-· (4-phenoxyphenyl) urea hydrochloride (GP 
13) was prepared using the procedure described above except that 
phenyl isocyanate was replaced with 4-phenoxyphenyl isocyanate. 
CN CN 
R-NCO + H2N--O --.. RNHCONH--d 




(4-Amidinobenzyl)benzyl ether hydrochloride (GP 9). A 
solution of benzyl alcohol (1.08 g, 0.01 mol) in dry THF (10 mL) 
was added slowly to sodium hydride (2.4 g, 0.10 mol) and the 
suspension stirred at room temperature for 15 min. To this 
stirred suspension was then added dropwise a solution of a-bromo-
p-tolunitrile (1.96 g, 0.01 mol) in dry THF (10 mL) and the 
reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction taken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
Dry HCl was passed through a cooled solution of the cyano 
ether (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporateq under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccat~or over KOH for 24 h. 
The imidate ester (1 g) was dissolved in dry isopropanol 
saturated with ammonia (50 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white crystals of the title compound (0.41 g, 44 %); mp 
102-104 °C. 1H NMR (DMSO-d6) 0: 4.58 (s, 2H); 4.65 (s, 2H); 7.25-
7.40 (m, SH); 7.59 (d, 2H); 7.84 (d, 2H); 9.23 (bs, 2H); 9.41 (bs, 
2H). Anal. Calcd. for C15H17Cl1N20: C, 65.10; H, 6.19 Cl, 12.81; 
N, 10.12. Found: C, 64.98; H, 6.20; Cl, 12.73; N, 10.02. 
Bis(4-amidinophenyl)urea dihydrochloride (GP 10). A 
suspension of urea (0.60 g, 0.01 mol) and 4-aminobenzamidine (4.16 
g, 0.02 mol) in water (5 mL) was heated under reflux for 24 h. 
The condenser was then removed and the heating further continued 
for 24 h. The reaction was then trichurated with water (25 mL) . 
The solid was filtered out dissolved in water and the clear 
solution acidified with HCl to get the product as a white solid 
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(3.1 g, 84 %); mp >250 °C. lH NMR (DMSO-d6) 0: 7.68 (d, 4H); 7.84 
(d, 4H); 9.00 (s, 4H); 9.23 (d, 4H); 10.45-(s, 2H). Anal. Calcd. 
for C15H18Cl2N60•0.3 H20: C, 48.07; H, 4.96; Cl, 18.96; N, 22.43. 
Found: C, 48.06; H, 5.05; Cl, 19.03; N, 22.55. 
1-(3-Amidinophenyl)-3-phenylurea hydrochloride (GP 
11). To a stirred sofution of 3-aminobenzonitrile (4.72 g, 0.04 
mol) in benzene (100 mL) was added phenyl isocyanate (5.00 g, 
0.042 mol) and the reaction refluxed for 5 hand further stirred 
at room temperature overnight. The separated white solid was 
filtered out and recrystallised from methanol (8.2 g, 84 %) . 
Dry HCl was passed through a cooled solution of the cyano 
urea (4.00 g, 0.016 mol) and dry methanol (2.7 g, 0.08 mol) in dry 
dimethoxyethane (100 mL) for 2 h and the reaction stored in a 
refrigerator for 14 h. Solvent was then evaporated under reduced 
pressure and the imidate ester obtained, as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (4 g) was dissolved in dry isopropanol 
saturated with ammonia (200 mL) and the reaction refluxed for 6 h 
and further stirred overnight at room temperature. Solvent was 
evaporated and the solid obtained was recrystallized from 2N HCl 
to get white solid of the title compound (2.1 g, 55%); mp 252-254 
°C. 1H NMR (DMSO-d6) 0: 6. 98 (t, 1H) ; 7. 20-7.35 (m, 3H) ; 7. 40-7.55 
(m, 3H); 7.70 (d, 1H); 7.95 (s, 1H); 9.1 (bs, 2H); 9.32 (bs, 2H); 
9.45 (bs, 1H); 9.18 (bs, 1H). Anal. Calcd. for C14H15Cl1N40: C, 
57.83; H, 5.20 Cl, 12.19; N, 19.27. Found: C, 57.74; H, 5.20; Cl, 
12.16; N, 19.21. 
(4-Amidinobenzyl)phenylethyl ether hydrochloride (GP 
12). This compound was prepared using the procedure described for 
compound GP 9 and replacing benzyl alcohol with phenyl ethyl 
alcohol. 1H NMR (DMSO-d6) 0: 2.88 (t, 2H); 3.69 (t, 2H); 4.60 (s, 
2H); 7.15-·7.30 (m, SH); 7.49 {d, 2H); 7.80 {d, 2H); 9.17 (bs, 2H); 
9.37 (bs, 2H). Anal. Calcd.. for C14H14Cl2N40: C, 66.09; H, 6.59; 
Cl, 12.19; N, 9.63. Found: C, 66.18; H, 6.61; Cl, 12.09; N, 9.56. 
1-(3-Amidinophenyl)-3-(4-phenoxyphenyl)urea 
hydrochloride (GP 13). This compound was prepared using the 
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procedure described for compound Gl? l:JL and substituting 4-
phenoxyphenyl isocyanate for phenyl isocyanate~ 1H NMR (DMSO-d6) 
0: 6.91-7.20 (m, 4H); 7.10 (t, 1H); 7.30-7.40 (m, 3H); 7.45-7.58 
(m, 3H); 7.70(d, 1H); 7.95 (s, 1H); 9.00 (s, 2H); 9.34 (s, 1H); 
9.36 (s, 2H); 9.55 (s, 1H). Anal. Calcd. for C2QH19Cl1N402·0.75 
H20: C, 60.60; H, 5.17; Cl, 8.96; N, 14.14. Found: C, 60.62; H, 
5.19; Cl, 8.96; N, 14.05. 
(4-Amidinobenzyl) -3-·phenylpropyl ether hydrochloride 
(GP 14). A solution of 3-phenylpropyl alcohol (2.72 g, 0.02 mol) 
in dry THF (20 mL) was added slowly to sodium hydride (2.4 g, 0.10 
mol) and the suspension stirred at room temperature for 15 min. 
To this stirred suspension was then added dropwise a solution of 
a-bromo-p-·tolunitrile (3. 92 g, 0. 02 mol) in dry THF (20 mL)' and 
the reaction stirred at room temperature for 24 h. Excess sodium 
hydride was destroyed by careful addition of water and the 
reaction taken up in ethyl acetate. The organic layer was washed 
successively with dil. HCl, water and brine, dried over anhydrous 
magnesium sulfate and solvent evaporated to get the cyano ether as 
a liquid. 
Dry HCl was passed through a cooled solution of the cyano 
et~er (1.00 g, 0.004 mol) and dry methanol (0.67 g, 0.020 mol) in 
dry dimethoxyethane (30 mL) for 1 h and the reaction stored in a 
refrigerator for 16 h. Solvent was then evaporated under reduced 
pressure and the imidate ester, obtained as a yellow solid, was 
stored in a vacuum desiccator over KOH for 24 h. 
The imidate ester (1 g) was dissolved in dry isopropanol 
saturated with ammonia (50 mL) and the reaction refluxed for 6 h 
and further stirred overnight at.room temperature. The solvent 
was evaporated and the solid obtained was recrystallized from 2N 
HCl to get white crystals of the title compound (0.295 g, 3;1. %); 
mp 76-78 °C. 1H NMR (DMSO-d6) 0: 1.84 (m, 2H); 2.62 (t, 2H); 3.45 
(t, 2H); 4.55 (s, 2H); 7.10-7.90 (aromatic, 9H); 9.20 (bs, 2H); 
9.45 (bs, 2H). Anal. Calcd. for C17H21Cl1N20: C, 66.99; H; 6.94 
Cl, 11.63; N, 9.19. Found: C, 67.05; H, 6.95; Cl, 11.54; N, 9.20. 
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(4-Amidinobenzyl)-3-phenoxylbenzyl ether hydrochloride 
(GP 15) . This compound was prepared using the procedure 
described for compound GP 1.4 and replacing 3-phenylpropyl alcohol 
with 3-phenoxylbenzyl alcohol. 1H NMR (DMSO-dG) 0: 4.55 (s, 2H); 
4.63 (s, 2H); 6.95-7.80 (aromatic, 13H); 9.16 (bs, 2H); 9.40 (bs, 
2H). Anal. Calcd. for C21H21Cl1N202: C, 68.38; H, 5.74; Cl, 9.61; 
N, 7.59. Found: C, 68.20; H, 5.78; Cl, 9.48; N, 7.44. 
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